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Abstract
A large number of studies have established that raised cholesterol levels increase the
probability of the development of atherosclerotic vascular disease, and that reducing
serum cholesterol will result in fewer cardiac events in the treated population, both in
those with and without evidence of pre-existing coronary disease. More direct
evidence that this is due to alteration of the progression of the atheromatous plaques
has resulted from angiographic studies demonstrating the halting of progression or
even regression of the stenotic lesions. Some workers have found a relationship
between the extent of lowering of the serum lipoproteins and the likelihood of
regression, although it has not been clear whether this continues to hold true at the
lower extremes, nor whether there may be a threshold level which requires to be
achieved before regression may take place.
The principal purpose of these studies was to investigate the effects of applying very
intensive lipid-lowering therapy, including LDL-apheresis, in a group of patients with
coronary artery disease and moderately severe hypercholesterolaemia to achieve sub¬
normal lipoprotein levels, and comparing the effects of such treatment with those
achieved in another group of subjects treated with drug therapy to the currently
recommended therapeutic targets for such patients. The studies involved the
measurement of lipids and lipoproteins before and after apheresis and at regular
intervals throughout the two-year study period. ApoB metabolism was assessed at
baseline and following completion of the treatment period, and the data analysed
using a multicompartmental mathematical model. The patients were assessed
non-invasively by exercise electrocardiography at regular intervals, and by thallium
scintigraphy at baseline and at annual intervals. The principal end-point was the
proportion of arterial segments undergoing regression or progression in each group
assessed by computer-assisted analysis of coronary angiograms performed at baseline
and on completion of the intervention.
The results from these studies demonstrated radical differences in lipoprotein
concentration and composition during treatment. There was increased catabolism of
LDL precursors with diminished flux of apoB which may reflect up-regulation of the
LDL-receptor, but a rapid return to pre-treatment lipid levels indicated the effects on
lipoprotein metabolism were transient. There was a reduction in the progression of
coronary disease in the majority of lesions, with a small number in each group
undergoing definite regression. There were significant differences in the changes in
exercise tolerance with treatment, and the likely mechanisms for this are discussed.
The thallium scans demonstrated no difference between the groups in the number of
segments with improved perfusion, but were shown to have some value in the
non-invasive assessment of predicting angiographic changes in the proximal
segments, particularly in the right coronary artery.
The findings are put into the context of the recent publications on cholesterol
reduction in coronary disease; implications for clinical management are drawn, and
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1.1 CORONARY ARTERY DISEASE
1.1.1 Incidence
Coronary artery disease in industrialized societies is the principal cause of
premature death, and imposes an enormous burden both on health service
resources and on national economic loss [National Forum for Coronary Heart
Disease Prevention, 1988].
The description of its commonest presentation - angina pectoris - was first
recorded two hundred years ago by William Heberden [Heberden 1772], and its
mechanism of imbalance between myocardial oxygen supply and demand was
recognised soon after [Parry 1799]. Despite its recognition, it appears (judging by
the paucity of publications) to have been an uncommon entity until the present
century. From the 1920's there has been a dramatic increase in the incidence of
coronary disease in most Western communities which has been described as an
epidemic. In the United Kingdom the incidence appears to have peaked around
1980 and may now be exhibiting a slow downward trend, as has been observed in
other countries over the past two decades (Fig 1.1).
FIG 1.1 TRENDS IN MORTALITY FROM ISCHAEMIC HEART DISEASE
Brazil Finland Luxembourg New Zealand USA
Denmark Greece Netherlands Portugal UK
[Figuresfrom Britannica World Data 1986 & 1994]
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Despite these changes in incidence, mortality rates from coronary heart disease in
Britain remain among the highest in the world. The impact of this condition may be
illustrated by a comparison with mortality rates from other common causes of
death including those which have received particular attention from screening
programmes (Fig1.2, [Government Statistical Service 1994]).
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Within the United Kingdom there are well-recognised areas which have an
incidence of coronary disease consistently above the national average, and the
West of Scotland in particular is an example (see Figure 1.3 [Government
Statistical Service 1994]).
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1.1.2 Pathology and pathogenesis
Ischaemic heart disease is usually due to obstruction of the coronary arteries, most
commonly by atherosclerotic plaque. This process appears to have its origins in
childhood, when "fatty streaks" may be observed even before ten years of age
[Stary 1983], These consist mainly of lipid-filled macrophages and smooth muscle
cells, and appear as an area of yellowish discolouration of the arterial intima.
These early lesions have a predilection to occur at the sites at which the more
advanced lesion, the fibrous plaque, also appear, and are believed to be the
precursors of the latter lesions [McGill 1984], Fibrous plaques are white, and -
unlike the fatty streak - usually elevated, often protruding into the lumen of the
artery where they may compromise blood flow. Microscopically they consist of
large numbers of intimal smooth muscle cells and macrophages containing a
variable amount of lipid, the origin of the cells confirmed by monoclonal antibody
studies [Tsukada efa/1986].
The cellular element is surrounded by proteoglycan and collagen and elastin
fibres, and are usually covered by a fibrous cap. The relative contribution to the
plaque by fibrous tissue and lipid-rich material varies between lesions even in the
one individual, but there is a relationship between the constitution of the plaques
and serum lipid levels, hypercholesterolaemic subjects tending to have greater
amounts of lipid within the lesions [Ross et al 1984],
The distribution of atherosclerosis in humans follows a general pattern: the
abdominal aorta is usually more extensively involved than the thoracic aorta,
particularly around the ostia of its branches. The coronary arteries tend to be
among the worst affected, usually in their more proximal part. It is thought that the
characteristics of the blood flow [Caro et al 1969, Caro et al 1971, Chien 1976]
may be of primary importance in determining the site, extent, and severity of the
lesions.
The pathogenesis of atherosclerosis is not completely understood, but the
"respose-to-injury" hypothesis was widely accepted for several years [Ross &
Glomset 1976], This view states that localised endothelial damage is the initiating
event, and was suggested by the experimental observations that deliberate
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denudation of the endothelium results in the aggregation of platelets which release
a growth factor (platelet-derived growth factor, PDGF) which induces the
proliferation of smooth muscle cells characteristic of the early fibrous plaque
[Sheppard & French 1971, Ross ef a/1974]. However, subsequent studies showed
that the precursor fatty streak develops under an intact endothelium [Davies ef al
1976], suggesting an alternative mechanism for the initiation of most lesions.
The majority of lipid-laden foam cells in the early human fatty streak have been
shown to be derived from monocytes [Aqel ef al 1984], In experimental studies in
non-human primates the adhesion of circulating monocytes to the arterial
endothelium may be observed within days of commencing an atherogenic diet
[Faggiotto ef al 1984], Following adhesion these monocytes may be seen to
migrate into the subendothelial space where they may undergo transformation into
macrophages, secreting further chemoattractants, recruiting more platelets and
monocytes, and producing free radicals with consequent local intimal damage.
Additionally, both the activated macrophage and the endothelial cell may release
growth factors which stimulate the migration and proliferation of fibroblasts and
smooth muscle cells leading to the development of a proliferative intimal lesion.
Proliferating smooth muscle cells themselves have been shown to produce growth
factors in some species, suggesting that the atherosclerotic process may then
proceed even if the initial stimulus to its formation is no longer present [Hansson ef
al 1989]. Platelets may also contribute to the endothelial-cellular interaction by
adhesion to exposed foam cells or connective tissue [Faggiotto ef al 1984], with
subsequent aggregation, formation of mural thrombi, and release of
platelet-derived growth factor and other mitogens.
Alternative theories regarding the pathogenesis of atherosclerosis have been
proposed. These include a monoclonal origin of cells in an atherosclerotic lesion,
with transformation of a single cell by mutagens such as viruses or chemicals. A
number of viruses have been shown to be associated with atherosclerotic-like
lesions in experimental animals, and evidence of virus antigens have been
demonstrated by electron microscopy and immunofluorescence studies in humans
with established atherosclerotic disease [Cunningham & Pasternak 1988, Melnick
ef al 1983, Melnick ef al 1990], The apparent epidemic nature of coronary disease
might, according to this hypothesis, be explained on the basis of food-chain
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transmission, and the recent decrease in coronary mortality ascribed to improved
sanitation and food hygiene [Mozar et al 1990]. In addition to their mere presence
in arterial smooth muscle cells in individuals with atherosclerosis, which clearly
need not be causative (particularly since such antigens have been identified in
only a minority of coronary patients [Melnick et al 1983]), there is also evidence of
alteration in cellular lipid metabolism and lipid composition and content in human
arterial smooth muscle cells [Hajjar & Grant 1986]. Chemicals such as
homocysteine may also be associated with increased vascular risk [Mudd & Levy
1983]. While this is of importance in small numbers of patients with inborn errors of
methionine metabolism [Harker et al 1976, Wilcken & Dudman 1989] and has been
reported to be elevated in patients suffering an acute myocardial infarction
[Olszewski & Szostak 1988], it is unlikely to be an aetiological factor for most
subjects with atherosclerosis [Wilcken et al 1983, Dudman et al 1990]. The finding
of complement antigens in atherosclerotic lesions suggest the possibility of a role
for other infectious agents or immunological stimuli [Hollander et al 1979], The
observation however that fatty streaks contain few antigens of complement
components compared to fibrous plaques [Hansson et al 1979, Vlaicu et al 1985]
suggests that these are more involved in the growth and propagation of the plaque
rather than its initiation [Seifert & Kazatchkine 1988]. Neuropsychological factors
may also be important, and result in direct pathological changes in the arterial wall,
rather than only an indirect effect mediated by behavioural changes [Gutstein
1990],
It is likely that there is more than one initiating event and that the atherosclerotic
process may result from a number of types of endothelial injury, including release
of cytotoxic factors from a subendothelial collection of modified macrophages, as
supported by the observation of cellular retraction over lipid-laden foam cells in
animal models [Gerrity 1981, Faggiotto & Ross 1984], The progression to the more
advanced lesion might then proceed mostly due to cellular proliferation and
release of growth factors irrespective of the nature of the original injury, although
the process is likely to be accelerated in the presence of factors which cause
continuing endothelial damage. A 'unifying hypothesis' is presented schematically
in fig 1.4 (adapted from Steinberg 1988).
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Figure 1.4 Hypothesis of initiation of atherosclerosis
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1.1.3 Clinical Manifestations of Ischaemic Heart Disease
Despite the continuing debate about the aetiology and pathogenesis of the
atherosclerotic process, the end result is reduction of the arterial lumen by plaques
which reduce the myocardial blood supply and are liable to superimposed
thrombus formation. The major epicardial coronary arteries, in which
atherosclerosis is most often seen to occur, normally offer little resistance to blood
flow. Regulation of blood flow is determined in health by vasomotor tone, which
may be influenced by neural control, circulating catecholamines, pharmacological,
myogenic, and endothelial factors. The normal coronary flow reserve in health
means that a reduction of as much as 80% in luminal diameter of a proximal artery
may not induce myocardial ischaemia at rest due to dilatation of the resistance
vessels distal to the obstruction. However any increase in oxygen demand
thereafter will inevitably result in myocardial hypoxia. If the obstruction is less
severe there remains some capacity for further dilatation, and the occurrence of
ischaemia depends on the extent to which demand is increased. A reduction of
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less than 40% of the luminal diameter is usually not associated with reduction in
blood flow even at maximal exercise. Thus although blood flow is little affected with
mild degrees of stenosis, since flow is inversely proportional to the fourth power of
the radius, it decreases precipitously with more severe degrees of narrowing.
In addition to the ischaemia which results when oxygen demand exceeds the
ability of the coronary vessels to maintain adequate flow because of fixed arterial
obstruction, it may also arise as a consequence of transient reduction of blood flow
caused by platelet aggregates or coronary vasospasm. In this way symptoms of
myocardial ischaemia may be present at more modest workloads than can be
achieved without any symptoms at other times due to these alterations in coronary
flow reserve [Maseri et al 1985].
One dramatic - and sometimes unheralded - presentation of coronary artery
disease is myocardial infarction. The relationship between atherosclerotic
narrowing and myocardial necrosis was not fully understood from earlier
post-mortem studies (which suffered from an obvious selection bias) [Roberts &
Jones 1980, Silver et al 1980], or from studies employing coronary angiography in
those who had survived one month [Betriu et al 1982], Studies with angiography
being performed acutely have demonstrated total occlusion in the artery
subtending transmural infarcts in about 90% of cases [DeWood et al 1980].
Plaques associated with total occlusion are seen to be more complex and irregular
at autopsy than those in arteries not associated with myocardial infarction [Levin &
Fallon 1982], and often show evidence of plaque fissuring or rupture [Falk 1983,
Davies & Thomas 1985, Onodera et al 1989]. Angiographic appearances
suggestive of plaque rupture have also been identified in most lesions associated
with unstable angina or myocardial infarction, and this finding is uncommon in
vessels of patients with chronic stable angina and in noninfarct-related arteries in
Ml patients [Wilson 1986], This has been graphically confirmed by angioscopy
which has allowed direct inspection of the fissuring plaque [Mizuno et al 1991]:
occlusive thrombus was observed in all 14 patients with acute myocardial
infarction, while the thrombus in unstable angina was more likely to be mural.
Xanthomatous plaques were seen in 50% of those with acute coronary
syndromes, compared with only 8% of those with previous myocardial infarction
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and 15% with chronic stable angina, suggesting that lipid-rich plaques may be
more liable to undergo fissure or rupture.
Despite these advances in our understanding, the exact sequence leading from
coronary atherosclerosis to myocardial infarction is not clear, but appears to
involve a dynamic interaction between obstructing lesion, vasospasm, platelet
activation and thrombotic mechanisms [Willerson et al 1984, Epstein & Palmeri
1984],
Much attention has been focused on the dramatic presentation of acute coronary
insufficiency syndromes, including sudden cardiac death and acute myocardial
infarction. However most of the morbidity associated with coronary disease is due
to chronic ischaemic heart disease. In addition to the common clinical syndrome of
chronic stable angina, the prevalence of significant coronary artery disease in
asymptomatic males aged 50 - 70 years with a normal exercise test has been
estimated in one population to be 2 - 3% [Diamond & Forrester 1979]. The lack of
symptoms does not correlate well with a lesser severity of disease as "silent
ischaemia" may be associated with advanced obstructive lesions [Singh 1986].
1.1.4 Natural History
Long-term follow-up studies have shown the average mortality in chronic stable
angina to be approximately 4 per cent per annum [Kannel 1973]. The likelihood of
fatal events for any individual with symptomatic coronary disease however is quite
variable, and depends on left ventricular function and the severity, location and
extent of coronary disease; for example, single vessel involvement with normal
ventricular function has an annual mortality of around 2%, compared to 7% for
single vessel disease with severely impaired LV function, 5% p.a. for three-vessel
disease with a normal ventricle or 12% p.a. for those with triple-vessel disease and
a left ventricular ejection fraction below 35% [Mock 1982],
Although surgical intervention is superior to medical management in the alleviation
of symptoms, and confers an initial improvement in survival in selected groups, i.e.,
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those with 3-vessel disease or left main coronary artery stenosis [Chaitman et al
1981, Kaiser et al 1985], the long-term survival for most patients is not significantly
improved [Veterans Affairs Study 1992, Alderman et al 1990] (although it is
important to recognise the improvements in event-free survival in surgically-
managed patients during the period spanned by these studies [Muhlbaier et al
1992]). One reason for this is the progression of the atherosclerotic process in the
bypass grafts, which may be related to risk factors, such as serum cholesterol
levels, identified at the time of surgery [Palac et al 1982],
There is a lack of predictability of the progression of any individual lesion: it is
recognised that coronary artery disease tends to be progressive, and that severe
lesions are more likely to progress than mild ones [Bruschke et al 1981], Although
chronic occlusion occurs more commonly with severe stenoses, 87% of severe
lesions in a 3-year follow-up study did not occlude [Bissett et al 1990]; of those
patients who did develop chronic occlusion only 25% had clinical evidence of
myocardial infarction. In another study in which serial angiography was performed
on three occasions only 19% of patients demonstrated progression of disease
during both intervals, and in only 28% of those was the progression in the same
lesion [Bruschke efa/1989].
Predicting which lesion may cause infarction is no less difficult. It is commonly
assumed that the "culprit lesion" will be the one identified at angiography as the
most severe, and intervention is frequently undertaken on the basis of this
assumption. However recent evidence suggests that this is not the case: a group
of patients who had undergone angiography shortly before a myocardial infarct
had this repeated at the time of the event, and in only 34% was the artery with the
most severe lesion at the time of the initial angiogram the infarct-related vessel
and the degree of stenosis in the culprit lesion was less than 70% in no less than
97% of patients [Little 1988], It is therefore likely to be the morphology of the
plaque and its propensity to fissure or rupture which is of greater importance in
determining its natural history rather than simply its severity [Davies & Thomas
1985, Lendon efa/1991].
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1.2 THE ASSOCIATION BETWEEN CHOLESTEROL AND CORONARY
DISEASE
1.2.1 Total and Low Density Lipoprotein Cholesterol
1.2.1.1 Epidemiology
Since Anitschow described cholesterol as being a prerequisite for the development
of atherosclerosis [Anitschow 1913] the relationship between hypercholesterol-
aemia and coronary disease has been one of the most intensively studied. The
evidence from a large number of cross-sectional and longitudinal studies is entirely
consistent, and indicate a direct association between cholesterol levels and
incidence of coronary disease. One of the early studies to show this relationship
between populations was the Seven Countries Study [Taylor et al 1970], which
related the incidence of coronary disease to the population mean total cholesterol.
Severity of atherosclerosis was related to the level of serum cholesterol in the
International Atherosclerosis Project [Holman et al 1958]. International cardio¬
vascular mortality is also correlated with mean population serum cholesterol, 45%
of the interpopulation variation due to differences in cholesterol levels (and 55% of
the variation attributable to variation in the total cholesterol/HDL cholesterol ratio)
[Simons 1986].
Studies within populations followed longitudinally have also consistently found the
same correlation between serum cholesterol and the likelihood of developing
coronary disease [Keys et al 1972, Heller et al 1984, Shaper et al 1985,
Gouldbourt et al 1985, Kannel et al 1986, Rose & Shipley 1986, Livshits et al
1989, Pekkanen et al 1990, Gouldbourt & Yaari 1990, Wilson et al 1991, Shipley
et al 1991, Assmann & Schulte 1992, Isles et al 1992], and indicate a curvilinear
association with a significant rise in coronary events being associated with
cholesterol levels above 5.2 mmol/l. Some smaller studies have failed to confirm
the association of total cholesterol with coronary events, but document the
increased risk associated with raised low density lipoprotein cholesterol levels
[Hargreaves et al 1991]. It has recently been proposed that the strength of the
association has been underestimated by failing to take account of regression
dilution bias and the 'surrogate dilution effect' [Law et al 1994],
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Most of this data relates the risk of a first cardiac event to the serum cholesterol
level, and it had previously been debated whether the lipids were of prognostic
significance in survivors of myocardial infarction. It is established that one of the
main determinants of their survival is left ventricular function (see Section 1.1.4),
but there is also observational data demonstrating a powerful predictive effect of
total cholesterol and LDL cholesterol levels on cardiac mortality. In a cohort of
middle-aged men followed up from the Lipid Research Clinics Prevalence Study
the ten-year risk of death from cardiovascular disease for those with pre-existing
cardiovascular disease was 3.8% in those with a total cholesterol of < 5.2 mmol/l
and 19.6% if total cholesterol > 6.2 mmol/l. This compares with rates of 1.7% and
4.9% respectively for those without pre-existing cardiovascular disease [Pekkanen
et al 1990]. This is consistent with the strength of this relationship after the first
cardiac event seen in other studies [Shaper et al 1985, Frost et al 1987, Phillips et
al 1988], and demonstrates an even greater potential for benefit from intervening
in this group of individuals.
One of the criticisms of the epidemiological data is the lack of information on
women, and that it may be a weaker risk factor for coronary disease in women
[Khaw 1993, Crouse 1989]. Some studies have shown that total cholesterol is not
significantly related to total or cardiac mortality in women, while serum triglycerides
is predictive [Bengtsson et al 1993]. This study however looked only at mortality
rather than other cardiac events, and followed only 1462 subjects. Other studies
using much larger populations with longer duration of follow-up however yield data
entirely consistent with that available for men. 45 000 Swedish women were
followed up for 18 - 20 years, and showed a highly significant positive relationship
between coronary heart disease mortality and baseline blood cholesterol levels
[Tornberg 1989]. Others confirm that the relationship between total cholesterol
concentration and coronary deaths is at least as strong for women as men, and
the relative risks may be slightly greater than those for men even if the absolute
and attributable risks may be lower [Stensvold et al 1993, Isles et al 1992],
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1.2.1.2 Familial Hypercholesterolaemia
The importance of elevated cholesterol as a risk factor for the development of
coronary disease is nowhere better illustrated than in familial hypercholesterol¬
aemia. This is inherited as an autosomal dominant disorder, with a gene frequency
in most populations of 1 in 500 [Brown & Goldstein 1976]. In the classical condition
there is a deficiency in the number of cell-surface receptors for LDL. Thus
cholesterol concentrations in heterozygotes range from 8 to 12 mmol/l, while the
levels in homozygotes are usually above 14 and may be as high as 30 mmol/l
[Thompson et al 1989, Allen et al 1980].
Homozygotes may present with premature atherosclerosis in childhood or
adolescence, and untreated the life expectancy is only 17.7 years [Thompson et al
1989], with no apparent protective effect from gender [Seftel et al 1980]. Some
series report a less ominous prognosis, with 50% survival at age 50 - perhaps a
consequence of a predominant 'receptor-defective' status in this particular
population [Haitas et al 1990]. The receptor status is clearly of importance in
determining survival, since 26% of 'receptor-negative' subjects die from coronary
disease before the age of 25 years, compared to just 4% of 'receptor-defective'
individuals [Thompson 1990], Recent advances in molecular genetics have
demonstrated a variety of defects affecting the LDL-receptor gene [Hobbs et al
1992], These defects give rise to differences in plasma cholesterol concentrations
resulting in variability of severity of coronary heart disease expression and life
expectancy [Moorjani et al 1993], and account for the spectrum of survival
reported in earlier observational studies.
The incidence of coronary disease is increased more than ten-fold in
heterozygotes, so that at least 50% of affected men have died or had a myocardial
infarct before the age of 60 [Stone et al 1974], and in untreated familial
hypercholesterolaemia it was the cause of death in about 70% of subjects
[Mabuchi et al 1986]. The risk for women is also greatly increased: first
manifestations of coronary disease were seen in 5.4% of men by the age of 30,
51% by 50 and 85% by 60 years, compared to 0%, 12% and 58% respectively in
women [Slack 1969], the mean age of onset being delayed by about 9 years
compared to male heterozygotes [Heiberg 1975, Mabuchi et al 1989]. The rates of
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coronary heart disease were approximately 20 years earlier than those
experienced in the same kindreds with normal cholesterol values [Stone et al
1974],
1.2.1.3 Cholesterol-Lowering Intervention Trials
The epidemiological data provide evidence of an association between cholesterol
levels and its long-term consequences. It requires a trial of intervention however
before any causal relationship may be implied, and much time, effort and money
has been expended in attempts to influence coronary disease by lowering serum
cholesterol levels. These have been performed almost exclusively in middle-aged
men, both in groups free of clinical manifestations of vascular disease (primary
prevention) or following myocardial infarction, utilised either dietary modification or
pharmacotherapy or a combination, varied with regard to length of follow-up, and
employed differing end-points (clinical events, mortality, and angiographic). There
are many difficulties inherent in such studies, including the relatively brief period of
intervention compared to the decades over which the disease process has
evolved, the presence of confounding variables, the relatively modest reductions in
cholesterol levels achievable with available therapies, the numbers required to
demonstrate the effects of the intervention - particularly on mortality, and the
adequacy of surrogate endpoints.
Trials of dietary therapy (Tables li and lii)
There is only one randomised trial of diet in the primary prevention of coronary
disease as a unifactorial intervention which has reported CHD incidence as an
endpoint [Frantz et al 1989], Although there was a reduction in cholesterol in the
experimental group of 15% and a polyunsaturated/saturated fat intake of 1.6
(compared to 0.3 in controls) in a study of 9057 institutionalized men and women
conducted over 4.5 years, there was no significant reduction in cardiovascular
events or total mortality. However the mean duration of time on the diets was only
384 days, with only 17% of the subjects consuming the diets for two years.
The Lifestyle Heart Trial [Ornish et al 1990] incorporated exercise and stress












































































































































but did not include pharmacological reduction of cholesterol levels. Smoking
intervention was also planned, though only one of the 28 subjects in the treatment
group smoked on admission to the study, and she stopped at baseline. The
endpoint in this study was however angiographic changes rather than CHD events
and will be discussed further below (Sect 1.5.2).
The Oslo diet-heart study also eschewed lipid-lowering drug therapy, but combined
rigorous dietary changes with smoking intervention [Hjermann et al 1981]. In this
study 1232 severely hypercholesterolaemic (but otherwise healthy) middle-aged
men were followed for 7.5 years. Cholesterol was lowered by 13% in the
intervention group, and 25% in this group reported that they had stopped smoking
compared to 17% in the control group. A significant reduction in nonfatal and fatal
myocardial infarction of 42% was observed, with a decrease in cardiac deaths of
56%. Follow- up at 15 years reveals this ultimately results in a significant decrease
in total mortality.
Both the MRFIT [Multiple Risk Factor Intervention Trial Research Group 1982] and
the WFIO multifactorial study [WFIO Collaborative Group 1983] included dietary
lipid reduction in the intervention groups, while using drugs to lower blood pressure
when indicated. The cholesterol reductions achieved in these very large studies
were only 2% and 1% respectively. MRFIT showed a non-significant decrease in
cardiac events with a non-significant excess of total mortality, while the WHO trial -
involving 49,784 men followed for 5 - 6 years - revealed a statistically significant
increase in overall mortality. A follow-up study in MRFIT after 10.5 years did result
in a significant reduction in all-cause mortality, but no difference in cardiac death
rate [Multiple Risk Factor Intervention Trial Research Group 1990]. Another large
randomised study of over 10,000 men subjected to reductions in cholesterol,
weight, and blood pressure over ten years also failed to demonstrate any
significant change in coronary mortality [Wilhelmsen et al 1986]. Although
reductions in cholesterol, blood pressure and smoking habit were achieved in the
intervention group there was also a reduction in risk factors in the control group,
and within the intervention group the successes were diluted by an excess
mortality amongst non-participants.
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Since the cardiac event rate in hypercholesterolaemic subjects is greater after the
first cardiovascular event (Sect 1.2.1.1), it might be anticipated that the effects of
lipid intervention might be more readily seen in this group. A number of trials of
dietary treatment in such patients have been carried out. These have involved
smaller numbers of subjects, but some have reduced mean cholesterol levels by
approximately the same extent as the drug trials. One of these, the Los Angeles
Veterans Administration Study, randomised 846 men with a mean age of 65 to
receive a different proportion of their fat intake as polyunsaturates [Dayton et al
1969]. The event rate in this study was particularly high - 41% mortality in each
group over the eight year follow-up period. Although this was not significantly
different between the groups, there was a significant reduction in combined
endpoints of nonfatal and fatal atherosclerotic events from 20.9% to 14.2%, a
reduction of 32%. In another study in Finland which achieved a 14% reduction in
cholesterol by diet, coronary events were 53% lower in men and 34% in women,
although neither the cardiac events nor total mortality overall was significantly
different [Turpeinen 1979]. The baseline characteristics of the participants and the
results of these and smaller dietary studies are presented in Tables 1 i - ii.
Trials of Drug and Surgical Therapy (Tables 1iii and 1 iv).
Several trials of primary prevention using drug therapy are now completed and
others are in progress. The first was a WHO trial started in 1965, in which
middle-aged men with cholesterol levels in the upper fertile were randomised to
receive clofibrate or placebo, and compared to a group of equal size with serum
cholesterol levels in the lowest fertile who were also given placebo [Committee of
Principal Investigators 1978]. Cholesterol was lowered by just 9%; nonfatal and
fatal myocardial infarctions combined were reduced by 20% (from 3.93% to
3.13%), due almost entirely to the reduction in nonfatal infarcts. However there
was an excess of noncardiac deaths in this study due to cancer and deaths from
violence and total mortality was significantly increased, although there was no
difference in age-standardized mortality in these categories between the
intervention group and the second control group. The adverse mortality outcome
continued long after discontinuation of the drug intervention [Committee of
Principal Investigators 1980].




















































































































































































































Between 1973 and 1976 the Lipid Research Clinics Coronary Primary Prevention
Trial (LRC-CPPT) screened over 480,000 men from twelve lipid clinics across the
U.S.A. to find 3806 middle-aged men with a plasma cholesterol above the 95th
percentile, LDL cholesterol of at least 4.9 mmol/l, triglycerides below 3.5 mmol/l,
and free from heart disease, hypertension and diabetes. They were randomized
after a period of dieting to receive either cholestyramine 24g daily or placebo and
followed for seven to ten years. Total cholesterol was reduced by 9% compared to
the control group, and LDL cholesterol by 13%. The combined endpoint of
coronary death or nonfatal myocardial infarction was reduced from 8.6% to 7%, a
reduction of 19%, which was significant. Total mortality was reduced also by 7%,
but this failed to achieve statistical significance [Lipid Research Clinics Program
1984a]. The power of the study was hampered by the small cholesterol-lowering
effect due to a minority of the subjects being able to tolerate the full dose of the
resin and fewer deaths than expected in the control group. An accompanying
analysis [Lipid Research Clinics Program 1984b] showed a dose-response
relationship between cholesterol reduction and coronary events: those individuals
who were able to tolerate the prescribed dose of cholestyramine experienced a
19% reduction in cholesterol and a 39% reduction in coronary events. The study
also documented significant reductions in secondary endpoints, such as
development of angina, new positive exercise tests and number of subjects
referred for coronary surgery.
The Helsinki Heart Study entry criteria were very similar to the LRC-CPPT, but
specified the elevation in cholesterol at baseline as non-HDL cholesterol, and the
trial attempted to test the efficacy of simultaneously raising HDL while lowering
non-HDL cholesterol [Frick et al 1987], 19,000 men were screened, and
randomised to gemfibrozil 1.2g or placebo if the non-HDL was persistently above
5.2 mmol/l and there was no clinical evidence of heart disease. Men with
hypertension and "mild" non-insulin-dependent diabetes were not excluded from
this study. Total cholesterol in the study group was lowered by 10%, non-HDL
cholesterol by 14%, and triglycerides by 43%; HDL-cholesterol increased over the
study period by a mean of 10%. Despite a dropout rate of 30% in both groups over
the five years of the trial cardiac end points were reduced by 34% from 4.14% to
2.73%, due to fewer nonfatal infarctions with no change in coronary mortality.
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Although the Familial Atherosclerosis Treatment Study was designed as an
angiographic study - and discussed further below (Sect 1.5.2) - it employed a
randomised design and described clinical endpoints in addition to the angiographic
changes [Brown et al 1990]. The subjects were included irrespective of their
personal history of vascular events, so included 45% with a history of previous
myocardial infarction. The authors randomized 146 men with elevated apoprotein
B levels, angiographic evidence of coronary disease, and a family history of
vascular disease to one of three treatment groups: combined colestipol and niacin,
combined lovastatin and colestipol, or placebo (or colestipol only if LDL cholesterol
above 90th percentile). LDL cholesterol fell by 32% while HDL rose by 43% in the
colestipol /niacin group, and changes for the lovastatin/resin group were 46% and
15% respectively. Treatment in one of the active arms reduced the incidence of
clinical events (death, myocardial infarction, or new ischaemia requiring peripheral
or coronary bypass or angioplasty) by 73% (p=0.01).
One multifactorial primary prevention study from Finland utilised drug therapy for
hyperlipidaemia (clofibrate or probucol) and hypertension when indicated, in
addition to advice about smoking, exercise, and diet. Despite a fall in predicted risk
from risk factor scores, the intervention group suffered more myocardial infarctions
and cardiac deaths [Miettinen et al 1985]. Follow up for ten years after the
intervention period has revealed progressively increasing cardiac deaths and total
mortality in the group allocated to special intervention compared with controls, and
that this adverse result is statistically significant [Strandberg et al 1991].
Clofibrate has featured prominently also in secondary prevention trials. In the
Stockholm Ischaemic Heart Disease Secondary Prevention Study consecutive
survivors of myocardial infarction were randomised to receive open clofibrate and
niacin or no lipid-lowering therapy [Carlson & Rosenhamer 1988]. Cholesterol was
reduced by 13% and triglycerides by 19%; there were significant reductions in
cardiac events, cardiac deaths and total mortality. A sizable subgroup of patients
with reductions in triglycerides of at least 30% experienced a 60% reduction in
CHD mortality. Interestingly in this study decrease in IHD deaths was directly
related to the degree of triglyceride lowering, but was not related to the decrease
in cholesterol levels.
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Two other trials of clofibrate therapy were carried out in the UK in middle-aged
men and women [Research Committee of SSP 1971, Group of Physicians of
Newcastle 1971], The former showed reduced mortality and combined events in
those with angina and in those with recent Ml with preceding angina; in the second
of these studies there were significant reductions in cardiac events and also in
total mortality. Although the degree of cholesterol-lowering in each study was
similar, in neither study was this related to the reduction in events.
The Coronary Drug Project, carried out between 1966 and 1975, assessed the
efficacy and safety of five different drug regimens in the secondary prevention of
coronary disease in 8341 male survivors of a myocardial infarction in 53 centres in
the US and Puerto Rico [CDP Research Group 1975]. The groups assigned to two
doses of oestrogen and that to dextrothyroxine were discontinued prematurely
because of adverse events, particularly adverse trends in total mortality. The
groups taking clofibrate, niacin or placebo continued to the planned end of the
study period, a mean follow-up of 6.2 years. There was no benefit in either active
treatment group with regard to overall mortality on study completion compared to
the placebo group, but patients in the niacin arm had a significantly lower
incidence of nonfatal myocardial infarction. A follow-up study nine years after
termination of the trial - initiated to detect any adverse trends prompted by excess
cancer mortality in the low-dose oestrogen group, and also the adverse results on
total mortality in the WHO clofibrate trial - revealed an 11% reduction in total
mortality in the niacin group compared to placebo (p = 0.0004) [Canner et al 1986].
Although compliance may have been a limiting factor in achieving the reductions in
cholesterol which had been anticipated in several of the trials, this was not a
feature of the POSCH Study (Program on the Surgical Control of the
Hyperlipidemias). They randomised 838 survivors of a first myocardial infarct to
either diet alone, or dietary instruction plus partial ileal bypass surgery, to test
whether the consequent cholesterol reduction would favourably alter coronary
mortality. In addition to serial coronary angiography, they reported on mortality and
cardiac events after a follow-up of 7 to 14.8 years. Despite reductions in total
mortality of 21% and in cardiac mortality of 27%, these failed to reach statistical
significance. The combined endpoint of coronary deaths and myocardial infarction
however was reduced by 35%, a result which is highly significant, the more so
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considering that by ten years 31.5% of the control group were taking lipid-lowering
medication [Buchwald ef al 1990],
Overview analyses of the randomised unconfounded trials involving cholesterol
reduction as the sole intervention both in secondary and primary prevention
studies show that a reduction in coronary heart disease of 21% has been
achieved, irrespective of the method used to reduce the cholesterol [SMAC Report
1990, pp 29-31], The intervention studies thus give results consistent with the
epidemiological data relating cholesterol levels to coronary disease, and help
provide evidence for a causal relationship.
1.2.1.4 Animal Studies
Atherosclerosis affects man to a much greater extent than other animals, at least
in part due to the greater cholesterol levels encountered compared to other
species. Several animal models have been studied in experimental
atherosclerosis, but many of these are limited by anatomical and metabolic
differences. Nonhuman primates appear to be the most suitable for study, and
readily develop lesions that are similar in structure and distribution to human
disease [Faggiotto & Ross 1984], Arterial lesions which are induced in rhesus
monkeys by feeding an atherogenic diet may be shown to regress when the diet is
altered to maintain the cholesterol level at a lower value [Clarkson et al 1984],
Studies in genetically hyperlipidaemic rabbits - metabolically resembling familial
combined hyperlipidaemia - which spontaneously develop atherosclerosis, have
shown that normalising cholesterol levels by administration of an HMG
CoA-reductase inhibitor almost completely prevents the development of disease
[La Ville et al 1989]. The extent of arterial disease in this study was shown to be
directly related to the concentration of LDL cholesterol.
1.2.2 The Association with High Density Lipoprotein
Several epidemiological studies have reported an inverse relationship between
serum HDL-cholesterol and cardiovascular events [Livshits et al 1989, Gouldbourt
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et al 1985, Castelli et al 1986, Heiss et a\ 1980, Simons 1986, Tyroler et al 1988,
MRFIT 1982, Hargreaves et al 1991, Assmann & Schulte 1992], This relationship
has been found to hold for men both with and without evidence of cardiac disease
at the time of recruitment [Pekkanen et al 1990, Phillips et al 1988], In some
populations the predictive value of HDL was higher than that for total cholesterol
[Livshits et al 1989, Nikkila et al 1990, Hargreaves et al 1991], and the HDL/TC
ratio has been shown to be of value in others [Gouldbourt et al 1985, Simons
1986, Nikkila et al 1990]. Within populations at high risk of coronary events the
lipoprotein fraction with the greatest predictive value is HDL [Manninen et al 1990].
Some studies reported a lack of a relationship [Keys et al 1984, Levy & Klimov
1987, Pocock et al 1986, Shaper et al 1985] between HDL and coronary events,
although in some cases this may be due to analytical differences [Gordon et al
1989], and the conclusions from one study were subsequently revised [Pocock et
al 1989], There are also reports which demonstrate no clear relationship between
HDL level and risk of coronary disease when comparing high- and low-risk
populations [Kesteloot et al 1985, Lewis et al 1978], and also a lack of risk
associated with reduced HDL levels in populations with low serum LDL [Robinson
& Williams 1979, Sacks et al 1975]. Amongst survivors of myocardial infarction,
one of the commonest dyslipidaemias is isolated low HDL, and this has been
found also in patients with desirable levels of total cholesterol undergoing coronary
angiography [Miller et al 1990].
There is a dichotomy in the effects of low HDL levels resulting from genetic causes
since Tangier disease is not associated with increased coronary risk [Schaefer et
al 1980], but both familial apolipoprotein A-l deficiency and apoC-l 11 deficiency
result in severe premature atherosclerosis [Norum et al 1982, Schaefer et al 1982,
Matsunaga et al 1991]. Some mutations in apoA-l are associated with low HDL but
not with increased atherosclerosis [Funke et al 1991], and other investigators
report very low HDL levels (< 0.38 mmol/l) without known genetic abnormality or
evidence of premature atherosclerosis [Rader et al 1993].
Comparisons with other species indicate that many animals that are resistant to
the development of atherosclerosis have HDL as the predominant lipoprotein, and
certain strains which are susceptible to diet-induced atheroma have lower levels
than those which are resistant [Chapman 1986, Lusis et al 1983].
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The effects of intervention with diet or drugs suggest that raising serum HDL may
be beneficial [Blankenhorn et al 1990, Manninen et al 1988, Levy et al 1984],
perhaps particularly for those with low HDL levels at baseline [Manninen et al
1990], although some agents which consistently lower HDL levels may have
antiatherogenic effects [Yamamoto et al 1986]. The infusion of homologous HDL
into cholesterol-fed rabbits however has been shown to reduce established
atherosclerotic lesions [Badimon et al 1990].
There are therefore several strands of evidence to suggest that high HDL levels
are protective, and have anti-atherogenic activity. However it is not a good
predictor of risk between populations, there is not a clear biochemical mechanism,
and genetic disorders resulting in low HDL levels are not universally associated
with increased risk of atherosclerosis.
1.2.3 The Association with Lipoprotein(a)
Lp(a) has been described as an independent risk factor for coronary artery disease
[Rhoads et al 1986, Rosengren et al 1990), although the associated risk may be
dependent on the co-existence of elevated LDL cholesterol [Armstrong et al 1986].
It has been shown to be less discriminating than apoB or apoA-l, but does explain
much of the association between parental history of ischaemic heart disease and
coronary risk [Durrington et al 1988]. There is evidence of a relationship between
the serum Lp(a) level and the extent of angiographically-defined coronary artery
disease [Armstrong et al 1986, Frick et al 1978, Dahlen et al 1986, Hearn 1990] -
including the development of disease in aortocoronary saphenous vein grafts [Hoff
et al 1988], and much to support an association with myocardial infarction [Dahlen
et al 1975, Rhoads et al 1986, Durrington et al 1988, Berg et al 1977, Kostner et al
1981]. In patients with heterozygous familial hypercholesterolaemia the median
level of Lp(a) was two to three times greater in those with symptomatic coronary
heart disease compared to patients without evidence of disease and the apo(a)
level was the most significant variable distinguishing between the groups [Seed et
al 1990, Wiklund et al 1990],
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1.3 LIPOPROTEIN METABOLISM
1.3.1 Absorption and Synthesis of Cholesterol
Cholesterol is a solid alcohol, and is the main sterol present in man. It is ubiquitous
in the tissues, being an integral part of cell membranes. It also serves as precursor
for steroid hormones and for bile salts, required for the absorption of fats and
fat-soluble vitamins. Thus every cell requires constant access to a pool of
cholesterol. This pool may be expanded from two sources: either preformed sterol
is absorbed from dietary sources, or the cholesterol is synthesized de novo from
acetyl-CoA in a variety of tissues, principally the liver (although almost all cells
retain the capacity for cholesterol synthesis).
The typical Western diet contains 0.2 - 1.0 grams of cholesterol per day, and 70 -
160 grams of fat which contains a high proportion of saturated animal fat, the
mean polyunsaturated:saturated fat ratio being 0.24 [Miettinen & Kesaniemi 1989].
In order to be absorbed cholesterol is solubilised by formation of mixed micelles,
which contain unesterified cholesterol, fatty acids, monoglycerides, phospholipids
and conjugated bile salts. 25 - 75% of the ingested cholesterol is absorbed
[Miettinen & Kesaniemi 1989], maximum absorption occurring in the middle and
terminal ileum [Stein 1987], After its absorption into the enterocyte, the cholesterol
is re-esterified within this cell and re-assembled into large chylomicron particles,
which enter the venous circulation via the lymphatic system [Dietschy & Wilson
1970],
Cholesterol absorption increases linearly with the dietary cholesterol (r=0.836, p <
0.001), but is negatively correlated with body mass index. There is also a strong
positive association with total fat intake, but no relationship between cholesterol
absorption and the P:S ratio [Miettinen & Kesaniemi 1989]. Fractional cholesterol
absorption was correlated with serum total cholesterol, LDL and HDL, although
only HDL2 cholesterol was significantly associated with absolute dietary cholesterol
absorption.
The requirements for cholesterol synthesis are very variable, and depend on the
intracellular cholesterol pool. When this is high, the synthetic enzymes are
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suppressed, particularly hydroxymethyl-glutaryl Coenzyme A reductase, the
rate-limiting enzyme in cholesterol synthesis. The synthetic rate is highly
dependent on the absorption of dietary cholesterol - a highly significant negative
correlation is observed (r = -0.643, p < 0.001).
Calculation of the regression equations show that for every increase of 1
mg/kg/day in absorption of dietary cholesterol, synthesis is reduced by about 2.2
mg/kg/day [Miettinen & Kesaniemi 1989], although the response is non-linear.
1.3.2 Structure of Lipoproteins
Since lipids are insoluble in plasma, their transport to the tissues where they are
required demands some hydrophilic adaptation. They are thus incorporated into
complex micellar structures consisting of an outer layer of water-soluble elements
- protein, phospholipid and free cholesterol - surrounding an inner hydrophobic
core of cholesterol esters and triglycerides. The lipoproteins consist of a series of
these structures, which continuously undergo hydrolysis and exchange
constituents both from the core and from the particle coat. The lipoproteins have a
distinctive composition, both in terms of their lipid content and the associated
apoproteins (See Fig1.5 - adapted from Stein 1987).
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Chylomicrons are large triglyeride-packed particles with small amounts of
cholesterol, phospholipid and protein. The proteins in the nascent particle, apo Al
and apo B, both differ from the mature forms found in the circulation. The apo Al is
secreted as a proprotein which has an attached oligopeptide which is cleaved in
the circulation [Bojanovski et al 1985]. The apo B differs from that of hepatic origin
in being only 48% of the molecular weight of the latter species (hence 'B48').
Immunological study shows that apo B48 represents the N-terminal half of apo B100,
so that the receptor-binding domain is absent [Hospattanker et al 1986]. On
entering the circulation the chylomicron rapidly acquires apoproteins C and E,
largely by transfer from HDL, which are vital for its metabolism [Havel et al 1973].
The liver secretes lipoproteins chiefly in the very low density range, the so-called
'VLDL' being the principal transporters of endogenously derived triglyeride.
Although these particles exist as a continuum, they may be separated into major
classes on the basis of their physical and chemical properties by their size,
electrophoretic mobility, or flotation density in a centrifugal field (Table 1 v).
Large VLDL (or 'VLDL 1') contains relatively more triglyceride than the smaller
species, and may undergo hydrolysis in the circulation to small VLDL ('VLDL 2').
Each has one apo B100 moiety associated with it, and also a significant amount of
apo C and apo E. The function of the C apoproteins appears to be as a cofactor
for lipoprotein lipase, and inhibiting the binding of VLDL to hepatic receptors. Apo
E exists as three major isoforms (E2, E3, and E4) and is essentially a ligand for the
B/E receptor.
Intermediate density lipoprotein ('IDL') are smaller particles than VLDL, contain a
higher proportion of apoprotein - more of which is apoB - and smaller amounts of
triglyeride. The density spectrum of 'low density lipoprotein' may be arbitrarily
subdivided into at least four subspecies of slightly varying composition and
metabolic behaviour. The associated apoprotein is virtually exclusively apoB, and
almost half of the composition of the particle by weight is esterified cholesterol.
While the formation and fate of LDL is reasonably well understood, less is known
about high density lipoprotein (HDL). It consists of small heterogeneous particles
which are rich in apoprotein Al and All, with small amounts of apo C and apo E.
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[TABLE 1v. PROPERTIES OF SERUM LIPOPROTEINS |
Measurement Chylomicron VLDL IDL LDL HDL
Hydrated density (g/ml) 0.93 0.97 1.003 1.034 1.121
Solvent density for <1.006 <1.006 1.006-1.019 1.019-1.063 1.063-1.21
isolation (g/ml)
Molecularweight (0.4-30)xE+9 (5-10)xE+6 (3.9-4.8)xE+6 2.75xE+6 (1.75-3.6)xE+
Diameter (nm) >70 25-70 22-24 19.6-22.7 4-10
Electrophoretic mobility Origin Pre-beta broad-beta beta alpha
It was found that the LDL of some individuals contained an antigen - Lp(a) - not
found in others [Berg 1963]. Further support that this was a distinct lipoprotein
species came with the description of an electrophoretic band moving between the
beta and prebeta lipoproteins [Dahlen et al 1975]. This lipoprotein has since been
widely investigated, and has been shown to consist of an LDL-like particle with an
associated apoprotein, apo(a) [Gaubatz et al 1983], thought to be linked to the
apoB-100 by a disulphide bond. Apo(a) exhibits structural homology with
plasminogen, consisting largely of repeating sequences of one of the plasminogen
kringles [Eaton et al 1987], Its average molecular mass varies widely between
individuals due to a series of genetic isoforms, and the expression of these
isoforms, at least in part, influence the serum concentration of Lp(a) [Utermann et
al 1987],
1.3.3 Metabolic Pathways of Lipoproteins
The 'remnant' of the chylomicron particle, having undergone hydrolysis by the
action of hepatic lipase and endothelium-bound lipoprotein lipase and exchange of
components with the circulating lipoproteins, is taken up by the liver by a receptor
protein, LDL receptor-related protein (LRP). This is thought to be specific for the
remnant particle, but is not yet fully established [Brown et a/1991]. This recognises
and binds the apoE (transferred to the particle with apoC from HDL) constituent of
the remnant particle, which is degraded within the hepatocyte lysosomes.
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Cholesterol derived either from exogenous or endogenous pathways may be
excreted in bile, stored within the cell, or secreted with triglycerides in VLDL. The
control of the secretion process is poorly understood, although there is some
evidence to show a degree of diurnal variation [Parker et al 1982] as well as
hormonal influences [Taskinen et al 1990]. Increased availability of fatty acids
(either dietary or newly-released from adipose tissue) determines the rate of
synthesis of triglycerides. VLDL is secreted as heterogeneous particles of varying
size and composition [Hamilton 1983], containing apoB-100 and also apoproteins
C and E which are augmented by transfer from HDL. Increased triglyceride
production results in the production of larger VLDL particles with an increased
triglyceride/protein ratio [Melish et al 1980],
VLDL catabolism is similar to that of chylomicrons in that they undergo hydrolysis
in the circulation by lipoprotein lipase using the same cofactor, apoC-ll. Studies of
radiolabeled apoB in VLDL indicate that the apoprotein moiety is associated with
a spectrum of particles, with the apoB being transferred progressively from VLDL.,,
(Sf 60-400) through 'VLDL,' (Sf 20-60) and IDL (Sf 12-60) to LDL [Berman et al
1978]. During this process triglyceride is released to the peripheral tissues by
lipolysis [Nilsson-Ehle et al 1980], but also exchanged for cholesterol ester from
HDL by the action of cholesterol ester transfer protein [Eisenberg 1985]. ApoC and
phospholipid from the surface of the VLDL also exchange with apoE from HDL
[Berman et al 1978], The formation of IDL from VLDL is analogous to the
metabolism of chylomicrons, and IDL particles are commonly referred to also as
'remnants'. A schema for lipoprotein metabolism is illustrated in Fig 1.6.
Both lipoprotein lipase and hepatic triglyceride lipase play a role in VLDL
metabolism. Studies in individuals with enzyme deficiencies show that the former
has a greater affinity for large, triglyceride-rich particles while the hepatic lipase
favours smaller VLDL. Thus patients with reduced lipoprotein lipase activity
accumulate large particles rich in triglycerides and smaller lipoproteins of greater
density disappear rapidly from plasma, while those with hepatic lipase deficiency
exhibit reduced clearance of small VLDL and IDL, with low LDL levels [Carlson et
al 1986, Demant et al 1988, Demant et al 1991],
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FIG 1.6 LIPOPROTEIN METABOLISM
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VLDL metabolism is also affected by the apoE component, which exists in three
distinct polymorphisms. These have differing affinities for the apo B/E receptor
sites, and this significantly alters the clearance rates of the lipoproteins [Demant et
al 1991]. This is best exemplified by type III hyperlipidaemia ('remnant
hyperlipidaemia'), in which individuals with E2/E2 genotype develop accumulation
of VLDL with a high cholesterol/triglyceride ratio.
Studies in most individuals show that a considerable proportion of the apoB in
VLDL does not complete the transformation into LDL [Packard et al 1984], due to
significant removal of VLDL remnants from the circulation. There appears to be
heterogeneity in the metabolism of the VLDL, with a greater part of the LDL being
derived from relatively rapid transformation of smaller VLDL [Demant et al 1988].
The weight of evidence suggests that LDL is formed mostly by the metabolism of
VLDL; it has been postulated that there may be direct hepatic synthesis of LDL,
and that this may be of importance in some hypercholesterolaemic states [Janus et
al 1980, James et al 1989]. As noted above, the density range of LDL
encompasses a number of subfractions separable by density gradient
ultracentrifugation and gradient gel electrophoresis [Krauss & Burke 1982, Griffin
et al 1990]. Elevated triglyceride levels and a predominance of VLDL1 appears to
give rise to an increased proportion of smaller, more dense LDL, while the more
bouyant LDL subfractions may arise from the metabolism of small VLDL.
The metabolic fate of LDL has been extensively investigated. Tracer kinetic studies
[Shepherd et al 1979, Kesaniemi et al 1983, Slater et al 1984] have shown that
most of the LDL is removed from the circulation by the apoB/E receptor [Goldstein
& Brown 1977], and that this is deficient in heterozygous familial hypercholesterol-
aemia and absent in the classical homozygous state. In normals the activity of this
receptor is closely regulated by the intracellular pool of sterols. Receptor
production and expression is increased when the requirement for cholesterol rises,
and is down-regulated (with HMG CoA reductase activity) when sterol pools are
replete [Clarke et al 1987], Since its discovery, a large number of different
mutations of the apoB/E receptor have been described which give rise to familial
hypercholesterolaemia [Hobbs et al 1992], Binding to the receptor may also be
impaired due to defects in the apoproteins [Innerarity et al 1990], with consequent
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reduction in receptor-mediated clearance. It is likely that minor alterations in
structure of either the receptor or its ligand account for some of the variation in
lipoprotein levels in moderate 'non-familial' hypercholesterolaemia.
LDL not removed by these specific receptors is catabolised by 'scavenger'
pathways by macrophages; it is thought these preferentially take up modified LDL,
since these cells have little affinity for native LDL [Goldstein & Brown 1977], An
increase in the proportion of LDL removed by this pathway has considerable
potential for atherogenicity [Steinberg et al 1989].
Lp(a) appears to be synthesised in and secreted from the liver. Little is known of
the influences affecting its synthetic rate, and the metabolic fate of apo(a) is not
known. The Lp(a) level in plasma is inversely correlated with the size of the apo(a)
protein, which is determined by the apo(a) genotype.
Nascent HDL particles are produced by the liver. The factors controlling this
process and the production of its apoproteins have not been elucidated. The role
of HDL in the transport of cholesterol and its interactions with the apoB-containing
lipoproteins is reviewed in 1.4.3.
1.3.4 Kinetic Studies of Lipoprotein Metabolism
Early attempts to study lipid metabolism employed labelled precursors and gave
information only about whole body turnover rates. More recently investigators have
employed exogenous labelling of apoproteins with regular sampling of blood
following re-injection to calculate the rate at which the isotope disappears from
plasma, the fractional catabolic rate (FCR), expressed as pools per day. Although
having been applied previously to lipoproteins, its potential was only appreciated
after the description of the synthetic and catabolic rates of LDL apoB in 1972
[Langer et al 1972] and the technique has since been used to investigate
lipoprotein kinetics in a number of different conditions.
The validity of the method has been rigorously examined, and assumes that the
labelling process does not perse alter the metabolism of the tracee, that the site of
catabolism is in rapid eqilibrium with the plasma compartment, and that the pool of
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the lipoprotein under study is in steady state. To date, it is generally accepted that
iodination of the protein moiety of lipoproteins does not influence the
immunological, electrophoretic or flotation characteristics, and does not affect the
properties on chromatography [Langer et al 1972, Eisenberg et al 1973, Kissebah
eta! 1982, Nestel efa/1983].
Labelling of LDL apoB with radioiodine by the iodine mono-chloride method
[Mcfarlane 1958] has shown that virtually all the radioactivity is associated with the
apoB. The radioactivity remains associated with the LDL fraction following
re-injection, and the plasma decay curve gives an estimate of LDL FCR. Since
VLDL contains significant quantities of other apoproteins (particularly C and E)
these also acquire some of the label. Following re-injection, the apoB is transferred
to other lipoprotein fractions while the non-apoB components are transferred
mostly to HDL. The specific activity of apoB however is calculated in each
lipoprotein fraction after subfractionation by density-gradient ultracentrifugation
and chemical separation of the apoprotein (see 3.1.1), so that all the radioactivity
detected is associated with apoB. In view of the heterogeneity of behaviour
observed within VLDL, VLDL1 and VLDL2 are labelled separately.
Most of the lipoprotein fractions display bi-exponential kinetics when plotted on
semi-logarithmic paper, and simple regression may be used to determine the lines
of best fit to the exponentials. The FCR can then be calculated by the method of
Matthews [Matthews 1957], This is however not adequate to analyse all the
relationships between fractions in VLDL metabolism, and the specific radioactivity
curves obtained may best be analysed by multicompartments! modelling which
generates a number of kinetic parameters to describe quantitatively the
metabolism of each of the fractions. The model was first proposed in 1975 [Phair
et at], and since then has increased in complexity as it has been adapted to
incorporate new experimental observations. The model used for the analysis in the
present studies is shown in fig. 3.15 (p 138).
In the modelling process each fraction is considered to consist of one or more
discrete metabolic compartments whose size is constant due to equilibration of
transfer rates into and out of the compartment. Transfer between compartments is
assumed to follow first-order kinetics, and can be described by a linear function:
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R(b,a) = L(b,a) x M(a),
where R(b,a) is the flux from compartment a to b in mg/day, L(b,a) is the rate
constant for this flux in pools/day, and M(a) is the mass of apoB in a (mg).
The shape of the appearance and decay curves determines the number of
exponentials required for a reasonable fit of the data. The total flux out of a
compartment is equal to the product of the mass and the sum of the individual rate
constants:
R(x,a) = [L(b,a) + L(c,a) + L(d,a)] x M(a)
The series of differential equations generated from the observed data can be
solved simultaneously using the SAAM (Simulation, Analysis And Modelling)
computer programme [Berman & Weiss 1978, Berman et al 1983]. This plots
calculated radioactivity curves by a 'least-squares' fit function; the individual rate
constants may then be adjusted manually to improve the approximation of the
observed and calculated data. When the sum of squares for the residual
differences between the data sets is achieved in this fashion, the programme will
further improve the fit in an iterative manner until the overall sum of squares
reaches a minimum value within the constraints imposed.
1.3.5 Effects of Intervention on Lipoprotein Metabolism
1.3.5.1 Effects of bile-acid sequestrant resins
Enhanced receptor-mediated clearance of LDL (increased LDL FCR) has been
described in heterozygous FH [Shepherd et al 1980] and in rabbits [Slater et al
1980] as a result of resin therapy. Other investigations in normolipaemic animals
[Witztum et al 1985, Fluff et al 1985] and in non-FFI individuals [Gaw 1992] have
failed to show increases in the catabolic rate. In the latter study, there was a
reduction in direct VLDL1 catabolism, increased synthesis and pool size of VLDL2,
decreased IDL apoB pool size, and a reduction in LDL pool size (due to reduction
in precursors and in total LDL synthesis, without significant change in LDL
catabolic rate).
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It had been thought that the upregulation of the LDL receptor resulting from
depletion of the intracellular sterol pool would be manifest in an increased FCR for
LDL. The LDL precursors however may also interact with the apoB/E receptor, and
the reduction in the IDL pool leading to decreased flux into LDL may explain the
apparent paradox.
1.3.5.2 Effects of HMG Co-A reductase inhibitors
Using the same methods in a similar group of patients with moderate
hypercholesterolaemia, it was shown that the reduced LDL pool size was
accounted for by an increase in direct catabolism of VLDL and IDL with reduced
LDL synthesis from its precursors as well as enhanced LDL FCR [Gaw et al 1993].
Earlier studies in FH also described the dual action of suppression of synthesis
and increased receptor uptake of LDL [Bilheimer et al 1983], and this has also
been seen in patients with non-familial (or 'polygenic') hypercholesterolaemia
[Grundy & Vega 1985]. Other reports however [Vega et al 1990] show no effect on
catabolism, but reduced VLDL apoB synthesis only.
1.3.5.3 Effects of a resin-statin combination
This powerful combination has been shown to normalise the cholesterol levels in
many patients with FH [Weisweiler 1988, Leren et al 1988, lllingworth 1984] and
result in regression of coronary disease [Brown et al 1990]. Kinetic tracer studies in
FH has shown the reductions in LDL to be attributed to increased LDL clearance
[Bilheimer et al 1983, Vega et al 1989], while the results in others show both
increased clearance and reduced synthesis [Grundy et al 1985]. Studies in non-FH
reveal the same heterogenous response as with the drugs used singly, but the
marked reduction in the LDL pool size was accounted for by a combination of
decreased production (particularly direct synthesis) and increased clearance [Vega
& Grundy 1987, Gaw 1992], There were also significant increases in HDL levels
but, as reported elsewhere, no alteration in Lp(a).
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1.3.5.4 Effects of a nicotinic acid derivative
Seven patients with non-familial hypercholesterolemia have been studied during
treatment with Acipimox [Gaw 1992], There was a reduction in pool sizes of
VLDL.,, VLDL2 and LDL; direct VLDL2 synthesis was increased, and there was
increased fractional transfer from this compartment to IDL and LDL. Direct
catabolism of IDL was increased, while direct LDL synthesis fell. The main
changes could be accounted for by reduced synthesis rather than alterations in
catabolism, and the reduction in transfer from IDL to LDL is consistent with the
known suppression of hepatic lipase by these agents.
1.3.5.5 Effects of LDL-apheresis
While the above studies can be performed while the subject is taking drug therapy,
the same techniques for studying metabolism are not usually applied during
apheresis treatment since the patient is not in a steady state. It has been shown
however that the marked abrupt change in plasma pool sizes did not alter the
clearance of LDL either in a normal volunteer or in an FH homozygote [Thompson
et a/1981].
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1.4 PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
As described above (1.1.2), atherosclerosis is a chronic process involving changes
in all layers of the arterial wall and much of the natural history of this process is
subclinical, manifest only in the final stages. Its relationship with several risk
factors is incontrovertible, although the pathogenesis remains incompletely
understood. It is clear from the epidemiological and clinical evidence that markedly
raised levels of low density lipoprotein cholesterol are neither necessary nor
sufficient to result in atherosclerotic disease. The putative initiating factors have
been reviewed in Sect 1.1.2, and the role of lipid factors in the progression of the
disease process will now be examined.
1.4.1 The Role of Low Density Lipoprotein
Although atherosclerosis consists of cellular and connective tissue elements as
well as a lipid component, and that in some lesions the first two may predominate,
the effects of lipid on the endothelium, monocytes, thrombocytes and smooth
muscle cells are of central importance to the process. It has been observed that
hypercholesterolaemia in animal models fed a high-fat diet leads within a few days
to attachment of large numbers of monocytes to the surface of the arterial
endothelium [Faggiotto et al 1984], These cells migrate to cellular junctions and
enter the subendothelial space, where they are converted into scavenger cells.
The lipid may enter the subendothelium in large quantities in the presence of
elevated plasma levels resulting within weeks in the establishment of fatty streaks.
The same process is observed in animals with more moderate lipid levels, albeit at
a slower rate [Masuda & Ross 1990a].
Some investigators have proposed another means by which elevated LDL levels
may predispose to endothelial dysfunction [Jackson & Gotto 1976]. They have
described an alteration of the viscosity of the endothelial cell membrane by
changes in the cholesterol/phospholipid ratio, resulting in the endothelium being
less malleable and more susceptible to cell retraction particularly at sites of altered
shear stress such as arterial bifurcations.
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Hypercholesterolaemia itself leads to alterations in normal endothelial function,
including impairment of production of endothelium-derived nitric oxide, even before
the formation of atherosclerotic lesions [Osborne, Siegman et al 1989, Zeiher et al
1991, Chowienczyk et al 1992], It may also stimulate the endothelial cells to
produce increased amounts of growth factor, particularly 'platelet-derived growth
factor' (PDGF), which binds avidly to cells derived from connective tissue, is a
highly potent mitogen and vasoconstrictor, and increases binding of LDL to cells
by increasing the number of LDL receptors [Heldin et al 1981, Grotendorst et al
1982, Ross et al 1986, Witte & Cornicelli 1980],
The fatty streaks continue to expand by the same processes of monocyte
adherence, subendothelial migration and lipid accumulation. As they expand, the
surface becomes more irregular while the intima is increasingly infiltrated with
smooth muscle cells which assume the characteristics of foam cells. After several
months of hypercholesterolaemia, retraction of the endothelium occurs at localised
areas overlying the fatty streaks, with a predilection for branch points and
bifurcations. The exposure of the underlying macrophages results in the
adherence of platelets and the formation of microthrombi, and ultimately the
fibrous cap [Faggiotto & Ross 1984, Masuda & Ross 1990b]. These plaques in the
animal model are indistinguishable from those found in human arteries. The
degree of change observed at various anatomical sites have been shown to
correlate with the level of plasma cholesterol and the duration of hyperlipidaemia
[Masuda & Ross 1990b].
It may be noted that the platelets themselves are altered in hypercholesterolaemia:
they are smaller, have an increased cholesterol/phospholipid ratio [Shattill et al
1977], exhibit increased TXA2 production, and are hyperaggregable with thrombin
and TXA2-mimetics [Gross et al 1991, DiMinno et al 1986].
While elevated serum levels of LDL are associated with accelerated
atherosclerosis, there exist several subclasses of LDL which can be differentiated
on grounds of size by gradient gel electrophoresis, or of density by density
gradient ultracentrifugation [Griffin et al 1990, Austin, Brunzell et al 1990, Austin,
King et al 1990]. These vary in composition, the small dense particles being
particularly enriched with cholesteryl ester. There is evidence that a
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preponderance of such particles increases the risk of coronary disease. Such a
subclass distribution is associated with raised serum triglycerides and
apolipoprotein B, raised VLDL and IDL mass, and reduced HDL-cholesterol, HDL2
mass, and plasma apolipoprotein A-l. This has been termed the 'atherogenic
lipoprotein phenotype' [Austin, King et al 1990] and may be inherited as a
single-gene trait.
1.4.2 The Role of Lipoprotein(a)
The physiological role of Lp(a) remains undetermined. In spite of the sequence
homology with plasminogen, evidence is lacking for a role in coagulation or
fibrinolytic pathways. Due to amino acid substitution the usual cleavage site of
plasminogen by streptokinase is unaffected [Eaton et al 1987], It does however
inhibit the binding of plasminogen to immobilised fibrin and fibrinogen, and impairs
the generation of plasmin by tissue plasminogen activator in the presence of fibrin
[Hajjar et al 1989, Harpel et al 1989, Rouy et al 1991, Loscalzo et al 1990], It also
impedes access of plasminogen to the endothelial cell surface receptors [Hajjar et
al 1989], and it has been suggested that it may induce plasminogen activator
inhibitor expression at this site [Etingin et al 1991].
It is clearly possible that Lp(a) may promote thrombosis and impair fibrinolysis at
atheromatous plaques, and thus be a risk factor for myocardial infarction. It may
also participate in atherogenesis by its binding to the fibrinogen of the evolving
plaque or to fibronectin, which is also present in early lesions [Mbewu & Durrington
1990]. Lp(a) has been demonstrated in biopsies from the aortic wall of patients
undergoing coronary bypass surgery; the quantity of apo(a) in the biopsies is
strongly correlated with the serum Lp(a) level, and elevated Lp(a) levels also are
associated with increased aortic deposition of apoB, most of which is co-localised
extracellularly with apo(a) [Rath et al 1989], Similar pathological findings have
been described in resected aorto-coronary bypass grafts, with co-localisation of
apo(a) and apoB in areas of atherosclerosis [Cushing et al 1989]. It has also been
shown that in this group the tissue apo(a)/apoB ratio is higher than the
corresponding plasma ratio, suggesting that Lp(a) has a propensity for deposition
in the vascular wall. In addition to binding to fibrinogen, it has recently been
demonstrated that Lp(a) may bind by a receptor to monocyte-derived
Introduction 54
macrophages [Zioncheck et al 1991], which is distinct from the apoB/E receptor
and probably also from the scavenger receptor, and this may represent a
significant route of entry into the vessel media. This is supported by evidence that
Lp(a) accumulates in plaques more readily than apoB not associated with apo(a)
[Smith & Cochran 1990],
In summary, Lp(a) is bound to fibrin at sites of vascular injury. It appears to be able
to traverse the endothelium, and may bind either to fibrin, the glycosaminoglycan
matrix [Bihari-Varga et al 1988] or to specific receptors on the macrophages.
Because of its binding in the subendothelial space, its residence time is prolonged
compared to LDL; this may enhance the likelihood of oxidative modification, with
the recruitment of other cells involved in the atherosclerotic process.
1.4.3 The Role of HDL
The widely held view of the function of the HDL fraction is the transport of
cholesterol from the periphery, including the arterial wall, to the liver via lipid
exchange with VLDL. This 'reverse cholesterol transport system' was first
suggested by Glomset and subsequently demonstrated in vitro [Glomset 1968,
Fielding et al 1983]. Cholesterol is taken up by HDL or apoA-l from macrophages
and other cells within the arterial wall and esterified by the action of lecithin
cholesterylacyl transferase, for which A-l is a cofactor. The apo-E-enriched HDL
particle may then deliver the cholesterol ester directly to the liver via the apoE
receptor, or may exchange the ester for triglyceride from VLDL by the action of
cholesteryl ester transfer protein [Tall 1986], the triglyceride then being removed
by lipases, allowing the HDL to take up further cholesterol in a complex series of
metabolic rearrangements [Franceschini et al 1991, Reichl & Miller 1989] (see Fig
1.6). This indirect pathway of transferring free cholesterol to the liver via lower
density lipoproteins appears to play a major role in humans, who have a high
concentration of LDL. However other pathways that operate in other species may
also do so in man, including individuals with familial CETP deficiency; such
individuals accumulate in plasma large, apoE-rich particles with high affinity for the
apoB/E receptor which can directly deliver cholesterol to hepatocytes.
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It is readily appreciated that a summary measure of the activity of this process is
elusive. Although it has been shown that most HDL particles probably efflux from
the arterial wall through the vasa vasorum and postulated that the
atherosclerosis-protective effect of high HDL levels is a function of the increased
flux of the HDL through the arterial wall [Nordestgaard et al 1990], this takes no
account of variation in function of the acceptor particles. For instance, the
peripheral mobilisation of cholesterol from the tendon xanthomata of patients with
familial hypercholesterolaemia treated with probucol [Yamamoto et al 1986] takes
place in the face of reduced HDL cholesterol, and is associated with an increase in
plasma CETP [Sirtori et al 1988]. In most circumstances however it does appear
that the inverse relation between HDL levels and the propensity to develop
atherosclerosis may be causal. This is further supported by animal experiments
demonstrating not only the inhibition of development of fatty streaks [Badimon et al
1989], but also the induction of regression in cholesterol-fed rabbits by the infusion
of homologous HDL [Badimon et al 1990].
Other possible anti-atherogenic roles have been proposed for HDL. Both HDL and
apoA-l inhibit the formation of aggregates of LDL - normally avidly phagocytosed
by macrophages - in response to vortexing or incubation with phospholipase C
[Khoo et al 1990]; it has been proposed that the high concentrations of LDL
present in the arterial intima, particularly at the site of lesions [Smith & Ashall
1983], might lead to LDL aggregates and that HDL may have a role at this site to
prevent their uptake by macrophages.
Certain classes of HDL may also directly inhibit uptake of LDL [Carew et al 1976].
Other workers have shown that HDL can prevent the oxidative modification of LDL
[Parthasarathy et al 1987, Klimov et al 1989], and ameliorate the cytotoxic effect of
oxidised LDL on vascular smooth muscle and endothelial cells [Hessler et al 1979].
The transmigration of monocytes induced by oxidative modification of LDL may be
abolished by HDL [Navab 1992], There is also considerable evidence for the role
of triglyceride-rich lipoproteins in the development of atherosclerosis (see 1.4.4),
and so it may be of importance that HDL inhibits the cytotoxicity of lipolytic surface
remnants to macrophages [Chung et al 1989].
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1.4.4 Role of Triglyceride-rich Lipoproteins
Most epidemiological studies have demonstrated a significant correlation between
serum triglyceride levels and incidence of coronary disease, but this usually
becomes non-significant on multivariate analysis after correcting for HDL levels
[NIH Consensus Development Panel 1993]. Recent studies have shown
triglycerides may be an independent predictor of coronary and total mortality for
women, and may be a weak risk factor for coronary heart disease also in men in
some populations [Carlson & Bottiger 1985, Lapidus eta! 1985, Tverdal efa/1989,
Stensvold et al 1993], Although triglycerides ceased to be an independent risk
factor in the PROCAM study [Assmann & Schulte 1992] after correction for HDL,
hypertriglyceridaemia indicated a substantial additional risk for those subgroups
with LDL-cholesterol > 4.9 mmol/l and LDL/HDL ratio > 5, the relative risk of a
triglyceride level above 3 mmol/l in the latter subgroup being 2.5. Similar findings
were documented in the Helsinki Heart Study, and treatment reduced CHD events
by more than 70% in this subgroup [Huttunen et al 1991]. Other groups have
however found an association between triglycerides and coronary disease only in
subjects with low cholesterol levels [Criqui et al 1993], and the place of serum
triglycerides in screening and in management of dyslipidaemias remains
unresolved [Garber & Avins 1994],
The severity of coronary disease assessed angiographically has been found to be
greatest in those patients with elevated triglycerides, low HDL-cholesterol levels
(particularly low HDL2 fraction) and low lipoprotein lipase activity [Breier et al 1989],
Another study showed a significant correlation between LDL-triglycerides and
angiographic severity of coronary disease in a group of Ml survivors, and that the
latter was also related to the degree of susceptibility to LDL oxidation [Regnstrom
et al 1992], Elevated triglycerides have been shown to be associated with the
formation of smaller, more dense LDL subfractions - which have a lower affinity for
the LDL receptor and which are more susceptible to oxidative modification - as well
as increased mass of very low density lipoproteins and decreased
HDL-cholesterol, HDL2 , and plasma apoA-l [Austin, King et al 1990, Griffin et al
1994],
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It is possible that the variability of the triglyeride levels and the heterogeneity of the
triglyceride-rich particles have combined to mask the association between
triglyceride levels and coronary heart disease. Certainly the strong inverse
correlation with HDL-cholesterol has consistently reduced the importance of the
triglycerides after statistical correction for HDL. Such statistical analyses have their
critics [Abbott & Carroll 1984]; the metabolism of the triglyceride-rich particles is
closely related to that of both LDL and HDL (see fig 1.6), and "to dismiss an
association between coronary heart disease and one class of lipoprotein on
statistical grounds ignores the fact that this may not be the way the arteries see it"
[Nestel 1990],
1.4.5 Role of Oxidative Modification
Atherosclerosis occurs in familial hypercholesterolaemia (FH) homozygotes at an
early age even in the absence of other risk factors because of the several-fold
increase in cholesterol levels, as it does in certain animal models [Goldstein et al
1983]. The lipid accumulating in the fatty streaks which initiate the formation of the
plaque does so within foam cells derived from transformed circulating monocytes
or from medial smooth muscle cells [Faggiotto et al 1984], It was recognised
[Steinberg et al 1989] that mechanisms other than the LDL-receptor were likely to
be involved, since receptor-negative homozygote FH patients and Watanabe
heritable hyperlipidaemic rabbits do develop foam cells; further, normal monocytes
and monocyte-derived macrophages in culture cannot be converted into foam cells
even with very high concentrations of native LDL [Brown & Goldstein 1983].
This alternative uptake of LDL was first described by Brown and Goldstein
[Goldstein et al 1979], demonstrating that chemically modified LDL could be avidly
taken up by a specific saturable receptor which did not recognise native LDL.
Subsequent work has established that such modification may be mediated by
endothelial cells, smooth muscle cells and macrophages themselves [Henriksen et
al 1981 & 1983, Morel et al 1984] and that cell-mediated oxidation results in
modified LDL which can be taken up by a high-affinity receptor distinct from the
acetyl-LDL receptor [Sparrow et al 1989]. Such modified-LDL have been shown to
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have reduced affinity for the LDL receptor, demonstrate chemotactic activity for
circulating monocytes, and are cytotoxic. A schema for the role of oxidised LDL in
the formation of foam cells has been proposed (Fig 1.7).
Foam cell
Steinberg et al 1989
i f
Fig 1,7 Role of oxidised LDL
Under normal circumstances oxygen metabolism generates only small amounts of
free radicals, and these are rapidly removed by serum and tissue antioxidants.
However the presence of hypoxia can accelerate oxyradical formation, overcome
local defence mechanisms and cause tissue damage [Crawford & Blankenhorn
1991]. Abnormalities of oxygen distribution may result from increased wall
thickness, abnormal wall composition, or increased metabolism, and experimental
evidence suggests that within the media or thickened intima there is a zone where
oxyradical production is favoured.
There is now increasing evidence that oxidation of LDL occurs in vivo and that the
resulting modified lipoproteins are involved in atherogenesis [Witztum & Steinberg
1991, Steinberg efa/1989]: antibodies against oxidised LDL show immunostaining
in atherosclerotic areas of rabbit aorta, but not in normal areas [Palinski et al
1989]; LDL extracted from human atherosclerotic lesions demonstrate the
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physical, chemical and biological properties of LDL oxidatively modified in vivo
[Yla-Herttuala et al 1989]; LDL from aortic lesions reacts with antibodies to
modified LDL [Palinski et al 1989, Yla-Herttuala et al 1989]; plasma from both
WHHL rabbits and humans contain antibodies to various forms of oxidised LDL
[Palinski et al 1989, Rosenfeld et al 1990]; anti-oxidants reduce the progression of
atherosclerosis in WHHL rabbits due to its inhibition of oxidation [Kita et al 1987,
Nagano et al 1989, Nagano et al 1992]; lipid peroxides in plasma are increased in
subjects with significant atherosclerotic disease [Stringer et al 1989]; the antibody
titres to epitopes of oxidised LDL may be an independent predictor of the
progression of atherosclerosis [Salonen et al 1992]; the susceptibility to oxidation
of low density lipoprotein is associated with severity of atherosclerosis in young
survivors of myocardial infarction [Regnstrom et al 1992]; and, antioxidants reduce
plasma lipid peroxides in hypercholesterolaemic patients [Paterson et al 1992].
The described cytotoxicity of the oxidised lipoproteins [Cathcart et al 1985] offers
one potential way in which the formation of subendothelial foam cells may lead to
the development of more complex lesions, since the oxidation products may cause
loss of the overlying endothelial cells. This would lead to the adherence and
aggregation of platelets, the generation of growth factors, leading to further
attraction of monocytes and recruitment and retention of other cells involved in the
growth of the plaque. Other post-secretory modifications may be as important as
oxidation and contribute to foam cell formation; for example, glycation in diabetes.
A schematic representation of some of the main factors believed to be involved in
the formation of atherosclerosis is shown in figure 1.8.
1.4.6 Interaction of Lipids with Other Factors
There are many individuals at risk of developing atherosclerosis without significant
abnormality of their serum lipid values. However if the final common pathway in the
initiation of the lesion is foam cell formation, factors other than hyperlipidaemia



























Fig 1.8 Development of atherosclerosis
Smoking is a powerful risk factor for cardiovascular disease [Kannel et al 1986,
Shaper et at 1985, Reid et al 1976], and its effects may not be limited to those who
choose to smoke [Hole et al 1989, He et al 1994], The adverse effects may be
seen in the earliest stages of the development of atherosclerosis [PDAY Research
Group 1990], and the increased risk of cardiac events persists for some years after
cessation [Robinson et al 1989, Rosenberg et al 1990]. Some studies however
show little increased risk in smokers, particularly in women [Skrabanek 1992],
Rats exposed to smoke inhalation have a reduced HDL level and increased
VLDL-cholesterol, similar to that seen in human smokers [Maida & Howlett 1990],
in whom these effects are reversed by cessation [Freeman et al 1994], In addition
LDL from smokers is more susceptible to oxidative modification, and contains less
antioxidant [Harats et al 1989, Scheffler et al 1990, Salonen et al 1991], although
thiobarbituric acid reactive substances (TBARS) are not different in plasma or LDL
in smokers compared to non-smokers. Peritoneal macrophages metabolise
labelled LDL conditioned by smooth muscle cells, this process occurring at twice
the rate when LDL is obtained from smokers [Harats et al 1989]. The reduction in
antioxidants may be, at least in part, attributed to differences in dietary intake
[Margetts & Jackson 1993].
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In addition to its effects on lipids, smoking may influence the atherogenic process
through influences on other factors. These include effects on clotting factors,
platelet function and plasma fibrinogen: smokers have increased platelet
aggregation and prolonged bleeding time [Meade et al 1987]; fibrinogen levels are
significantly higher than in non-smokers, and the levels may remain elevated for up
to five years after giving up [Kannel et al 1987], Fibrinogen has itself been
demonstrated to independently predict risk of cardiovascular events [Ernst 1991].
Smoking also affects the response to antihypertensive therapy, since treated
smokers have twice the mortality of non-smokers [Langford et al 1986], and
directly affects endothelial cell function as evidenced by the impaired production or
release of prostacyclin [Nowak et al 1987],
Hypertension is another major modifiable factor which is independently related to
the risk of cardiovascular disease [Kannel et al 1986, Shaper et al 1985, Reid et al
1976, Tverdal 1987], The lack of significant reduction in the incidence of
myocardial infarction or coronary mortality in the antihypertensive drug trials has
been both surprising and disappointing, and these trials and their implications for
management are summarised by Mclnnes [Mclnnes 1991]. It has been suggested
that the drug treatment of hypertension may actually contribute to atherogenesis,
and thereby explain the lack of reduction in coronary events in virtually all the
blood pressure-lowering trials; many of the agents used have a deleterious effect
on lipoprotein metabolism and it may be this rather than the hypertension per se
which is responsible for the lack of benefit in the treatment groups [Lardinois &
Neuman 1988, Freis 1989, Kaplan 1989].
Direct mechanisms by which hypertension contributes to the development of
atherosclerosis is not established. Increasing the transmural pressure in animal
aortas with intact endothelium leads to significantly greater deposition of labelled
LDL and decreases efflux from the wall [Curmi et al 1990] and this may be due to
increased endothelial permeability, or pressure-driven convection which is
supported by the uniform distribution of labelled albumin across the media at
higher pressures compared to the greater concentration of the larger LDL on the
luminal side of the media.
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More important than the pressure effects or the adverse effects of therapy may be
the metabolic abnormalities increasingly recognised to be associated with
hypertension. There is an increased incidence of hypertension in subjects with
hyperlipidaemia, and it has been shown [Williams et al 1988, Hunt et al 1988] that
familial hypertension may also be associated with either the fully expressed or a
partially expressed 'atherogenic lipoprotein phenotype' [Austin, King et al 1990],
discussed above in 1.4.1. This has been termed 'familial dyslipidemic
hypertension'.
It has been demonstrated that insulin resistance is a common finding in essential
hypertension, and that the degree of reduction in insulin-mediated glucose uptake
is proportional to the severity of the hypertension [Ferrannini et al 1987],
Interestingly therapy with thiazide diuretics or beta-adrenergic blocking agents
exaggerated these metabolic defects compared to untreated patients [Swislocki et
al 1989]. Insulin levels are not associated with blood pressure independent of body
mass index (BMI) or plasma glucose, but the simultaneous elevation of BMI,
glucose and insulin is strongly associated with blood pressure [Cambien et al
1987], These authors also showed a positive correlation between plasma insulin
and serum triglycerides and a negative association with HDL cholesterol which are
independent of plasma glucose and BMI, findings confirmed also in an elderly
population [Ostlund et al 1990]. In a recent study of European University students,
plasma insulin level was one of the factors which was found to be significantly
increased in offspring of men with premature myocardial infarction compared to
age- and sex-matched controls. An imbalance in the action of insulin and the
counter-regulatory hormones (as in the insulin-resistant state) have been
postulated to explain the effects of such diverse factors as diabetes, obesity,
hypertension, stress and altered lipoprotein metabolism on atherosclerosis and
their interaction [Brindley & Rolland 1989]. Interestingly, increased lipoprotein (a)
concentrations have been found in patients with impaired glucose tolerance, with a
five-fold increase in the proportion with levels > 30 mg/dl [Davies et al 1992],
Although a causal link is not established, the association may contribute to the
mechanisms whereby glucose intolerance may accelerate coronary disease.
There are a number of other 'minor' risk factors for atherosclerosis whose role is
incompletely understood. Some of these however do interact with lipids and a
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possible pathogenic role may be suggested. For example, the progression of
carotid atherosclerosis in men with elevated LDL levels may be accelerated in the
presence of high serum copper levels (which acts as a pro-oxidant) and reduced
serum selenium concentrations (which is a cofactor for glutathione peroxidase, an
enzyme which scavenges free radicals) [Salonen eta! 1991].
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1.5 REVERSIBILITY OF ATHEROSCLEROSIS
1.5.1 Experimental studies
The early recognition that lipid is one of the major components of atherosclerotic
lesions led to the search for suitable animal models for the disease. Anitschow
[Anitschow 1933] first demonstrated in rabbits that it was possible to regress
diet-induced atherosclerosis on withdrawal of the cholesterol-rich diet.
Subsequently many studies have confirmed these results in other vertebrate
models, including fowl [Horlick & Katz 1949], dog [DePalma et al 1977], swine
[Fritz efa/1976], and non-human primates [Clarkson et al 1984, Eggen efa/1987,
Wissler & Vesselinovitch 1990]. The disease which develops in these models may
vary in several respects from that in humans; such differences include the
propensity to develop spontaneous atherosclerosis, the sensitivity to the induction
of disease by diet, the distribution of disease in the aorta and involvement of
different calibre of arteries, and the histological appearances [Wissler &
Vesselinovitch 1989]. The non-human primate models develop lesions that closely
mimic the progressive human atherosclerotic disease, although the rabbit strains
which develop disease spontaneously are a useful model for human familial
hypercholesterolaemia.
Several studies using rhesus monkeys indicated that there is depletion of foam
cells and disappearance of extracellular lipid in animals fed an atherogenic diet
over a short period when cholesterol is then removed from the diet and plasma
cholesterol concentrations return to normal [Eggen et al 1974, Stary 1978]. Further
work demonstrated regression of established disease induced by fat-feeding over
a more prolonged period in both cynomolgus and rhesus monkeys, with reduction
in plaque size in both aorta and coronary arteries (Armstrong et al 1970,
Armstrong & Megan 1972, Armstrong & Megan 1975, Eggen et al 1987], although
some workers have found significant differences in resistance to regression
between the macaques [Wissler & Vesselinovitch 1990]. Disease which had been
established in rhesus monkeys even longer has been demonstrated to be partly
reversible: Clarkson and colleagues followed a 38-month period of atherosclerosis
induction with a low cholesterol diet for 24 - 48 months. They found that the
incidence and extent of regression was determined by the cholesterol level during
Introduction 65
the regression phase and also the length of this period [Clarkson et al 1984].
Intensive lipid-lowering therapy (using a combination of an HMGCoA reductase
inhibitor and a bile acid sequestrant resin) given over a shorter period of time was
found to induce regression of disease in Watanabe Heritable Hyperlipidemic
(WHHL) rabbits, an animal model deficient in LDL receptors and thus resembling
familial hypercholesterolaemia [Shiomi efa/1990].
In addition to the accumulation of lipid deposits, the atherosclerotic process
involves a loss of elasticity of the involved vessels [Blankenhorn & Kramsch 1989].
This is more difficult to measure, but is associated with increased collagen and
elastin [Greenwald & Berry 1978]; reversal of fibrous plaques in animal models is
associated with reduction of calcium, collagen and elastin [Kramsch 1985]. The
elasticity of the aorta - reflected by the aortic pressure pulse wave velocity - is
reduced in animals fed an atherogenic diet for a prolonged period, and this is
restored after cessation of cholesterol-feeding [Farrar et al 1980]. Similar
experiments indicate that the reversal of the sclerosis may be mediated by EDRF:
the intimal lesion formation reduces production or delivery of EDRF; an increase in
EDRF production by reduction of cholesterol may account for reduction in sclerosis
without the vessel architecture returning completely to normal [Harrison et al 1987,
Heistad et al 1987).
1.5.2 Evidence for Regression of Atherosclerosis in Humans
Observational studies of human autopsies suggested that subjects who had been
deprived nutritionally showed much less evidence of atherosclerosis than those
who had been well nourished [Vartainen & Kanerva 1947, Wilens 1947], There
was however no reliable means of assessing the extent of atherosclerosis in living
subjects until the development of angiography. Early attempts to demonstrate the
efficacy of cholesterol-lowering in man to induce regression of atheroma using
repeated angiography were disappointing. Favourable trends were seen in
non-randomised trials: nine of twenty-eight patients treated with hypolipidaemic
agents over a period of seven years showed no evidence of progression of
disease, while only one of thirteen untreated patients with coronary disease with
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similar risk factor profiles at baseline failed to progress over a five year follow-up
[Nikkila et al 1984], There was no evidence of regression in either group. In
thirty-nine patients treated by intensive dietary therapy in the Leiden Intervention
Trial, there was progression of lesions in twenty-one patients and stabilisation in
the remainder, the extent of progression being correlated with the mean lipid levels
during the period of intervention [Arntzenius et al 1985].
A randomised (but unblinded) study of femoral atherosclerosis in twenty-four
patients with claudication was described, with 10 patients treated with diet, niacin,
cholestyramine or clofibrate for an average of 19 months [Duffield et al 1983].
Treatment reduced LDL-cholesterol by 28%, triglycerides by 45% and resulted in a
rise of 41% in HDL. There was a significant reduction in the number of femoral
segments exhibiting disease progression by nonquantitative analysis but no
regression was seen, and the number of subjects in the trial was too small for
analysis by treatment group .
The first placebo-controlled double-blind angiographic study of lipid-lowering
therapy in coronary artery disease was performed in just 40 patients with
established disease [Cohn et al 1975], 16 of these were treated for one year, with
reductions of only 6% in total cholesterol and 16% in triglycerides. There was no
difference between the groups in the incidence of progression.
Early trials with larger numbers of subjects which were randomised, controlled and
double blind failed to show a significant treatment effect. The National Heart, Lung
and Blood Institute (NHLBI) Type II Study tested the effects of lipid-lowering
intervention with diet and a fixed dose of a resin against the effects of diet alone
[Brensike et al 1984], This showed a non-significant reduction in the number of
subjects with progression of disease and no difference in regression. This study
however was designed to detect differences in a study population of 250 subjects.
Only 143 were recruited, and of these only 116 underwent repeat angiography
through death, drop-out or refusal to complete the trial. In addition the angiograms
were analysed by a panel-reading method, which is less sensitive and less reliable
at detecting and quantifying changes in lesions than computerised methods
[Blankenhorn et al 1992, Reiber et al 1984). On the other hand the initial design
was for repeat angiography at 24 months, but this was changed to five years after
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the initial two-year angiograms failed to show any significant change. However
post-trial analysis showed a significant inverse relationship between HDL/LDL and
angiographic change when the subjects were analysed independent of treatment
group [Levy et al 1984],
Following these inconclusive results have been other studies which together
demonstrate convincingly that alteration of the serum lipids may result in
favourable changes in the angiographic appearances (Tables 1 vi and 1 vii).
The first of these was the Cholesterol-Lowering Atherosclerosis Study (CLAS)
which recruited 188 nonsmoking men between 40 and 59 years of age, who had
undergone coronary bypass surgery on average four years previously
[Blankenhorn et al 1987], Following a pre-randomisation assessment of their
tolerance to the study medication, they underwent coronary, femoral and carotid
angiography before being assigned to the treatment group (taking colestipol and
niacin) or placebo. The total cholesterol level before the trial ranged from 4.8 to 9.1
mmol/l, mean LDL-cholesterol was 4.4 mmol/l, and HDL 1.1 mmol/l. In the
treatment group there was an average reduction of 26% in total cholesterol and
43% in LDL, while HDL rose by an average of 37%. 162 subjects completed the
study and had repeat angiography after two years; these were assessed by
panel-reading. The treatment group showed significant reduction in progression of
disease in the native coronary arteries and in the percentage of patients with new
lesions in both the native arteries and the bypass grafts, and the coronary 'global
change score' showed regression in 16.2% of subjects in the treated group
compared to 2.4% in the controls and progression in 39% compared to 61%. The
benefits were observed for both those above and below a baseline total
cholesterol of 6.2 mmol/l. Subsequent analysis of a randomly selected number of
film-pairs by computerised quantitative methods confirmed the angiographic
benefits of treatment and showed a highly significant correlation between the
change in percent diameter stenosis by this method and the change in global
score obtained by the initial panel-reading [Blankenhorn et al 1992].
61% of the CLAS placebo group exhibited progression over two years compared
with a rate of progression in the placebo group of the NHLBI type II study of 49%
over five years. Thus it may appear that the differences between the CLAS groups
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were largely because of acceleration of disease in the placebo group rather than a
beneficial effect of treatment. However the patients in CLAS were nearly ten years
older, had more severe disease at entry, and did not appear to have mixed
regression and progression of lesions within individuals which complicated
interpretation of the NHLBI study. Follow-up for a further two years in a subgroup
of the original cohort showed a slight increase in the likelihood of regression in the
treatment group, and significantly more subjects exhibiting non-progression in the
treatment group compared to controls, with far fewer new lesions [Cashin-Hemphill
etal 1990],
Another angiographic study examined the effects of combination drug therapy in
patients with familial hypercholesterolaemia, mostly using a combination of niacin
and colestipol as in the CLAS study [Kane et al 1990], Differences from CLAS
include a lower average age (41.7 vs 54.2 years), higher lipid levels (9.65, 7.2, 1.3
and 1.38 mmol/l in Kane for TC, LDL, HDL and triglycerides respectively, vs 6.3,
4.4, 1.14 and 1.72 mmol/l in CLAS), inclusion of women and smokers, exclusion of
patients with previous revascularisation, and use of quantitative coronary
angiography as opposed to a 'global change score' by a panel of viewers. Of note
also is that only 3 of the 97 patients entering the study had symptomatic coronary
disease; there were however an average of 6.1 lesions per patient of greater than
10% area stenosis on visual inspection.
LDL fell by 38% in the treatment group, and HDL rose 28%, both effects being
smaller than those achieved in CLAS despite almost half of the treatment group
having lovastatin added to their drug regimen when this became available during
the course of the study. There was an overall reduction in the mean (per patient)
percent area stenosis in the treatment group in contrast to an increase in the
controls, the difference being statistically significant, albeit of small magnitude. The
changes in the lesions in the women were no different from that observed in the
male subjects. The change in the mean percent area stenosis was correlated with
on-trial LDL levels (r = 0.282, P = 0.018).
The St Thomas' Atherosclerosis Regression Study (STARS) was similar to the
NHLBI study in comparing the effects of diet plus fixed dose of cholestyramine
against diet alone [Watts et al 1992], and recruited 90 men with coronary heart
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disease and total cholesterol levels above 7.2 mmol/l. Although the diet was more
rigorous in STARS, the dose of resin used was 16gm compared to 24gm and the
period of intervention was three years rather than five. On the other hand, STARS
used a computerised method of evaluating the angiograms, and also included a
'usual care' group for comparison. The group treated by diet alone experienced a
fall of 14% in total cholesterol, 16% in LDL, and 16% in TC/HDL. The other
intervention group achieved respective reductions of 25%, 36% and 24%, while
there was no significant change in any of the serum lipids in the usual care group.
The mean width of the arterial segments decreased by 0.13 mm in the usual care
group, and was slightly increased in the other groups - by 0.01mm in the dietary
group and 0.08mm in the drug-treated group. Progression or regression was
defined by an overall measure of the change in mean arterial width of the segment
(MAWS) per patient of 2 SD, 46% of the control group being classified as showing
progression. There was a significant reduction in disease progression and more
patients exhibited regression in the treatment groups compared to the controls,
although there was no significant increase in regression when analysed by lesion.
Although some of the differences may be ascribed to the 'usual care' group being
older by 5 years on average, and that the mean diameter stenosis was lower in
this group compared to the intervention groups (while the "most striking changes in
diameter stenosis were seen in the worst affected segments"), there were highly
significant negative associations between the change in MAWS and the average
on-trial LDL and LDL/HDL ratio. In addition, despite the relatively small numbers in
the groups and the short intervention period there was a significant reduction in
total cardiac events in the intervention groups compared to the controls.
Two other recent studies investigating regression of coronary disease
angiographically have also shown a significant reduction in clinical events. The first
randomised 146 men at high risk for cardiovascular events because of family
history and elevated serum apolipoprotein-B levels into three treatment groups,
comparing a 'usual-care' group on diet +/- colestipol with two treatment groups
receiving either lovastatin and colestipol or lovastatin and niacin [Brown et al
1990]. Treatment was given over two and a half years, and resulted in reductions
of 46% and 32% in LDL and rises in HDL of 15% and 43% in the two active
intervention groups respectively. Progression of disease (taken as a 10-point
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difference in percent diameter stenosis) without evidence of regression was seen
in 46% of the conventionally treated group and in 21% and 25% of the
drug-treated groups; 11% of the usual care subjects showed regression compared
to 32% and 39% in the intensively treated groups (p for trend < 0.005). Regression
of lesions was independently correlated with a reduction in LDL cholesterol, a rise
in HDL and a fall in systolic blood pressure. Adverse clinical events (myocardial
infarction, revascularization or death) was reduced from 19.2% to 6.5% and 4.2%.
The second studied 838 survivors of myocardial infarction over 9.7 years, the
subjects being randomised to undergo partial ileal bypass surgery or to a control
group on dietary therapy only [Buchwald et al 1990]. Total cholesterol was 19%
lower in the intervention group, LDL 34% lower and HDL 6% higher at ten years
compared to the controls. Angiograms were analysed by a panel-reading method,
using the global score as used in the CLAS trial [Blankenhorn et al 1987]. Definite
disease progression was seen in 85% of controls at ten years and in 55% in the
surgery group while regression occurred in 3.8% and 6.4% respectively (P for
trend 0.0002). There were non-significant reductions in total and cardiac mortality
(the primary endpoints for the trial), while a significant reduction in total mortality of
36% was observed in a retrospective subgroup analysis of subjects with an
ejection fraction above 50% at baseline. There was a reduction of 35% when the
two endpoints of coronary deaths and nonfatal myocardial infarctions were
combined (p < 0.001), and also significant reductions in the surgical group in
subsequent coronary artery bypass grafting and coronary angioplasty.
The latter study also illustrates that the natural history of the atherosclerotic
process may be modified by the alteration of the lipid milieu irrespective of the
means used to accomplish this change. One group of investigators have studied
the short term effects of more comprehensive lifestyle changes, but without the
use of cholesterol-lowering drugs or surgery [Ornish et al 1990]. The programme
included a low-fat diet, aerobic exercise, relaxation techniques, and group therapy,
and the effects were analysed by quantitative angiography after one year. Total
cholesterol was reduced by 24% in the treatment group and 5% in controls (p <
0.02), LDL fell by 37% and 6% respectively (P < 0.01), while HDL fell by 3% in
each group (N.S.). Fat and cholesterol intake was drastically reduced in the
intervention group and was associated with a mean fall in body weight of 11.1kg
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(12.2%) in contrast to a rise of 1.4kg in controls. The analysis of the angiograms
per lesion indicates a reduction in the mean percent diameter stenosis by 2.2
percentage points in the treatment group and an increase of 4.4 points in controls,
this difference within one year of intervention in a small study population being
highly significant (P = 0.001). The changes in the angiographic appearances were
directly correlated with the "overall adherence score".
A further study employing only diet and exercise in men with coronary disease
divided the 113 subjects into a 'control' group, to receive the AHA-I diet and
exercise advice, and an 'intervention' group which followed the AHA-I 11 diet and
were given a group and home exercise programme. The differences in lipids
between the groups were modest, with a difference of just 12% in LDL, but
quantitative coronary angiography at one year showed a significant decrease in
progression in the more intensively treated group, with regression in 15% [Schuler
et a/1992].
The inclusion of diet and exercise was added to lipid-lowering therapy in the
'special intervention group' to achieve an LDL level of less than 2.85mmol/l in the
Stanford Coronary Risk Intervention Project (SCRIP), while the control group
received 'usual care' by their own physicians [Alderman et al 1991]. During the
four years of the study, LDL was lowered by 28% from baseline in the treatment
group compared to 9% in the controls; HDL rose by 14% compared to 7%, while
the respective reductions in triglycerides were 18% and 4%. The results were
analysed in the treatment group according to the LDL subtraction pattern (types 'A'
and 'B'): there was no difference in the treatment group between type A and type B
individuals in terms of the changes in LDL or HDL. However there was a 70%
reduction in serum triglycerides in the type B sub-group compared to just 10% in
the type A subjects. The 'usual care' group sustained a mean decrease of
approximately 0.035mm in mean arterial diameter of the diseased segments
irrespective of their LDL phenotype. There was no difference between the controls
and the degree of progression seen in the treated group when the latter were type
A, but the response in the treated type B subjects was significantly different both
from the controls and from the treated type A subgroup.
Introduction 72
The most recent angiographic studies to be reported have all used fixed dose
schedules of HMGCoA reductase inhibitors with control groups taking placebo and
diet. The Monitored Atherosclerosis Regression Study (MARS) treated 270
subjects (men and women) with at least one coronary lesion greater than 50%
diameter stenosis [Blankenhorn et al 1993]. Lovastatin in a dose of 40mg twice
daily for two years was compared with placebo. There was a reduction in LDL of
38%, triglycerides were reduced by 18%, and HDL increased by 7%. There was a
non-significant difference in minimum lumen diameter between the two groups.
'Regression ' was seen in 23% in the treatment group compared to 11 % of controls
(p = 0.05), while progression occurred in 47% and 65% respectively (p = 0.007). A
significant difference in minimum lumen diameters was seen between the groups
for those lesions > 50% at baseline.
The Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) also compared
lovastatin and placebo over a two-year period [Waters et al 1994], Although the
reduction in LDL was 29%, there was a significant improvement of 0.04mm in
minimum lumen diameter, with less progression and fewer new lesions. Neither
CCAIT nor MARS showed any significant reductions in clinical events.
The Multicentre Anti-Atheroma Study has recently reported the results of four
years of intervention with simvastatin 20mg or placebo in 381 men and women
with at least two-vessel coronary disease (and at least 5 coronary segments
suitable for analysis in two projections), and total cholesterol levels of 5.5 - 8.0
mmol/l. The study did not exclude smokers, but patients who had previously
undergone bypass surgery were not entered. Compared with placebo, the
treatment group had a mean reduction in total cholesterol of 23%, LDL 34% and
triglycerides 18%; HDL was increased by 9%. The mean lumen diameter per
patient decreased by an average of 0.02mm in the treatment group and 0.08 mm
in the controls (p < 0.05); there were also significant benefits of therapy on
minimum lumen diameter and percent diameter stenosis. There was no correlation
between the degree of change in the serum lipids and change in lumen diameter.
23% of the simvastatin-treated patients showed angiographic progression,
compared to 32% in the placebo group, while the proportion undergoing
regression was 18.6% and 12% respectively (combined p = 0.02). Only 1.8% of
lesions from both groups underwent > 15% decrease in diameter stenosis. There
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were no differences in clinical outcomes between the groups, although when
definite angiographic progression is combined with cardiac events and
interventions, there is a risk reduction with treatment of 29% (95% C.I. 5 - 47).
All these studies show a reduction in the progression of disease during long-term
treatment with the statins. Like MARS, STARS, and FATS, MAAS demonstrated
the greatest effects on those lesions with an initial diameter stenosis of greater
than 50%, although in the CCAIT the greatest benefit was in the less severe
lesions. Despite the larger numbers in the statin trials, the reduction in clinical
events seen in FATS was not replicated - although they were not designed to have
the power to show this.
The angiographic studies extend our understanding of the benefits of lipid
reduction documented in the primary and secondary prevention trials. They have
been regarded as a surrogate endpoint for clinical events by some, although in the
light of the statin trials, it is not certain whether clinical benefit will ultimately be
obtained in those who show the greatest angiographic change. They have
however shown that atherosclerosis may be stabilised in the majority of lesions in
individuals with moderate hypercholesterolaemia and that regression can occur in
a small number.




































































































































































































































































































































































































































































































































1.6 PLASMA EXCHANGE THERAPY AND LDL-APHERESIS
1.6.1 History and Development
Physical removal of cholesterol as a treatment for hyperlipidaemia was first
reported in 1967 [De Gennes et al 1967], In a patient with homozygous familial
hypercholesterolaemia a 40% reduction in plasma total cholesterol was achieved
by the removal of 400 mis of plasma every 2-3 days over some months. The
advent of continuous-flow cell separators made this a more practicable procedure,
and its use was demonstrated by Turnberg et al. (1972) for the treatment of the
hypercholesterolaemia of primary biliary cirrhosis. The principle was then applied
to the treatment of homozygous familial hypercholesterolaemia by Thompson et al
The extracorporeal circuit for continuous-flow plasma exchange is illustrated
diagrammatically in Figure 1.9. Venous blood is separated by centrifugation or a
hollow-fibre membrane separator; plasma is collected and discarded, to be
replaced by a suitable plasma substitute. This is most frequently 5% human
albumin solution, which has superseded the use of fresh frozen plasma and
plasma protein fraction because of the theoretical possibility of anaphylaxis or the











Fig 1.9 Continuous-flow plasma exchange :
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In view of the above drawbacks, the cost and limited availability of the replacement
solutions, and the non-specific loss of other plasma proteins (including HDL), more
selective techniques of LDL removal would seem preferable. Plasma lipoproteins
had been shown to adhere to glass powder [Carlson 1960], and Lupien et al
(1976) demonstrated the affinity of the apoprotein B-containing lipoproteins for
heparin-agarose. The principles of on-line blood separation were combined with
those of batch affinity chromatography to produce selective continuous removal of
LDL [Burgstaler et al 1980]. Subsequent additions to the circuit have included
regenerable affinity columns in series, with automated devices to divert the plasma
through each of the two columns in rotation [Mabuchi et al 1987], In this way the
volume of plasma treated may be almost infinite, although the rate of reduction in
plasma constituents will gradually diminish with increasing plasma volumes treated
(see Figure 1.10). One such system is illustrated in Figure 1.11 (p 79) [Kaneka
MA-01 circuit]: blood is obtained from venepuncture with a wide-bore cannula, and
separated by a membrane separator (or centrifugal cell separator). The plasma is
then pumped through the affinity columns, and the LDL-depleted plasma returned
with the cells to be re-infused.
1.6.2 Methods of LDL-apheresis
Immunoadsorption
Stoffel and Demant first described an in-vivo technique specific for apoprotein
B-containing lipoproteins in a swine model, preparing from the serum of sheep
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immunised against pig LDL anti- LDL antibodies which were bound to sepharose
[Stoffel & Demant 1981]. The method was adapted for clinical application using
monospecific anti-human LDL antibodies from sheep immune serum [Stoffel et al
1981]. The columns may be used in pairs, and desorbed off-line. Following
treatment, the columns may be stored under sterile conditions and re-used many
times without loss of adsorptive capacity.
Double Membrane Filtration
This technique was first described in 1980, but did not find clinical application for
six years [Mabuchi et al 1986]. After separation of the blood by the primary filter
which has an average pore diameter of 0.2 microns, the secondary filter with a
pore diameter of 0.03 - 0.06 microns fractionates plasma proteins according to
their size. A slight modification to the technique involves the use of a cell separator
instead of the primary filter.
Heparin Extracorporeal LDL Precipitation ('HELP')
Plasma obtained by filtration in this system is mixed continuously with heparin
which forms a precipitate with apoprotein B at low pH. The precipitate is filtered
out, and the filtrate passed through an adsorber to remove excess heparin before
being dialsyed to restore physiological pH and electrolyte balance [Eisenhauer et
al 1987], In addition to removing LDL, HELP also eliminates fibrinogen and C4, but
has no significant effect on HDL.
Precipitation with Dextran Sulphate
Dextran sulphate has been shown also to precipitate apoprotein B containing
lipoproteins; the dextran sulphate may be covalently linked to an inert matrix, such
as porous cellulose, and packed into columns through which plasma is pumped
[Yokoyama et al 1985], As in the system illustrated in Figure 1.11, two columns
may be employed alternately in an automated device with off-circuit regeneration
by hypertonic saline.
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Of the alternative methods available, the cheapest and most simple is the double
membrane (or, 'cascade') filtration. It is however the least selective, and has the
disadvantage of requiring protein replacement if performed at intervals of less than
two weeks. HELP is highly effective, and the removal of fibrinogen in addition may
well be advantageous. The system though is more complex, and the time required
to set up is greater. Immunoadsorption and dextran sulphate are also both highly
selective and appear equally effective. Immunoadsorption columns require more
time to prepare, and since they require to be re-used need more thought regarding
proper storage and sterilisation between treatments than the alternatives. The
dextran sulphate columns are presently available only as single-use devices; while
this ensures their sterility and reduces preparation time, it also makes them
expensive to use. Whichever method of removal is adopted, it is the degree to
which cholesterol is lowered and the interval between treatments which determine
the effects.
1.6.3 Effects of Apheresis
The rapid decrease in cholesterol levels produced by plasma exchange or
LDL-apheresis is followed by a comparatively slow rebound phase. The slope of
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the rebound curve of the plasma cholesterol is determined by its fractional
catabolic rate [Apstein et al 1978], which is uninfluenced by the rapid decrease in
LDL pool size [Thompson et al 1981], The mean cholesterol concentration during
repeated apheresis sessions may be calculated by integrating the area under the
rebound curve joining each set of post-treatment and pre-treatment values.
However this necessitates frequent blood sampling, and if the interval between
treatments is less than the time taken for the pretreatment value to be reached, the
arithmetic mean may be used as an approximation for the calculated average.
Very low time-averaged levels may be maintained by shortening the time interval
between treatments, although protein losses would limit this approach with the less
specific techniques such as plasma exchange or cascade filtration.
Treatment with double membrane filtration reduces total and LDL cholesterol by
approximately 55%. Complement components, fibrinogen, and immunoglobulins
are all significantly reduced. Similar reductions in total cholesterol are observed
during HELP treatment, but albumin and immunoglobulins are not reduced to the
same degree. Dextran sulphate and immunoadsorption have been reported to
reduce LDL cholesterol acutely by 54 - 80%, and time-averaged LDL by 40 - 70%.
HDL may be decreased by these methods by 10 - 20%, perhaps partly a dilutional
effect, although a time-averaged twofold rise in HDL has been documented
[Parker et al 1986]. This contrasts with the long-term effects of double membrane
filtration on HDL levels, which are reduced by about 15%.
No major side effects have been reported with any of the techniques described. All
have been associated with occasional chills, shivering and episodes of
hypotension in a small minority of treatments, but on the whole therapy has been
well-tolerated.
1.6.4 Clinical Benefits of Apheresis
Longterm effects of regular plasma exchange have been most striking in
homozygous familial hypercholesterolaemia, in which the progression of
atherosclerosis is usually inexorable. Exchange of 2 - 4 litres at 2-weekly intervals
over more than two years in two homozygotes resulted in a reduction of 45% in
mean total cholesterol, associated with reduction in tendon xanthomata and
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stabilisation of coronary lesions. Over the same period two other homozygotes
were treated monthly; they experienced a reduction in cholesterol levels of 33%,
but had an increase in pressure gradient across the aortic valve and no xanthoma
regression [Thompson et al 1980]. Thompson has shown an improvement in life
expectancy in homozygotes undergoing longterm plasma exchange compared to
untreated siblings: age at death of the untreated subjects was 17.7 year (SD 3.8),
compared to current age or age at death in the treated group of 25.7 (SD 3.7), p <
0.001 [Thompson et al 1989].
The manifestations of atherosclerosis have also been shown to improve by long
term weekly treatment with LDL-apheresis. In eleven subjects with familial
hypercholesterolaemia, xanthomata of skin and tendons resolved or were
significantly reduced [Borberg et al 1988]. After a mean of 35 months severity of
angina was significantly improved, associated with a mean increase in exercise
capacity of 48%. At angiography, of 23 stenoses identified in this group of patients,
10 showed evidence of regression while only one appeared to have progressed.
A larger series of patients with familial hypercholesterolaemia treated regularly by
LDL-apheresis and evaluated by interval angiography has recently been described
[Tatami et al 1992], These include 7 homozygotes, who had been treated for
several years and had undergone 2 coronary angiograms on average four years
apart. Although there are a number of methodological problems, the authors
document regression in a significant proportion of the lesions analysed, including
several in homozygous patients in whom the pre-apheresis LDL cholesterol
averaged 10 mmol/l.
Experience with plasma exchange therapy and LDL-apheresis has shown that it
may safely be carried out over prolonged periods. The acute perturbations in the
plasma lipids are profound, and there is a highly significant reduction from baseline
when this is applied regularly. It enables the maintenance of exceptionally low
plasma lipid levels, and its effects may be further augmented by the addition of
lipid-lowering drugs. It is well-established in the management of patients with
homozygous familial hypercholesterolaemia, and has proved of value also in
heterozygotes. Its application in non-familial hypercholesterolaemia has not been
examined previously.
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2.1 RATIONALE
Evidence for a possible threshold effect
2.1.1 Epidemiological evidence
The evidence linking the incidence of coronary disease, and particularly coronary
mortality, to serum total or low-density lipoprotein cholesterol is convincing and
consistent. Coronary heart disease and cholesterol are strongly correlated
between populations [Keys et al 1984] and within populations (see Sect. 1.2.1.1).
The table showing the 6-year age-specific coronary mortality from follow-up of
subjects screened for the Multiple Risk Factor Intervention Trial illustrates that the
relative risk for subjects in the top quintile are high compared to those with the
lowest serum cholesterol [Kannel et al 1986]. The curves however are clearly
non-linear (Fig 2.1), and the attributable risk between the first and the second
quintiles even among the men aged 55 to 57 years is only 1.7 deaths/1000. At
these levels of cholesterol there is virtually no increase in relative risk, including
among those with the highest absolute risk of cardiac death (ie. cigarette smokers
in the older age groups) unless significant hypertension is also present (see Table
2ii).
AGE No. Mean TC 6-vr CHD mortality (Der 10001
(mmol/l) TC < 4.7 TC 4.7 - 5.2 Q2/Q1 Q5/Q1
35-39 65,664 5.34 0.6 0.8 1.3 8.2
40-44 70,328 5.53 1.4 2.6 1.9 6.1
45-49 77,068 5.64 3.1 4.5 1.5 4.1
50-54 77,290 5.68 6.2 7.9 1.3 3.0
55-57 35,034 5.68 10.2 11.9 1.2 2.4
TOTAL 325,384 5.57 3.7 4.9 1.4 5.2
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TABLE 2ii. I
RATIO OF 6-yr CARDIAC MORTALITY IN 1st AND 2nd CHOLESTEROL
QUINTILES IN MEN AGED 46-57 YEARS BY SMOKING AND Bp QUINTILE
DIASTOLIC Bp
<76 76-80 81-85 86-91 >91
NON-SMOKERS 1.1 1.1 1.9 1.2 1.1
SMOKERS 1.1 1.0 1.0 0.8 2.3
Similar results are seen in the other large prospective epidemiologic studies
including the Framingham study [Kannel et al 1971], the British Regional Heart
Study [Shaper et al 1985], the Whitehall study [Rose & Shipley 1986], and a study
of Israeli civil servants [Gouldbourt et al 1985]. The latter two studies used death
from coronary heart disease as an endpoint, rather than incidence of coronary
heart disease. In the Whitehall study the relative risk of ten-year coronary mortality
was 1.9 in the top quintile compared to the lowest quintile, but only 1.2 for the
second quintile to the lowest. Fifteen-year follow-up of ten thousand men in Israel
(in whom the distribution of serum cholesterol levels was virtually identical to the
MRFIT screenees) showed that the relative risk of coronary death in this
population was not increased in either the second or third quintiles for total
cholesterol, although the follow-up period was considerably longer than in MRFIT
and the mean age at entry 50.6 years compared to 46.1 years. A later follow-up of
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this group at twenty-three years also confirmed this trend of slowly rising risk for
coronary mortality at low cholesterol levels and rapidly escalating risk with higher
levels, the curve rising only beyond the third decile (total cholesterol > 4.8 mmol/l)
[Goldbourt & Yaari 1990],
Although the relative risks between the study populations were very similar, the
absolute incidence of coronary mortality was greater in the U.S. than in Israel.
Other comparisons between populations have reported similar findings: predictions
of incidence of coronary disease in American men derived from regression
coefficients in Europeans (and vice versa) were highly correlated with observed
incidence, although there was a significant difference in absolute risk [Keys et al
1972],
Most of the epidemiological data accrue from observation only in men. Although
the absolute and attributable risks of serum cholesterol for coronary death is much
less in middle-aged women than in men, a similar curvilinear distribution is seen in
women with a relative risk of 1.2 for those in the second quintile and 1.8 for the
fifth (compared to 1.1 and 1.7 for men in this study) [Isles et al 1992, DJ Hole -
personal communication].
HDL Quartile TOTAL CHOLESTEROL QUARTILE
1st 2nd 3rd 4th
Men 1st 171 170 129 143
4th 22 131 87 109
Women 1st 94 76 126 131
4th 13 0 23 20
(Adapted from Wilson 1990)
HDL-cholesterol is also of considerable importance as assessed by
epidemiological data. Twelve year follow-up of the Framingham data show that for
women there was a statistically significant effect of HDL-cholesterol levels within
each quartile of total cholesterol [Wilson 1990] (Table 2iii). This inverse
relationship was strongest for those in the top quartile (total cholesterol 6.9-10.7
Description of the studies 85
mmol/l), with a relative risk of 6.6 for those in the lowest quartile of HDL compared
to those in the fourth. This trend was significant in men only for those in the lowest
quartile for total cholesterol [Castelli et al 1986, Abbott et al 1988].
Other studies - the Lipid Research Clinics (LRC) Prevalence Mortality Follow-up
Study, the LRC Coronary Primary Prevention Study, and MRFIT - which examined
separately the effects of HDL levels also demonstrate that crude coronary event
rates were generally highest in those with HDL-cholesterol below 1.04 mmol/l and
lowest in those with levels above 1.3 mmol/l for both men and women [Gordon et
al 1989].
The Israeli civil servants study [Goldbourt et al 1985, Livshits et al 1989] found
HDL to be a better predictor of cardiac mortality than total cholesterol, and that
describing the HDL as a proportion of the total cholesterol is the best of all the
parameters (see Table 2iv).
TABLE 2iv.
15-yr CHD RATE BY QUINTILES OF HDL and TC/HDL RATIO
INTILE HDL Cardiac mortality Relative risk
(mmol/l) (per 1000)
I <0.75 88 2.3
II 0.75-0.85 77 2.0
III 0.86-0.96 66 1.7
IV 0.97-1.11 46 1.2
V >1.11 38 1
TC/HDL Cardiac mortality Relative risk
ratio (per 1000)
I >7.1 99 3.7
II 7.1 -6.7 70 2.6
III 5.4-6.6 62 2.3
IV 4.3-5.3 45 1.7
V <4.3 27 1
Adapted from Gouldbourt 1985
In keeping with the other studies above, the TC/HDL ratio in the Israeli study was
of particular value in accurately predicting coronary events in the group with a
"normal" total cholesterol.
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The PROspective CArdiovascular Munster (PROCAM) Study screened 19 698
subjects for the prevalence of cardiovascular risk factors, and have followed
longitudinally 7220 men between 40 and 65 years who had no history of previous
myocardial infarction or stroke. 73 of the 2815 subjects who had completed four
years of follow-up to 1989 had sustained a non-fatal Ml or coronary death. The
single most predictive parameter was HDL cholesterol - more than 64% of those
who had a cardiac event had HDL below 0.9 mmol/l compared to just 18% of those
without cardiac disease. The relative risk was further enhanced by the substitution
of HDL with TC/HDL [Assmann & Schulte 1992],
2.1.2 Phylogenetic
With the exception of a few species with strains which may exhibit metabolic
disorders, man is virtually alone in developing atherosclerosis spontaneously. The
incidence of atherosclerotic disease is roughly inversely proportional to the
average serum cholesterol. Below a level of approximately 3.4 mmol/l, and LDL
below 1 mmol/l, the development of atherosclerosis is very uncommon.
2.1.3 Animal Studies
Many species can be induced to develop atherosclerosis in response to fat
feeding, although it is readily apparent that their lipoprotein metabolism and the
susceptibility to atherosclerosis differs significantly from man. Non-human primates
readily develop atherosclerosis on high-fat diets. The restoration of the normal diet
after the disease has developed affords us the opportunity to test the 'threshold
hypothesis', ie. that a particular level of cholesterol is required to consistently
achieve regression of established disease. One elegant study of regression in
diet-induced atherosclerosis was carried out by Clarkson and colleagues in rhesus
monkeys [Clarkson eta! 1984],
Those animals in which the TC/HDL ratio remained above 5 exhibited almost
universal progression of disease, whereas regression was the rule when TC/HDL
was lowered to 2.8 or less (Fig 2.2). Other studies in non-human primates have
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shown that regression will occur when the plasma cholesterol level is lowered
below 150 mg/dl (3.9 mmol/l) [Eggen et al 1987], although with significant
variability between animals when the atheromatous lesions are produced by
maintenance of moderately elevated lipid levels for prolonged periods. It is also of
interest that while the component of the lesion showing the greatest change is the
cholesteryl esters, both collagen and elastin in the plaques are also reduced
[Wissler & Vesselinovitch 1989, 1990],
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2.1.4 Intervention Studies
The plasma lipoprotein concentrations required to induce egress of cholesterol
from plaques in man is not known. A few studies have angiographically
documented reduced progression of disease in most lesions with a minority of
lesions undergoing regression, but none of the intervention studies previously
published have achieved the goals outlined in the above animal studies.
Nikkila demonstrated significant differences in the occurrence of progression
between subjects above and below the median cholesterol value (6.30 mmol/l),
and between those with HDL levels above and below the median (1.10 mmol/l)
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[Nikkila et al 1984], There were clear trends in lipid levels between subjects when
grouped for the degree of progression, (including LDL/HDL ratio) but the
correlation between proportional increase in luminal narrowing and lipid variables
was significant only for HDL-C (r = -0.36, p < 0.05). No regression was observed in
the treatment group in this uncontrolled study.
In the uncontrolled Leiden Intervention Trial there was a mean progression of
coronary lesions of 4.5 percentage points in diameter stenosis over two years (p <
0.001) despite a reduction in total cholesterol and TC/HDL ratio of 10% which was
achieved by diet alone [Arntzenius et al 1985]. There was however a significant
association between disease progression and the on-trial and baseline TC/HDL
ratio. Subjects with a baseline TC/HDL ratio below the median of 6.9 who reduced
this by at least 2% during the study had no evidence of disease progression. In
subjects with baseline TC/HDL above 6.9, those in whom TC/HDL was lowered by
13 percent to below this value had no progression whereas for those in whom this
parameter remained above 6.9 (even if it had been reduced by 8%) exhibited
decrease in mean luminal diameter.
Following adjustment for baseline inequalities between randomised groups in the
NHLBI Type II Coronary Intervention Study, there was a significant reduction in
progression of lesions greater than 50% stenosed at baseline in the intervention
group. Analyses which included all lesions showed trends in favour of the
treatment group, but overall these were non-significant [Brensike et al 1984],
Analysis of the relationship between changes in lipid values and likelihood of
progression however, demonstrate that the subjects with the greatest decrease in
TC/HDL ratio had progression rates of less than 50% of those with the least
decrease. The mean decrease in the TC/HDL ratio in the treatment group was
23% (from a mean ratio of 7.7 to 5.9).
In the other randomised placebo-controlled angiographic trial available before
commencement of this study [Blankenhorn et al 1987], the reduction in the serum
lipids were much greater than in previous studies and the on-trial lipids
approached the levels at which regression might be expected (table 2v).
Description of the studies 89
r \
ITABLE 2v. LIPID LEVELS DURING ANGIOGRAPHIC TRIALS
STUDY GROUP BASELINE LEVELS ON-TRIAL LEVELS % CHANGE
ID LDL HDL TC/HDL TC LDL HDL TC/HDL ID LDL HDL TC/HDL
NHLBI C 7.6 5.9 1.0 7.6 7.5 5.7 1.0 7.5 -1 -5 +2 -1
I OT—COCDOCO 7.7 6.6 4.6 1.1 5.9 -17 -26 +8 -18
CLAS C 6.3 4.4 1.1 5.6 6.0 4.1 1.2 5.2 -4 -5 +2 -6
I 6.4 4.4 1.2 5.5 4.6 2.5 1.6 3.0 -26 -43 +37 -47
C = Controls, I = Intervention group From Brensike 1984 & Blarkenhorn 1987
The angiographic results were not presented as correlations with changes in
serum lipids on an individual basis, but demonstrate a significant reduction in
coronary global score in the treatment group for both those above and below a
baseline total cholesterol level of 6.25 mmol/l. Despite the impressive reductions in
lipids maintained for two years, progression continued in 39% of the treatment
group (Table 2vi).
TABLE 2vi. OUTCOME OF ANGIOGRAPHIC TRIALS
STUDY GROUP No. No. (%) of SUBJECTS WITH :
REGRESSION UNCHANGED PROGRESSION
NHLBI C 57 4 (7%) 24 (37%) 29 (51%)
I 59 4 (7%) 31 (53%) 24(41%)
CLAS C 80 2 (2%) 29 (36%) 49(61%)
I 82 13(16%) 37 (45%) 32 (39%)
C = Controls, I = Intervention group
It cannot be concluded from the above that atherosclerosis in man will necessarily
respond to lipid lowering at the same levels as in the experimental models. Apart
from possible species differences, human disease is often far advanced before
resulting in symptoms and the lipid component may be less accessible due to
greater degrees of fibrosis and calcification. It remains unclear whether there is a
threshold for serum cholesterol (or TC/HDL) which requires to be achieved or
whether the extent of reduction is the more important - the NHLBI study did
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suggest a threshold for non-progression even when the TC/HDL ratio was reduced
to a greater extent in some individuals above that level than in others below it; on
the other hand the CLAS results demonstrate as much benefit for those at the
lower end of the cholesterol distribution as those with higher levels, and suggest
that the proportional reduction in lipids is of greater importance for the induction of
regression.
The central thesis of these studies is that the achievement and maintenance of
extremely low cholesterol levels (< 3.4 mmol/l) and TC/HDL ratio (< 2.8) will
increase the frequency of regression and stabilisation of human atherosclerotic
plaques than currently recommended targets for therapy (total cholesterol < 5.2
mmol/l) in this group. The importance of this goal is clear from the observation that
"patients whose lesions do not show progression have improved chance of
survival and lower rates of myocardial infarction" [Moise et al 1985].
These goals were applied in a group of patients with coronary disease and severe
hypercholesterolaemia in a pilot study in New York [Saal et al 1989]. The proposed
lipid levels were achieved in the majority of their subjects using combination drug
therapy and regular LDL-pheresis. The subjects reported an improvement in their
angina with universal improvement in objective exercise testing after treatment for
> 1.5 years, and without any serious adverse event in up to 4 years of therapy.
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2.2 DESIGN
2.2.1 Patient recruitment, selection and exclusion criteria
Participants in these studies were recruited from various sources within Glasgow
Royal Infirmary. The principal source was the pool of patients undergoing
diagnostic coronary angiography for investigation of angina. All of the patients in
our institution undergoing angiography had blood drawn for fasting lipoprotein
profile, and the angiograms of those with hypercholesterolaemia were reviewed.
Those with at least two significant stenoses in the major epicardial arteries and
who were deemed unsuitable for re-vascularisation procedures were considered
for the study, and this identified 15 of the 22 participants. I also identified
individuals attending the lipoprotein clinic with possible angina or with a bad risk
factor profile; if these patients had evidence of significant reversible ischaemia on
an exercise treadmill test, they were further investigated by coronary angiography
using the study protocol. In addition all patients attending the 'Chest Pain Clinic'
had fasting lipid levels checked, and those who proceeded to angiography
following a positive exercise test were investigated according to the study protocol.
Patients who had undergone coronary artery bypass surgery or angioplasty more
than 12 months previously were considered suitable.
The lipid levels were checked after a minimum of three months on a
low-cholesterol diet and on no lipid-lowering drugs. To be suitable the total
cholesterol had to be less than 10.5 mmol/l and above 7 mmol/l with a TC/HDL
ratio of at least 4.5, or above 6.5 mmol/l with a TC/HDL ratio exceeding 6. Fasting
triglycerides were required to be below 2.8 mmol/l. The patients - who had to be
below the age of 60 at the time of the baseline angiogram - were required to be
non-smokers or to have given up the habit at least six months before study entry.
The fasting blood sugar had to be less than 6.5 mmol/l, and there was to be no
evidence of renal or hepatic dysfunction. Other exclusion criteria included
uncontrolled hypertension, dysrhythmias, intractable cardiac failure, coagulation
disorders and any other condition which might limit life expectancy. An ejection
fraction less than 30% on ventriculography was considered unsuitable.
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2.2.2 Patients - Baseline Characteristics
Using the above criteria I identified 22 patients who were suitable, whose general
practitioner and cardiologist both agreed to their participation, and who gave
informed consent. They were aged between 37 and 60 years, and 20 of them were
men.
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The first twenty patients were allocated at random to one of the two treatment
groups. It had initially been intended to have a third group of patients to be
Description of the studies 93
assigned to 'usual care1, but the recruitment rate was much slower than planned
and time constraints prohibited extension of the recruitment phase.
2.2.3 Study protocol
The selection of the patients for the studies was performed if, following three
months on a cholesterol-lowering diet, the mean of at least two samples for
lipoprotein analysis fulfilled the criteria outlined above, the other entry criteria were
met and there were no grounds for exclusion. The proposed subjects were
required to consent to allocation to any of the three planned treatment groups, and
those who agreed to participate conditional on their allocation to any particular
group were excluded. Since those assigned to regular apheresis would require
regular venous cannulation, the ease of venous access was also considered at
this time before their consent to the study was sought. The patients then
underwent tracer studies of lipoprotein metabolism. During this time they were
required to complete 7-day weighed dietary records and undergo treadmill
exercise testing, bicycle ergometry and coronary angiography (if not performed
according to the study protocol within the previous three months).
Following assessment of the dietary records all the patients were instructed by a
qualified dietitian on a suitable diet to achieve their ideal body weight, restrict daily
intake of cholesterol to a maximum of 200 mg/day, the fat intake to no more than
25% of total calories, and maintain a polyunsaturated:saturated fat ratio greater
than 1.
The patients were then allocated to one or other of the treatment groups: one
group ('Group 1') was to maintain a time-averaged total cholesterol of 3.4 mmol/l or
below and a TC/HDL ratio of 2.8 (with a secondary goal of a time-averaged LDL
level of 1.5 mmol/l); another active intervention group ('Group 2') was to maintain
an average total cholesterol of 5.2 mmol/l (with a secondary goal of TC/HDL of 3.5
- 4.0), and a third to be assigned to 'usual care' without a defined lipid goal, the
treatment being prescribed by the patients' own doctor or cardiologist. This
process was random, in that the patients were not selected by age, sex,
angiographic results or lipoprotein levels. The first six patients to complete the
baseline tests were allocated to the lower treatment goal, since this was the
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maximum number of patients which could be readily accommodated weekly on a
single apheresis machine. The next six were allocated to the more conservative
goal, and it had initially been planned to have the third six allocated to 'usual care'.
This was abandoned when the recruitment rate failed to meet original
expectations, and the treatment allocation altered to have the remaining eight
subjects assigned alternately in pairs. According to this amended randomisation
schedule, patient #14 was to be treated by LDL-apheresis. Although ease of
venous access had been considered satisfactory at the time of study entry, regular
sampling during the tracer studies proved difficult. We attempted apheresis on a
single occasion in this individual, but failed to obtain satisfactory blood flow rates
despite repeated repositioning of the venous cannulae. Having undergone
extensive baseline investigation and prepared for regular intensive therapy, rather
than exclude him from the study he was assigned to the other active treatment
group. Patient #15 took his place in the apheresis schedule, #16 allocated as
planned to group 2, and the remaining pairs allocated alternately to each group as
planned.
The subjects in group 1 were commenced on weekly LDL-apheresis without
concomitant lipid-lowering drugs for four weeks to assess the effects of apheresis
alone in patients with non-familial hypercholesterolaemia. At the fourth treatment
they were commenced on either cholestyramine, or pravastatin, depending partly
on previous tolerance of the resin but also in order to compare their effects when
added to regular apheresis. For both treatment groups cholestyramine was
commenced at one sachet daily for the first week and increased by increments of
one sachet daily at intervals of one week, to an initial maximum of four sachets.
The pravastatin was initiated at 20 mg daily. After four weeks if the primary lipid
targets were not being maintained the dosages were increased (cholestyramine
gradually to eight sachets daily, and pravastatin to 40mg) and unaltered for a
further four weeks.
The other agent was later added to the first if one drug alone was insufficient, the
resin being added in increments of two sachets daily and the HMG CoA reductase
inhibitor at doses of 20, 40 and 80 mg. When 80mg of pravastatin was reached
together with the maximum tolerated dose of the resin, Acipimox (a nicotinic acid
derivative) was added incrementally until the serum goals were achieved.
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For the patients in group 1, LDL-apheresis was performed weekly using the
Kaneka 'MA-01' system (Kaneka Chemical Industries, Osaka, Japan) [Mabuchi et
al 1987], Blood is obtained by peristaltic pump following forearm venepuncture
with a wide-bore fistula needle, and the plasma separated by a polysulfone
membrane separator (effective pore size 200 microns). The plasma is then
pumped through one of two columns containing dextran sulphate covalently bound
to an inert cellulose matrix, the columns used in rotation and regenerated off-line
by rinsing with hypertonic saline. The lipoprotein-depleted plasma is then returned
to the patient with the blood cells (Fig 1.11, p 79). We attempted to treat
approximately 5000 mis plasma on each occasion.
Blood was taken before and after each apheresis session in the patients in group
1, although alterations in therapy were made at intervals of not less than one
month according to the recent trends. Lipoproteins were measured monthly in
group 2. For both groups therapy was adjusted throughout the study to maintain
the primary goals only as much as possible; further alterations were not made in
group 2 if the total cholesterol was 5.2 mmol/l or less even if the TC/HDL ratio was
higher than desired. Similarly in group 1, I aimed to achieve the time-averaged
LDL goal as much as possible, but adjusted therapy only on the basis of the total
cholesterol and TC/HDL levels. If these were exceeded after one month, the
patient was counselled appropriately by the dietitian or myself, and drug therapy
adjusted only if results after a further month remained above target levels.
The lipid goals were maintained for a period of two years. During this time the
response to the treatment was assessed subjectively by the completion of
questionnaires at intervals (the Nottigham Health Profile), and objectively by
exercise tests on the treadmill at 6-monthly intervals and by thallium scanning
once yearly. At the completion of the two-year period all the subjects underwent
repeat coronary angiography according to the study protocol, and after stopping
apheresis and drug therapy for one month had further tracer studies of lipoprotein
metabolism.
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2.2.4 Statistical considerations
The primary endpoint of greatest importance was the demonstration of a
significant difference in the proportion of patients in groups treated to different lipid
goals showing angiographic evidence of regression. The standard for comparison
was chosen to be the lipid goals widely recommended for the management of
patients with established coronary disease, and the expected proportion of
patients treated to this goal was estimated from CLAS data to be approximately
10%. The sample size required to show a 20% difference between the two
treatment groups in the proportion of patients demonstrating a reduction in the
global coronary score with 80% power on a one-sided test at the 95% level was
calculated to be 100. A 30% regression rate was felt to be the minimum worthwhile
to justify the more aggressive regime with extracorporeal therapy.
To achieve this recruitment a multicentre study was planned with colleagues in
four centres in the U.S., and the USSR Cardiological Research Centre in Moscow.
Regrettably the joint study did not proceed due to funding difficulties, and the
twenty Glasgow patients alone were studied. This number is clearly too small to
detect a significant difference between two active treatment schedules. It may
however be sufficient to establish the feasibility of such alternative therapy and to
demonstrate its safety in the treatment of individuals with advanced coronary
disease. It will also extend the lower limits of previously achieved lipid levels and
enable us to examine whether the relationship between the extent to which
cholesterol is lowered and the rate of disease progression continues to hold at
these extremes.
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3.1 EFFECTS ON LIPIDS AND LIPOPROTEINS
3.1.1 Methods of measurement
3.1.1.1 Lipoproteins
Plasma was collected from each subject (after a 14-hour overnight fast) from a
large antecubital vein with minimal venous occlusion, into disodium-EDTA
containers. This was spun immediately, and the plasma separated by pipette
leaving approximately 0.5 mis above the buffy coat. The plasma was stored at
+4°C and analysed usually within 24 hours, and always within 72 hours, of
venepuncture.
Triglycerides were measured in whole plasma using a colorimetric method
(Boehringer Kit No 704113), which utilises the following principle:
TRIGLYCERIDE + 3H20 GLYCEROL + 3RCOOH
GLYCEROL +ATP ^ GLYCEROL-3-PHOSPHATE + ADP
\






The resulting colour changes were then measured on a Hitachi 704 auto-analyser
at 505nm.
Lipoprotein classes were prepared by ultracentrifugation and selective precipitation
by standard methodology [Lipid Research Clinics Program Manual of Laboratory
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Operations, 1984], A 5-ml aliquot of plasma was overlaid with 2 mis of d 1.006 g/dl
density solution in a Beckman Ultra-clear tube which was capped and centrifuged
overnight at 4°C in a Beckman 50.4 rotor at 35000 rpm. VLDL were measured in
the supernatant in a standard volume, and the bottom fraction was transferred to a
volumetric flask and made up to 5 mis. The IDL and LDL in an aliquot of the
bottom fraction was then precipitated by a heparin/Mn2+ reagent and separated by
centrifugation in a Beckman centrifuge at 10000rpm for 30 minutes. HDL were
measured in the supernatant, and the cholesterol in the IDL-LDL fractions (density
range 1.006 - 1.063) calculated by subtraction of the VLDL- and HDL- from the
total cholesterol. Cholesterol was determined in each fraction by an enzymatic
colorimetric assay (Boehringer kit No 704121) according to the following principle:
CHOLESTEROL ESTERS + H2O CHOLESTEROL + RCOOH
CHOLESTEROL + O2 — 4-CHOLESTENONE + H 2O 2
2H2O2 + 4-AMINOPHENAZONE + PHENOL
4H20 + 4-(p-BENZO Q XJINONE-M ONO-IMIN0)-PHENAZONE
To calculate the 'time-averaged' lipoprotein levels during the period of apheresis I
have used the arithmetic mean of the post-treatment value from one week and the
pre-apheresis value of the following week. This may under-estimate the value
obtained by integrating the area under the individual rebound curve by about 10%
[Apstein et al 1972], but is a reasonable estimate and more readily calculated.
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3.1.1.2 Lipoprotein composition
The apoprotein B-containing lipoproteins were obtained by sequential ultra
centrifugation of plasma. 2 ml aliquots were adjusted to d 1.182g/ml by the
addition of 0.341g NaCI and placed on 0.5 mis d 1.182 g/ml solution in six
Beckman Ultra-Clear™ tubes before being overlaid with a discontinuous density
gradient using a Technicon Autoanalyzer II gradient-mixer (Technicon (Ireland)












The tubes were placed in the buckets of a Beckman swing-out SW40 rotor, and
centrifuged at 23°C in a Beckman L8-60 ultracentrifuge under conditions previously
described [Lindgren et al 1972], After removal of the top 1 ml containing the VLDL1
(Sf 60-400), the gradient was relayered with d 1.058g/ml solution and
recentrifuged. Further centrifugation steps yielded VLDL2 (Sf 20-60), IDL (Sf 12-20)
and finally LDL (Table 3i).




AW2t TOTAL W2t SAMPLE
mis
VLDL1 (60-400) 39 01:38 1.03x1000 1.03x1000 1.0
VLDL 2 (20-60) 18.5 15:41 2.12x1000 3.15x1000 0.5
IDL (12-20) 39 02:35 1.63x1000 4.78x1000 0.5
LDL (0-12) 30 21:10 7.52x1000 12.3X1000 1.0
✓
For each lipoprotein, the cholesterol content (esterified and free), triglycerides,
phospholipid and protein concentration was measured. Free cholesterol was
determined on a Centrichem Encore centrifugal analyser (Baker Instruments) by
an enzymatic colorimetric assay (Boehringer Kit No 310328) in which the first step
in the reactions outlined above resulting from the action of cholesterol esterase is
omitted. Esterified cholesterol was calculated by the difference of total less free
cholesterol. Phospholipid was determined by an enzymatic assay (Boehringer Kit
No 691844) on the Encore analyser which measures the liberation of choline by
phospholipase D. Total protein was measured in each fraction by the method of
Lowry [Lowry et al 1951]: suitable aliquots - adjusted for each fraction according to
the protein content to ensure the result lay in the middle of the standard curve: 400
pi for VLDL1, 300 pi VLDL2 , 50 pi IDL and 25 pi for LDL - adjusted to 0.4mls with
deionised water were mixed with 2mls of freshly-constituted working Biuret reagent
(100mls 2% Na2C03 in 0.1 M NaOH, 1ml 2% Na K tartrate in H20 and 1ml 1%
CuS04 in H20) to which had been added 1 pg/ml of sodium dodecyl sulphate
(Eastman Fine Chemicals) [Curry et al 1978]. To these samples were added 200 pi
Folin-Ciocalteu reagent (BDH) diluted 1:1 with deionised water, and immediately
vortexed. The standard curve in the range 0-100 pg/ml was prepared
simultaneously by taking duplicate aliquots of 0, 25, 50, 75 and 100 pi of a stock
human serum albumin standard (1mg/ml) adjusted to a final volume of 400 pi.
Quality control of the standards was assured by the routine inclusion of control
samples of human serum albumin, using 100 pi aliquots of 150 and 300 mg/l
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adjusted to a final volume of 400 pi. Absorbances were measured after 30 minutes
at 750nm on a Beckman DU-70 spectrophotometer; the regression line was
obtained after entering the data from the standard curve into a statistics software
package, 'Minitab' (Minitab Inc. 1989), and the protein concentration calculated. An
example of a curve is shown in figure 3.2; the coefficient of variation of protein
assay by this method was 7.1%, while the mean square of the correlation
coefficient for 62 curves was 0.9904 (S.D. 0.006).




The apo-B content of each of the fractions was derived from the difference
between the total protein content (method described above) and the TMU-soluble
protein [Kane et al 1975], 250 pi aliquots of each fraction were incubated with
equal amounts of warmed tetramethylurea (Sigma Chemical Co. Ltd, Poole,
Dorset). The precipitated apoproteins were discarded while 80 pi of the
supernatant obtained following centrifugation at 3000 rpm for 30 minutes were
subjected to a modified Lowry assay, in which the standards were made up to a
final volume of 400 pi with deionised water and 40 pi of TMU. The protein content
was then assayed by the method outlined above.
The mass of each of the components of the lipoprotein was calculated per 100mg,
and the proportion of each expressed as a percentage.
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The statistical analysis of compositional data poses particular difficulties. Standard
tests are not valid for their analysis since the proportions of the components are
subject to a unit-sum constraint, and different statistical techniques have been
developed to analyse such data. These have been utilised and validated in a
number of settings (such as geology and medical diagnosis) where statistical
models have been sought, and the techniques are expounded in a monograph on
statistics and applied probability [Aitchison 1986],
The methods employed reject the inadequacies of crude variances and
covariances, and formulates compositions as a covariance structure of logarithms
of ratios of components. The resulting 'compositional variation array' provides a
useful descriptive summary of the pattern of variability of the composition. Since
the apoprotein B is a subcomponent of the protein content, I have expressed the
compositions as consisting of five parts: free cholesterol (FC), cholesterol ester
(CE), triglycerides (TG), phospholipids (PL), and protein (P). The compositional
variation array then consists of a symmetrical 5x5 table, with the logratio means
displayed on the lower triangle and the logratio variances set out in the upper
triangular array:
FIG 3.3 THE COMPOSITIONAL VARIATION ARRAY
FC CE TG PL P
FC var{log(FC/CE)} var{log(FC/TG)} var{log(FC/PL)} var{log(FC/P)}
CE m{log(CE/FC)} var{log(CE/TG)} var{log(CE/PL)} var{log(CE/P)}
TG m{log(TG/FC)} m{log(TG/CE)} var{log(TG/PL)} var{log(TG/P)}
PL m{log(PL/FC)} m{log(PL/CE)} m{log(PL/TG)} var{log(PL/P)}
P m{log(P/FC)} m{log(P/CE)} m{log(P/TG)} m{log(P/PL)}
where m{log(x/y)} and var{log(x/y)} are, respectively, the mean and the variance of
logarithm of ratio of x:y.
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In addition to summarising a number of related compositions (eg., pre-treatment
and post-treatment) into a meaningful form, the format above is used to specify
matrices for subsequent analysis of the covariance structure. For ease of
visualisation, and comparison with previously published data, the crude means of
the components are also given, although not used for analytical purposes.
The compositions are converted from the format above into additive logratio
compositions and then analysed by multivariate statistical procedures, after
validation of the distributional assumption of logistic normality. The initial
hypothesis tested is that both the means and the covariances for the two
composition sets being compared are equal; if this is rejected at the 0.05 level, the
model (fig 3.4) calculates the maximum likelihood ratios for rejecting one or both of
the alternative hypotheses that either the means or the covariances are equal; the
null hypothesis - that the compositions are not different - is rejected only if this





FIG 3.4. LATTICE OF HYPOTHESES TO TEST
DIFFERENCES BETWEEN COMPOSITIONAL DATA
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Since the logratio cannot be calculated if one of the components is zero, some
device to replace these values is required. The zero values were substituted with a
value representing a fifth of the maximum rounding-off error for the measurement
of that parameter (see discussion, 3.1.3).
3.1.1.3 HDL Subtractions
Plasma concentrations of HDL2 and HDL3 were estimated by analytical
ultracentrifugation using a Beckman L8-70 centrifuge incorporating an ultraviolet
scanner, and an AnF rotor with double sector centrepiece [Shepherd etal 1984],
3.1.1.4 Lipoprotein(a)
Plasma Lp(a) was measured using 'Innotest Lp(a)', a commercially available kit
(Innogenetics SA, Belgium) [Dagen eta/1991]. This utilises a mouse monoclonal
anti-Lp(a) antibody, and a second (labelled with a peroxidase) sheep anti-apoB
polyclonal antibody which binds to the apo B moiety of the antibody/Lp(a) complex.
Inter- and intra-assay variances were 2.3% and 4.5% respectively.
3.1.2 Results
3.1.2.1 Serum Lipids
The baseline serum lipids for each individual were derived from a mean of at least
eight samples taken after an overnight fourteen-hour fast during the initial
apoprotein B turnover studies. Patients initially fulfilling the entry criteria (Sect 2.2)
on the basis of a mean of at least two lipoprotein profiles before commencing the
trial were included even if the results given in the table deviated slightly below
these criteria. There were no significant differences between the groups for any of
the parameters (Table 3ii).
The main determinant of the degree of reduction achieved acutely with apheresis
was the volume of plasma treated. The percentage reduction for successive
treatments was similar within each individual subject, but after the first week the
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VLDL,LDL and HDL are expressed as cholesterol concentration in mmol/l; TC and
TG are also in mmol/l, while TC/HDL and LDL/HDL are numeric ratios.
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inter-subject variation was also small. Pre- and post-apheresis lipid profiles were
obtained on a regular basis for the first weeks of treatment in six individuals
(#05-10). These show that the pre-apheresis total cholesterol (TC) and
LDL-cholesterol (LDL) were significantly reduced from baseline after just one
week, and that after week 3 there were no further significant changes in these
variables when apheresis was continued as sole therapy (Fig 3.5). The
time-averaged levels of TC and LDL after the first treatment fell by 41.7% and 51 %
to 4.6 and 2.85 mmol/l respectively (P < 0.001), with further significant falls after
the second treatment before reaching a new steady-state. There were no
significant changes in pre-treatment or time-averaged HDL levels with apheresis
alone, but acute reductions of up to 29% were observed.
Rebound curves were plotted from a number of treatment sessions in eight of the
patients undergoing apheresis. These show that the initial recovery in LDL levels
was rapid after the first 12 hours following apheresis, reaching 63% of the
pre-apheresis value by the third day, before the rate of rebound slowed. HDL
levels were little changed at the end of the procedure, but fell in the ensuing hours
before recovering rapidly (Fig 3.6).
Since none of the subjects achieved the primary lipid targets on apheresis alone,
drug therapy was added. Six patients were commenced initially on a resin - either
cholestyramine ('Questran' and 'Questran A', Bristol Myers-Squibb, Staines,
Middlesex, UK) or colestipol ('Colestid', Upjohn Ltd, Crawley, Sussex) - at
increasing doses. Compared to the results on apheresis alone, there was a steady
decrease in the pre-apheresis total and LDL-cholesterol which reached statistical
significance after four weeks, and resulted in a further reduction in time-averaged
LDL (Fig 3.7) as well as marked falls in TC/HDL and LDL/HDL. The remaining four
apheresis patients - together with two patients who had initially been commenced
on a resin which had been discontinued because of side-effects - were
commenced on pravastatin (Bristol Myers-Squibb, Princeton, New Jersey, USA).
This was associated with significant reductions in both pre- and post-apheresis
total cholesterol and LDL levels compared to results in steady-state on apheresis
alone, the additional reductions in pre-treatment TC and LDL being 20% and 25%
respectively and 29% for post-apheresis LDL (Fig 3.8).
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WEEKS ON APHERESIS
FIG 3.5. CHOLESTEROL LEVELS ON APHERESIS ONLY
Data represent means, with 7=0 the pre-treatment values (n=6).
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FIG 3.6. REBOUND OF LIPOPROTEINS FOLLOWING
APHERESIS THERAPY.
Data represent means of several apheresis treatments from 8 subjects
before introduction of lipid-lowering drug therapy.
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WEEKS ON APHERESIS + RESIN
No OF APHERESIS TREATMENTS
FIG 3.7. CHOLESTEROL LEVELS ON APHERESIS
AND BILE-ACID SEQUESTRANT RESIN
Data represent means, with 7=0 the apheresis treatment
immediately prior to introduction of resin (n=4).
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WEEKS ON APHERESIS + STATIN
No OF APHERESIS TREATMENTS
FIG 3.8. CHOLESTEROL LEVELS ON APHERESIS
AND HMGCoA REDUCTASE INHIBITOR
Data represent means, with 7=0 the apheresis treatment
immediately prior to introduction of pravastatin (h=6).
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None of the subjects achieved both primary lipid goals on apheresis alone. Of
those in whom a resin was used as sole adjunctive therapy, only one reached
these targets (patient #07), but he was unable to tolerate any of the resin
preparations due to gastric upset. Three subjects (#07, 08 & 09) consistently
achieved the primary goals on the addition of pravastatin to apheresis, the first two
of these also reaching the secondary objective of a time-averaged LDL level below
1.5 mmol/l. The remainder were commenced on combination therapy: the
introduction of a second drug reduced pre-apheresis total cholesterol from 5.51
mmol/l (SD 0.51), achieved with apheresis and a single agent, to 4.76 mmol/l (P <
0.001). This resulted in a reduction of the time-averaged TC to 3.4 mmol/l (Fig
3.9). Two subjects with familial hypercholesterolaemia required the addition of a
third agent, acipimox, a nicotinic acid derivative ('Olbetam', Farmitalia Carlo Erba,
St. Albans, Herts, UK). Although the percentage additional reductions achieved
were not of large magnitude, the triple drug combination permitted the
achievement of the TC target level in one subject (#05), and enabled the
other,(#06), to reach both primary goals and the secondary LDL goal rather than
only the TC level as achieved with the two-drug combination (fig 3.10).
A resin alone was sufficient to maintain the more conservative TC goal of group 2
in only one of those subjects; another one was maintained satisfactorily on statin
as sole therapy, while five required the combination of the two agents. The
remainder were not able to maintain the target cholesterol value despite treatment
with the maximum tolerated doses of these drugs, and to this combination
acipimox was added.
Seven of the nine patients to complete the study in group 1 maintained the total
cholesterol goal and eight the time-averaged TC/HDL goal for at least 50% of the
period of intervention. Eight maintained at least one of the primary lipid targets on
70% of occasions or more, including the first fourteen weeks (the mean time to
achieve the treatment goals). Six of these nine subjects averaged an LDL level of
1.5 mmol/l or less while on their optimal drug combination. Six of the patients in
group 2 maintained a total cholesterol of 5.2 mmol/l or less 50% of the time, and
this was achieved on at least 70% of occasions in five. The mean levels at
baseline and during intervention are illustrated in table 3iii and fig 3.11.
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WEEKS ON APHERESIS + TWO AGENTS
No OF APHERESIS TREATMENTS
FIG 3.9. CHOLESTEROL LEVELS ON APHERESIS
AND RESIN/STATIN COMBINATION
Data represent means, with 7=0 the apheresis treatment
immediately prior to the addition of a second agent (n=8).
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FIG 3.10a. EFFECTS OF DIFFERENT TREATMENT
REGIMENS ON CHOLESTEROL LEVELS IN SUBJECT #05
WITH FAMILIAL HYPERCHOLESTEROLAEMIA
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PRE-APH APH ONLY APH+PRAV APH+2DRUGS APH+3DRUGS
PRE-APH APH ONLY APH+PRAV APH+2DRUGS APH+3DRUGS
FIG 3.10b. EFFECTS OF DIFFERENT TREATMENT
REGIMENS ON CHOLESTEROL LEVELS IN SUBJECT #06
WITH FAMILIAL HYPERCHOLESTEROLAEMIA
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GROUP 1 GROUP 2
BASELINE ON THERAPY CHANGE BASELINE ON THERAPY CHANGE
mean (SD) mean (SD) mean mean (SD) mean (SD) mean
TC (mmol/l) 8.0(1.3) 3.2 (0.3) -59% 8.2(1.3) 5.38 (0.43) -34%
LDL (mmol/l) 5.8(1.2) 1.6 (0.2) -74% 6.2(1.1) 3.43 (0.45) -44%
HDL (mmol/l) 1.16 (0.23) 1.3(0.26) +12% 1.1 (0.15) 1.21 (0.2) +11%
TC/HDL 7.3(2.4) 2.5 (0.3) -60% 7.7(1.7) 4.59 (0.81) -40%
FIG 3.11 EFFECT OF INTERVENTION ON LIPID LEVELS
TCBSL TC LDLBSL LDL HDLBSL HDL TC/HDL BSLTC/HDL
*
= p < 0.05 vs baseline # = p < 0.001 Gp1 vs Gp2
**
= p < 0.001 vs baseline
3.1.2.2 Compositions of apoprotein B-containing lipoproteins
The crude averaged lipoprotein compositions are tabulated in table 3iv, and the
treatment groups at baseline compared in table 3v. The latter suggests that the
groups are well-matched at baseline, although the variability of the subjects'
compositions cannot be appreciated from the data in this format.
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TABLE 3iv. BASELINE LIPOPROTEIN COMPOSITION
FC
MEAN % COMPOSITION
CE TG PL TOT PROT APO B
VLDL1 2.54 14.40 57.83 14.86 10.37 6.23
VLDL2 5.84 25.66 33.21 19.40 15.89 12.69
IDL 8.49 37.10 11.19 22.20 21.03 17.60
LDL 10.04 37.75 4.67 20.19 27.35 23.85
TABLE 3v. BASELINE COMPOSITION BY TREATMENT GROUP
MEAN % COMPOSITION
FC CE TG PL TOT PROT APO B
VLDL1 GROUP 1 3.08 12.38 59.66 14.88 9.99 5.26
GROUP 2 2.05 16.22 56.18 14.83 10.71 6.91
VLDL2 GROUP 1 6.25 24.48 33.93 19.54 15.80 11.37
GROUP 2 5.47 26.72 32.56 19.28 15.97 13.61
IDL GROUP 1 9.28 35.24 10.61 23.14 21.73 15.29
GROUP 2 7.78 38.77 11.71 21.36 20.39 19.22
LDL GROUP 1 9.28 38.29 4.50 19.49 28.45 23.62
GROUP 2 10.73 37.27 4.82 20.83 26.35 24.04
The variation array of each lipoprotein from the two groups are contrasted in Table
3vi. These show that there are no marked differences between the groups either in
the logratio means or in the variances. Statistical analysis using the Behrens
Fisher iterative method [Aitchison 1986] confirmed there were no significant
differences.
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ITABLE 3vi. VARIATION ARRAYS FOR BASELINE COMPOSITIONS'
GROUP 1
VLDL1 FC CE TG PL P
FC * 7.52 5.03 4.29 5.99
CE -2.33
* 0.72 0.99 0.50
TG -4.08 -1.75 * 0.10 0.07
PL -2.65 -0.33 1.43 * 0.28
P -2.27 0.06 1.81 0.38 *
VLDL2
FC
* 0.11 0.10 0.08 0.14
CE -1.39 * 0.05 0.04 0.07
TG -1.72 -0.33 * 0.02 0.03
PL -1.17 0.22 0.55
* 0.07
P -0.95 0.44 0.78 0.22 *
IDL
FC
* 0.53 0.36 0.10 0.20
CE -1.39 * 0.05 0.28 0.12
TG -0.21 1.18 * 0.14 0.06
PL -0.98 0.40 -0.78 * 0.09
P -0.93 0.45 -0.73 0.05 *
LDL
FC * 0.18 0.14 0.04 0.08
CE -1.44 * 0.04 0.09 0.06
TG 0.70 2.14 * 0.07 0.06
PL -0.76 0.68 -1.46 * 0.08
-1.15 0.30 -1.85 -0.38 *
GROUP 2
FC CE TG PL P
* 6.06 4.50 4.60 5.23
-3.20 * 0.19 0.16 0.15
-4.50 -1.30 * 0.01 0.11
-3.17 0.04 1.33 * 0.09
-2.82 0.39 1.69 0.35 *
* 2.59 2.40 2.27 2.45
-1.98 * 0.11 0.05 0.07
-2.18 -0.20 * 0.02 0.04
-1.67 0.31 0.52 * 0.04
-1.47 0.51 0.71 0.20 *
* 0.08 0.20 0.05 0.05
-1.63 * 0.08 0.01 0.03
-0.41 1.22 * 0.08 0.07
-1.04 0.60 -0.63 * 0.02
-0.99 0.64 -0.58 0.05 *
* 0.05 0.16 0.02 0.13
-1.26 * 0.16 0.01 0.10
0.85 2.11 * 0.15 0.28
-0.68 0.58 -1.53 * 0.09
-0.89 0.36 -1.74 -0.22 *
Compositional analysis of the lipoproteins was performed on serum taken
immediately before and after apheresis on 59 occasions from patients #1-6. The
crude means and variation arrays are presented in Tables 3vii and 3viii
respectively. The changes in composition with apheresis are highly significant for
all the lipoproteins (P < 0.00001). The biggest change was in the proportion of free
cholesterol, which was greatest in the VLDL1 fraction.
Although the lipoprotein species appear distinct, and the compositions between
the classes at baseline were highly significantly different, the variation arrays for
VLDL1 and VLDL2 post-apheresis appear very similar. The lack of difference was
confirmed on analysis only between these two lipoproteins, and may be
attributable to the variances of the components in the post-apheresis VLDL2 being
rather higher than expected.
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ITABLE 3viii. VARIATION ARRAYS PRE- AND POST-APHERESIS \
UUUUIU-MJUUUWUUUUUUUWULIJUIJUUUUIJUUUUIJUUUUUUJUUUJUUU^^
PRE-APHERESIS
VLDL 1 FC CE TG PL P
FC * 9.70 6.75 5.64 6.53
CE -1.79 * 3.94 4.49 3.08
TG -3.93 -2.14 * 1.86 1.13
PL -2.52 -0.72 1.42 * 1.40
P -2.25 -0.46 1.68 0.26 *
VLDL 2
FC * 2.7 2.84 2.54 4.02
CE -1.86 * 0.16 0.09 1.12
TG -2.48 -0.62 * 0.05 0.99
PL -1.74 0.12 0.74 * 1.07
P -1.42 0.45 1.06 0.32 *
IDL
FC
* 2.78 2.06 1.39 1.60
CE -1.92
* 1.70 1.25 1.25
TG -1.10 0.81 * 0.22 0.23
PL -1.47 0.44 -0.37 * 0.05
P -1.59 0.32 -0.49 -0.12 *
LDL
FC * 0.33 1.22 0.12 0.28
CE -1.64 * 0.45 0.10 0.21
TG 0.56 2.20 * 0.89 0.99
PL -1.00 0.64 -1.55
* 0.12
P -1.26 0.38 -1.82 -0.27 *
POST-APHERESIS
FC CE TG PL P
* 1.04 1.54 0.95 0.83
-0.47 * 0.86 0.51 0.37
-0.55 -0.08 * 0.59 0.37
-0.46 0.02 0.09 * 0.3
-0.49 -0.02 0.06 -0.04 *
* 1.31 1.03 0.98 1.01
-0.46 * 0.13 0.14 0.14
-0.52 -0.07 * 0.02 0.01
-0.44 0.01 0.08 * 0.03
-0.44 0.02 0.08 0.00 *
* 1.05 1.09 0.99 1.06
-0.54 * 0.06 0.04 0.07
-0.47 0.08 * 0.02 0.04
-0.48 0.07 -0.01 * 0.04
-0.50 0.04 -0.03 -0.02 *
* 0.87 1.05 0.78 0.86
-0.39 * 0.17 0.01 0.01
-0.18 0.21 * 0.17 0.18
-0.30 0.09 -0.12 * 0.01
-0.35 0.04 -0.17 -0.05 *
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Compositional analysis was performed also on specimens taken at 12 months and
24 months in both groups, and these results are tabulated in Tables 3ix-xii. In both
treatment groups the two-year compositions of VLDL and IDL reveal a relative
reduction in esterified cholesterol, with an increase in the proportion of
triglycerides. The free cholesterol component is more affected at one year, but
appears to increase after further therapy. Compositions analysed on average two
months after withdrawal of therapy demonstrate no significant alteration from
pretreatment results, except for LDL (when treatment groups are combined),
although there is no significant change in the LDL composition at two years
compared to baseline. As expected there were differences in composition after
therapy was discontinued compared to the two-year specimens, except in VLDLr
In LDL, the contribution of total cholesterol was virtually identical to that on
treatment and beforehand, but a greater proportion was present in the
non-esterified form.
This impression from the data is confirmed by analysis of the amalgamation
matrices of LDL when free and esterified cholesterol are combined (Table 3xiv). By
contrast, the compositions of VLDL2 and IDL at two years remain significantly
different from baseline even when the cholesterol components are amalgamated.
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TABLE 3xi. VARIATION ARRAYS DURING TREATMENT
GROUP 1
12 MONTHS 24 MONTHS
VLDL 1
FC CE TG PL P FC CE TG PL P
FC
* 9.04 8.66 8.16 9.64 k 0.72 0.44 1.47 0.44
CE -2.1
k 5.64 4.83 5.82 -0.1 k 0.09 0.99 0.09
TG -4.8 -2.7
* 0.32 0.19 -0.3 -0.3 k 0.74 0.00
PL -3.5 -1.4 1.28
k 0.41 -0.1 -0.0 0.22 * 0.69
P -3.1 -1.1 1.65 0.37
k -0.1 -0.1 0.19 -0.0 *
VLDL 2
FC
* 0.19 0.10 0.06 0.05 * 0.47 0.11 7.10 0.08
CE -1.4
k 0.16 0.06 0.14 -0.8 k 0.23 8.75 0.23
TG -2.2 -0.8
k 0.04 0.04 -1.9 -1.1 * 7.93 0.02
PL -1.4 -0.0 0.79
* 0.03 -0.2 0.60 1.64 * 7.31
P -1.4 0.01 0.83 0.04
* -0.8 0.01 1.06 -0.6 *
IDL
FC
* 5.13 4.02 4.49 4.26 k 0.41 0.26 7.46 0.18
CE -2.4
* 0.15 0.05 0.20 -1.5 * 0.25 8.80 0.13
TG -2 0.42
* 0.05 0.07 -0.9 0.62 k 7.70 0.18
PL -2 0.43 0.01
* 0.07 -0.2 1.33 0.72 k 7.10
P -2.2 0.17 -0.3 -0.3
k -1 0.45 -0.2 -0.9 *
LDL
FC
* 8.42 9.36 8.6 7.41 k 0.26 0.77 0.28 0.21
CE -3.3
k 0.05 0.10 0.09 -1.6 k 0.20 0.07 0.02
TG -1.4 1.86
k 0.04 0.15 0.32 1.88 * 0.18 0.28
PL -2.6 0.68 -1.2
k 0.13 -0.9 0.62 -1.3 k 0.07
P -3 0.26 -1.6 -0.4
k -1.2 0.33 -1.6 -0.3 *
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TABLE 3xii. VARIATION ARRAYS DURING TREATMENT
GROUP 2
12 MONTHS 24 MONTHS
VLDL 1
FC CE TG PL P FC CE TG PL P
FC
k 1.23 0.90 0.91 0.98 * 0.72 0.25 0.22 0.17
CE -0.5
* 0.03 0.03 0.02 -0.8 * 0.24 0.23 0.43
TG -0.6 -0.2
k 0.00 0.01 -2.8 -2 * 0.05 0.09
PL -0.5 -0.0 0.15
k 0.01 -1.5 -0.7 1.28 k 0.08
P -0.4 0.03 0.18 0.04
k -0.90 -0.1 1.89 0.61 k
VLDL 2
FC
* 0.15 0.16 0.05 0.02 * 0.42 0.27 0.24 0.16
CE -1.5
k 0.34 0.10 0.07 -1.5 k 0.07 0.05 0.13
TG -2.1 -0.6
k 0.08 0.18 -2.1 -0.6 * 0.05 0.04
PL -1.4 -0.1 0.67
k 0.04 -1.5 -0.0 0.60 k 0.09
P -1.2 0.26 0.85 0.17
* -1.1 0.33 0.94 0.34 k
IDL
FC
* 0.13 0.14 0.08 0.23 * 0.37 0.37 0.24 0.18
CE -1.7
k 0.01 0.02 0.04 -1.8 k 0.11 0.03 0.12
TG -1.2 0.57
* 0.01 0.04 -1 0.84 * 0.12 0.15
PL -1.3 0.45 -0.1
* 0.07 -1.3 0.49 -0.4 k 0.14
P -1.4 0.37 -0.20 -0.1
k -1.20 0.62 -0.2 0.14 *
LDL
FC
k 0.13 0.35 0.09 0.18 k 0.19 0.24 0.12 0.10
CE -1.9
* 0.16 0.01 0.05 -1.7 * 0.09 0.02 0.02
TG -0.2 1.74
k 0.13 0.09 0.35 2.04 * 0.08 0.07
PL -1.3 0.69 -1.1
* 0.05 -1 0.65 -1.40 * 0.02
P -1.7 0.21 -1.5 -0.5
* -1.3 0.36 -1.7 -0.3 k
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TABLE 3xiii. COMPOSITIONAL CHANGES (GROUPS COMBINED)
FC CE IG PL PROT APO B P P vs
BASELINE
V1 2.54 14.40 57.83 14.86 10.37 6.23
vs 2-yr pre-Rx
V2 5.84 25.66 33.21 19.40 15.89 12.69
IDL 8.49 37.10 11.19 22.20 21.03 17.60
LDL 10.04 37.75 4.67 20.19 27.35 23.85
1 YR
V1 1.94 10.77 60.12 16.08 11.09 7.63
V2 4.68 19.87 39.66 18.67 17.12 14.33
IDL 5.40 31.30 19.13 19.91 24.26 21.48
LDL 5.21 38.38 6.48 19.39 30.54 28.56
2 YR
V1 4.18 8.12 61.88 16.55 9.26 5.11 N.S.
V2 6.09 18.49 40.55 19.98 14.90 11.38 < 0.001
IDL 7.15 34.81 16.97 20.86 20.20 17.95 < 0.001
LDL 8.11 38.43 5.75 20.47 27.24 24.58 N.S.
POST-Rx
V1 4.40 9.84 59.36 17.39 9.02 5.36 N.S. N.S.
V2 7.22 23.15 34.93 20.28 14.41 11.61 < 0.05 N.S.
IDL 8.71 37.78 11.45 22.64 19.43 18.36 < 0.001 N.S.
LDL 12.71 34.98 4.66 21.45 26.20 22.78 0.001 < 0.05
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TABLE 3xiv. VARIATION ARRAYS FOR AMALGAMATED COMPOSITIONS
BASELINE 2 YR POST-Rx
VLDL2 TC TG PL PROT TC TG PL PROT
TC * 0.07 0.03 0.06 * 0.07 3.97 0.06
TG -0.06 * 0.02 0.03 -0.51 * 4.01 0.03
PL 0.48 0.53 * 0.05 0.62 1.12 * 3.68
PROT 0.69 0.74 0.21 * 0.50 1.00 -0.12 *
p < 0.0001 vs baseline
IDL TC TG PL PROT TC TG PL PROT
TC * 0.06 0.04 0.03 * 0.14 4.19 0.07
TG 1.43 * 0.11 0.07 0.93 * 3.95 0.15
PL 0.73 -0.70 * 0.05 1.11 0.18 * 3.66
PROT 0.78 -0.65 0.05 * 0.74 -0.19 -0.19 *
p < 0.001 vs baseline
LDL TC TG PL PROT TC TG PL PROT TC TG PL PROT
TC * 0.09 0.03 0.07 * 0.16 0.03 0.01 0.10 0.01 0.03
TG 2.36 * 0.10 0.17 2.16 * 0.13 0.17 2.37 * 0.10 0.11
PL 0.87 -1.50 * 0.09 0.83 -1.33 * 0.04 0.80 -1.57 * 0.02
PROT 0.57 -1.8 -0.30 * 0.54 -1.62 -0.29 * 0.60 -1.76 -0.20 *
p = N.S. vs baseline p = N.S. vs baseline
p = N.S. vs 2 yrs
3.1.2.3 HDL subfractions
HDL2 was lower in Group 1 at baseline, 34.3 mg/100ml (SD 14.26) vs 47.7
mg/100ml (SD 16.36), although this difference was not statistically significant (p =
0.081); HDL3 was similar in each group. The HDL2/HDL3 ratio was significantly
lower in the apheresis group (see Fig 3.12) before the intervention period.
The subfractions were measured in fasting plasma from subjects in both treatment
groups after one year and after two years of therapy. There was an increase of
more than 100% in HDL2 over the two years from 41.0 (SD 17.2) to 88.8 mg/dl
(SD 52.3), (P < 0.001). The increase was greater in the apheresis subjects, so that
the initial non-significant difference between the groups at baseline was abolished.
HDL3 did not alter in either group, while the baseline difference in HDL2/HDL3
between the groups was no longer evident on repeat sampling at one year or
beyond.
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FIG 3.12 HDL SUBFRACTION CHANGES DURING TREATMENT





HDL subtractions were measured before and after approximately 50 apheresis
treatments, and results are available for 47 (Table 3xv). The mean increase in
HDL2 level (treatments averaged for each individual since these are not
independent) was 4.1 mg/dl (SEM 2.4), which was not statistically significant.
Changes in HDL3 were even more variable, although there was a trend towards a
decrease following apheresis. HDL2/HDL3 increased from a mean of 0.215 (SEM
0.021) to 0.245 (SEM 0.029), which was significant (p < 0.05).
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TABLE 3xv. HDL SUBERACTION CHANGES WITH APHERESISj
PRE-APH POST-APH MEAN DiFF P
MEAN (S.E.M.)
HDL2 53.7(6.2) 57.8(8.1) 4.1 (2.42) 0.12
HDL3 248.1(8.0) 235.5(11.2) -12.5(8.7) 0.18
HDL2/HDL3 0.22(0.02) 0.24(0.03) 0.03(0.01) 0.04
Following eight apheresis procedures the subtractions were measured to
determine the rate of recovery. This showed that at 12 hours (at the nadir of the
total HDL-cholesterol), HDL2 had increased significantly above the pre-treatment





48 * = p < 0.05
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3.1.2.4 Lp(a)
Lp(a) was measured in all the subjects on several occasions before and after
apheresis sessions. The mean acute reduction during apheresis was 70%, and
this was correlated with the reductions in LDL (r = 0.59, P < 0.02). The rate of
rebound of the lipoprotein following apheresis was studied in four subjects, all of
whom were taking lipid-lowering drugs at the time. The pre-apheresis levels were
reached by day 3 in one subject, day 5 in another, and by day 7 in all cases
(Fig14a).






Lp(a) levels were measured at baseline, and repeated at one year and two years.
The range in the cohort was 5-167 mg/dl, and the median levels were very similar
in the two groups (Fig 14b). There was no significant reduction in the levels over
time in the apheresis group. The group treated with drugs alone however showed
a rise in Lp(a), and this change was significant after two years of therapy.
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3.1.3 Discussion
The reduction in lipids achieved in the drug-treated group (Table 3iii) were
comparable with that seen in the active-treatment groups in all the angiographic
regression studies (Table 1 vii), the mean reduction in TC and LDL being 34% and
44% respectively. The additional effects of LDL-apheresis resulted in even greater
reductions from baseline, with highly significant differences between the groups
during the period of intervention. No study reported to date has maintained serum
lipids at these levels, which were achieved consistently in the whole group, and
permitted the attainment of the specified primary lipid goals.
Simvastatin has been reported to slow the rate of rebound of lipoproteins and to
enhance the acute reduction with plasmapheresis in patients with familial
hypercholesterolaemia [Thiery et al 1988], but in other FH patients no additional
effects of resins was seen during regular plasma exchange [Keller et al 1985]. The
present studies demonstrated that both agents will significantly reduce serum total
cholesterol and LDL during repeated LDL-apheresis in non-familial hyperchol¬
esterolaemia and that these effects are additive.
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The acute reductions in lipids (up to 93% reduction from pre-apheresis levels in
LDL-cholesterol) resulted in alteration in composition of the lipoproteins; the overall
effect was a reduction in free cholesterol, with a relative increase in the proportions
of cholesterol ester and protein. It is not clear whether this may in itself be
beneficial, but may imply that less cholesterol per lipoprotein particle is available
for deposition in the tissues.
The analysis of the compositions immediately following apheresis was complicated
by the frequent finding of undetectable quantities of free cholesterol, particularly in
the VLDL fractions. Alternatives for dealing with the problem of zero values include
amalgamating the zero with another component, replacing the zero with a trace
value, or excluding the composition as a probable outlier. With few exceptions the
zero values recorded occurred in the free cholesterol component, and most of
these following apheresis. Amalgamation (most reasonably with esterified
cholesterol, as in Table 3xiv) would result in a loss of sensitivity, while the notion of
outliers may be dismissed in view of the frequency of this finding post-apheresis.
The most plausible explanation is a quantitative one, rather than qualitative, ie. it is
likely that the zero denotes not that the part is completely absent, but that the
accuracy of the measurement process is unable to quantify the proportion present.
It has been shown that replacement of the zero with a trace value related to the
accuracy of the measurement and/or rounding process is reasonable, providing
that the replacement value lies in the range of 0.2 - 2 X the maximum rounding-off
error. These minimum and maximum trace values were substituted in turn into the
compositions taken pre- and post-apheresis, and the variation of the zero
replacement procedure was shown to have no effect on the significance
probability. It is therefore justified to use the minimum replacement value for these
datasets.
Free cholesterol was reduced in the LDL fraction in both treatment groups at 1 and
2 years of treatment (Tables 3ix - 3xii), while the largest change in VLDL and IDL
was the reduced proportion of cholesterol ester. The lipoproteins were relatively
enriched with triglycerides, an effect which may increase the atherogenicity of the
particles, leading to more dense LDL which binds less avidly to the apoB/E
receptor.
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The increase in HDL2 and HDL2/HDL3 ratio both acutely following apheresis and in
both groups in the longer term may represent an increase in uptake of free
cholesterol. LCAT activity has been shown to increase by 40% after LDL-apheresis
after an initial reduction, and it has been suggested that these compositional
changes may induce mobilization of tissue cholesterol [Franseschini et al 1988].
Lp(a) accumulates in the arterial wall and is thought likely to contribute to the
development of atherosclerosis [Rath et al 1989]. It is associated with an
increased risk of coronary artery disease [Armstrong et al 1986, Seed et al 1990,
Wiklund et al 1990, Genest et al 1991], increases the risk of vein graft stenosis
after bypass surgery [Hoff et al 1988, Cushing et al 1989], and is associated with
accelerated coronary artery disease in transplant recipients [Barbir et al 1992],
Although it is known that none of the drugs employed cause any reduction in Lp(a)
levels [Vessby et al 1982, Thiery et al 1988, Leren et al 1988, Wiklund et al 1990],
the rise in group 2 was unexpected. This may be a spurious finding rather than a
true 'treatment effect', but a significant increase in Lp(a) levels with both lovastatin
[Jiirgens et al 1989] and simvastatin [Kostner et al 1989] has been reported, which
may be due to genetic differences in the response to this class of drugs [Berg &
Leren 1989]; other studies have not replicated this finding with lovastatin and
pravastatin [Jacob et al 1990] or with simvastatin [Crook et al 1992], and in
Kostner's paper the increase reported was primarily due to a marked increase in
Lp(a) levels in one subject. Significant reductions in this lipoprotein are seen in
hyperlipidaemic patients treated with nicotinic acid [Carlsson et al 1989], although
this is less pronounced with the nicotinic acid derivative, acipimox, used in a
minority of patients in this study, and the response of Lp(a) in the subjects
receiving this did not differ from the remainder. Sustained-release bezafibrate has
been demonstrated in one study to lower Lp(a) levels to a significant degree,
particularly in those with higher baseline values [Bimmermann et al 1991].
There has been an observed acute reduction in Lp(a) with LDL-apheresis
[Eisenhauer et al 1987, Armstrong et al 1989, Ritter et al 1990], as would be
expected due to the binding and elimination of the apoB moiety. Acute reductions
in Lp(a) have been reported with both HELP and immunoabsorption, with a highly
significant correlation with the fall in LDL and apoB levels [Ritter et al 1990]. The
ensuing rebound post-apheresis appears to follow that of LDL-cholesterol,
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although the degree of recovery may be greater following immunoabsorption
compared to HELP [Ritter et al 1990, Schenck et al 1988]. Over a period of two
years Ritter et al reported a significant reduction from baseline in a small number
of patients treated with either HELP or immunoabsorption: this appears to be true
for two individuals with very high pre-treatment values of 880 and 760 U/l, but is
probably not significant for the remaining six subjects who had a mean baseline
level of 191 U/l compared to a two-year average for the eight patients of 219 U/l.
Since the weight of evidence points conclusively to Lp(a) being an independent
risk factor for atherosclerosis, and the available therapies for cholesterol-lowering
are largely ineffectual in reducing its serum concentrations, the reports that regular
apheresis therapy may maintain significantly lower levels indicates a possible role
for such treatment in high-risk individuals with high Lp(a) levels. The evidence for
such an effect however is weak, and none of the subjects in the present
investigation experienced reduction in Lp(a) over two years. The rebound curves
for Lp(a) (Fig 3.14a) increase more quickly than those of LDL before the
introduction of drug therapy (Fig 3.6), and suggests different control mechanisms
for the synthesis and/or release of these lipoproteins.
The finding of an increase in the subjects treated by drugs alone is in keeping with
other published reports, although these are not consistent. Most of these studies
are in small groups of patients, and generally over a short time period. The
Multicentre Anti-Atheroma Study [MAAS 1994] recently reported the effects of
20mg simvastatin over four years in a placebo-controlled study in 178 patients with
coronary disease: no significant difference of treatment was observed. This would
suggest that the findings in the present study and also in the previous reports are
likely to arise only by chance, although a variation in response in Lp(a) to the
different HMG CoA reductase inhibitors cannot be excluded on the current
evidence.
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3.2 LIPOPROTEIN METABOLISM
The metabolism of apolipoprotein B in VLDL and LDL was studied by established
tracer techniques at baseline and on completion of the period of intervention. The
results were analysed using multi-compartmental mathematical modelling.
3.2.1 Methods
(a) Preparation of VLDL:
Following an overnight fast, 200 - 250 mis citrated plasma was obtained from the
patients by plasmapheresis. VLDL was obtained from this by ultracentrifugation in
a Beckman Ti60 rotor for 24 hours at 39,000 rpm at 10°C. The density of 13 mis of
the supernatant fraction was adjusted to 1.118 g/ml by the addition of 2.2165 mg
of NaCI, and layered in six 2 ml aliquots over 0.5mls of d 1.182 g/ml solution of
NaBr in Beckman SW40 rotor tubes which had been pre-coated with
polyvinylalcohol. Above each aliquot was constructed a discontinuous
density-gradient, from 1.099 to 1.058 g/ml, as illustrated in figure 3.1.
The gradient was centrifuged in a Beckman SW40 rotor for 1 hr 38 mins at 39,000
rpm and 23°C. The top 1 ml from each of the six tubes was removed by pipette,
yielding the Sf 60-400 fraction (VLDL.,). This was replaced with 1 ml of d 1.059
g/ml solution, and the remaining samples centrifuged in the same rotor for a further
15 hrs 41 mins at 18,500 rpm and 23°C. VLDL2 was subsequently obtained by
removal of the top 0.5 ml of solution from each of the tubes.
(b) Radio-iodination of the VLDL subtractions:
Labelling of the VLDL species with radio-iodine was performed using the iodine
monochloride method [MacFarlane et al 1958] as modified by Bilheimer [Bilheimer
et al 1972], To each of 2 ml aliquots of VLDL, and VLDL2 were added 0.5 ml 1.0 M
glycine (pH 10) and 1.0 - 2.0 mCi of 1-131 (to the former) or 1-125 (to VLDL2). 6 pi
of ICI (25mM in M NaCI) was then added and mixed gently. Both radio-iodinated
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preparations were then dialysed at 4°C overnight to remove free iodide, using 3x2
litres of 0.15 M NaCI.
(c) Sterilisation of prepared material:
Following dialysis, the labelled lipoproteins were retrieved into sterile containers.
Membrane filters with a pore size of 0.45 pm (Acrodiscs, Gelman Sciences) were
primed with the patient's plasma, before the VLDL preparations were passed
through them into sterile containers. These were then drawn up under aseptic
conditions into sterile disposable graduated syringes.
(d) Patient preparation:
The patients were commenced on oral potassium iodate for three days before
injection, and this was continued for 28 days to block thyroid uptake of
radio-iodide. During the turnover study the patients maintained their usual diet and
activities to maintain steady state conditions. A lipoprotein profile was obtained
every 3 - 4 days during the turnover study to ensure this consistency.
(e) Patient injection and blood sampling:
The concentration of radioactivity for each isotope was calculated from counts from
10 pi aliquots of sterilised VLDL when compared against standards of 1-131 and
1-125. A suitable quantity was injected after an overnight fast via a large
antecubital vein to provide 100-150 pCi of VLDL^I-131 and 50-100 pCi of
VLDL2/I-125. From the opposite arm regular 10ml venous blood samples were
taken via a previously-sited indwelling cannula, which was flushed with
physiological saline between samples. These were taken at 10 minutes, 30
minutes, 1, 1.5, 2, 3, 4, 6, 8, 10 and 14 hours after injection of the tracers, and
then daily fasting specimens for twelve successive days. The samples were
collected into K2EDTA at a final concentration of 1mg/ml, the plasma separated by
centrifugation at 2000rpm for 10 minutes and stored at 4°C.
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(f) Re-isolation of tracer:
2ml aliquots of plasma obtained at each of the time-points above were adjusted to
d 1.118 g/ml by the addition of 0.341 mg of NaCI, and layered over 0.5mls of d
1.182 g/ml solution of NaBr in pre-coated Beckman SW40 rotor tubes. Above each
aliquot was constructed a discontinuous density-gradient, as in (a), above (figure
3.1).
The gradient was centrifuged in a Beckman SW40 rotor to isolate sequentially
VLDL1 and VLDL2 as in (a) above. Following removal of the VLDL fractions, the
IDL and LDL species were obtained by two further ultracentrifugation steps: IDL
was removed in the top 0.5 mis after centrifuging for 2.58 hours at 39,000 rpm,
and LDL in the top 1 ml after a further 21.17 hours at 30,000 rpm and 23°C (see
Table 3i).
(g) Measurement of specific activity:
The apoB for each specimen (ie 24 X VLDL.,, VLDL2, IDL and LDL) was
precipitated by the addition of an equal volume (1ml to VLDL., and LDL, 0.5ml to
VLDL2 and IDL) of 1,1,3,3-tetramethylurea (TMU) at 37°C [Kane et at 1975], The
mixture was immediately vortexed and incubated at 37°C for one hour. The
resulting precipitate was separated by low-speed centrifugation (2000 rpm for 30
minutes) from the TMU-soluble phase, and the latter removed by suction and
discarded. The lipids were extracted from the apoprotein by the addition of organic
solvents (ethanokdiethyl ether 3:1 v/v) which was kept overnight at -20°C, following
which the pellet was re-formed by further centrifugation (2000 rpm for 20 minutes
at 4°C) and the solvent removed and discarded. The residual apoprotein pellet was
then washed with diethyl ether for two hours at -20°C; following removal of the
ether by suction, the pellets were dried by incubation at 40°C.
The apoprotein pellets were solubilised in 1 ml of 0.5 M NaOH by overnight
incubation at 37°C. The radioactivity present was measured over 5 minutes in a
twin-channel automated gamma scintillation counter (Auto gamma 500C, Packard
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Instrument Co, Pangbourne, Berks,UK), and the correction factor calculated for
spillover of 1-131 into the l-125channel (% spillover in I131 tracer = (cpm125 channel
- background 125)/(cpm131 channel - background 131) x 100). Protein
concentrations for each sample were determined by a modification of the method
of Lowry [Lowry et al 1951] in which the NaOH is omitted from the Cu/alkali
reagent.
(h) Calculation of pool sizes:
3 - 4 mis of plasma obtained from each of the days the lipoprotein profile was
checked were pooled, and from this was prepared VLDL.,, VLDL2, IDL and LDL by
cumulative flotation ultracentrifugation, as described above. Apo-B concentration
was measured by two methods: (i) the calculated difference between total protein
and TMU-soluble protein measured by the methods of Lowry and Kane
respectively (Lowry et al 1951, Kane et al 1975); (ii) the average concentration of
apo B in each lipoprotein fraction during the period of study. The latter
measurements were generally adopted in the calculations due to its greater
reliability. Plasma volume was estimated as 4% of the body weight measured on
the day of injection of the tracers, and the pool sizes for each lipoprotein fraction
calculated as the product of the plasma concentration of apo B and the plasma
volume. Correction for centrifugal losses was made by comparison of the
recovered VLDL + IDL + LDL cholesterol to the "non-HDL cholesterol" measured in
plasma.
(i) Data analysis:
The total radioactivity was calculated for each fraction as the specific activity
multiplied by the average pool size, and expressed as a fraction of the total apo B
radioactivity at 10 minutes after injection. This was plotted on a logarithmic scale
as the ordinate axis in apo B decay curves. The decay curves and associated
masses were used to model apo B metabolism, utilising a digital computer
programme SAAM30 (Simulation, Analysis and Modeling) [Berman & Weiss 1978].





FIG 3.15. MODEL OF APO-B METABOLISM FROM VLDL
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The model employed has been described previously to provide an acceptable fit
for the observed data [Packard efa/1984, Demant ef a/1991], and is illustrated in
Fig 3.15.
In this model there is apo B synthesis into the VLDL1 and VLDL, compartments,
the latter required to account for the discrepancy between the amount of apo B
observed in VLDL2 and the smaller mass known to be derived from large VLDL. In
addition, directly labelled VLDL2 appears to be metabolised at a different rate from
that derived from labelled VLDL.,, and this pathway (-> 5 -> 7 -> 10) is distinct from
the parallel pathway ( 2 -> 4 -> 8 -> 11). Pools of more slowly catabolized lipo¬
proteins are proposed for VLDL2 and IDL to account for the second exponential
functions observed in the decay curves of these fractions.
Fractional catabolic rates (FCR) were calculated from the slope of the lines of the
decay curves by a 'least squares' method. Absolute catabolic rates (ACR) were
calculated from the plasma apo B concentration for the fraction, the plasma
volume (PV)and the FCR:
ACR (m g/kg/day) = FCR x PV (I) x apoB (mg/l)
body weight {kg)
3.2.2 Baseline results
The labelled apoB in VLDL, disappeared rapidly from this density range, and by 24
hours less than 1% of the injected radioactivity was present in this fraction (fig
3-16a). One-third of the apoB from VLDL, was transferred to VLDL2; the peak of
radio-activity of apoB derived from precursors was at 4 hours, and it took an
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considerably slower than the lighter VLDL species, and also took a mean of 96
hours to fall to less than 1% (see Fig 3.16b). A greater proportion of the apoB from
VLDL2 was transferred through IDL to LDL and the rate of transfer in this pathway
was also quicker, although the proportion of apoB in VLDL2 derived from VLDL1
transferred to the higher density ranges was very similar to that which was directly
labelled.
There was a wide variation between the patients in many of the kinetic parameters,
and this was reflected in the range of values obtained for VLDL1 synthesis, from
1.3 to 39.7 mg/kg/day; the mean value was 9.6 mg/kg/day (S.E.M. 2.09). The
fractional transfer to VLDL2 was less variable, with a mean value of 3.8 pools/day
and S.E.M. of 0.43. The rate of direct VLDL1 catabolism was on average twice the
rate of transfer to VLDL2 (see fig 3.17 and table 3xvi), and was positively correlated
with the synthetic rate (R = 0.76, P < 0.001).
There was no correlation between the synthetic rate and the serum triglyceride
level or the level of cholesterol in the VLDL fraction, and the rate of catabolism was
independent of the plasma pool size. The latter was however significantly
correlated with the synthetic rate (R = 0.77, p < 0.001).
Direct synthesis contributed two-thirds of the production of VLDL2, and a
considerably smaller proportion of this lipoprotein was catabolised directly
compared to the VLDL2 derived from VLDLr There was no correlation between the
rates of direct synthesis of the two VLDL fractions.
The IDL pool was significantly correlated with the rate of transfer into this
compartment (R = 0.66, p < 0.001), but not to the catabolic rate. The correlation
between synthesis or transfer into LDL and the LDL pool was weak, neither was
the latter significantly correlated with the FCR.
While the ratio of directly removed VLDL1 to fractional transfer of VLDL1 to VLDL2
was 2:1, the ratio of directly catabolised VLDL2 to transfer by delipidation was 1:3,
and 1:9 for direct removal of IDL compared to conversion to LDL. There was a
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FIG 3.17. VLDL METABOLISM AT BASELINE
Nos. at arrows - transfer of apoB in mg/day; nos. in circles - mean pool
size in mg (SEM); n -17.
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TABLE 3xvi(a) VLDL 1 APO-B METABOLISM AT BASELINE
PATIENT # Syn Rate Pool Direct catabolism Flux to VLDL 2
(mg/day) (mg) (pools/day) (pools/day)
01 1025 73 11.6 2.4
02 803 90 6.9 2.1
03 263 67 0.5 3.4
04 379 23 11.1 5.4
05 260 43 2.7 3.4
06 199 26 3.7 3.8
07 822 93 6.4 2.3
08 722 67 5.7 5.1
09 586 57 5.8 4.4
10 104 7 9.6 4.4
11 151 21 0.0 7.2
12 389 85 2.5 2.0
13 523 45 3.9 7.7
14 1037 82 8.1 4.6
16 1217 143 6.7 1.8
17 828 72 8.5 3.0
19 2484 123 18.3 1.9
MEDIAN 586 67 6.5 3.4
MEAN 694 66 6.6 3.8
SEM 139 9 1.1 0.4
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TABLE 3xvi(b) VLDL 2 APO-B METABOLISM AT BASELINE
3ATIENT Direct synthesis Flux from VLDL1 Pool Direct catabolism Flux to IDL & LDL
# (mg/day) (mg/day) (mg) (pools/day) (pools/day)
01 1019 175 170 4.5 2.4
02 912 186 227 1.3 3.5
03 531 227 349 0.2 1.8
04 1121 124 198 1.3 4.7
05 152 144 204 0.3 1.0
06 255 101 186 0.2 1.6
07 253 220 202 0.3 1.7
08 723 339 357 0.9 2.0
09 450 251 154 1.2 3.3
10 419 33 97 0.0 4.4
11 451 151 277 0.2 1.8
12 317 175 235 0.5 1.6
13 33 346 127 1.3 1.6
14 358 374 165 1.5 2.4
16 345 263 266 0.3 1.8
17 445 219 176 0.1 2.4
19 256 231 268 0.0 1.5
MEDIAN 420 219 202 0.3 1.8
MEAN 473 209 215 0.8 2.3
SEM 74 22 17 0.3 0.3
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TABLE 3xvi(c) IDL APO-B METABOLISM AT BASELINE
PATIENT Flux from VLDL2 Pool Direct catabolism Flux to LDL
# (mg/day) (mg) (pools/day) (pools/day)
01 407 617 0.1 0.5
02 792 452 0.1 1.6
03 644 720 0.0 0.9
04 930 995 0.0 0.9
05 196 435 0.0 0.4
06 303 300 0.0 1.0
07 343 436 0.0 0.7
08 703 541 0.2 1.1
09 505 270 0.5 1.4
10 427 253 0.1 1.6
11 503 359 0.0 1.4
12 378 409 0.0 0.9
13 209 337 0.2 0.4
14 402 314 0.1 1.1
16 486 551 0.3 0.5
17 418 325 0.1 1.2
19 395 754 0.1 0.4
MEDIAN 418 435 0.1 0.9
MEAN 473 475 0.1 1.0
SEM 48 49 0.0 0.1
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TABLE 3xvi(d) LDL APO-B METABOLISM AT BASELINE
Direct Flux from VLDL-derivedTotal apoB Total apoB
3ATIENT synthesis IDL & VLDL2 plasma pool pool FCR synthesis
# (mg/day) (mg/day) (mg) (mg/day) (pools/day) (mg/day)
01 111 355 2520 3307 0.1 2155.1
02 155 738 3856 4664 0.2 1869.6
03 49 660 3961 4253 0.2 842.9
04 0 914 3912 3713 0.2 1499.4
05 3 220 4874 4934 0.0 414.8
06 45 326 2901 3302 0.1 499.7
07 82 364 3191 3907 0.1 1156.4
08 116 627 4040 4788 0.2 1561.1
09 64 374 2474 2897 0.2 1099.5
10 140 433 2073 2741 0.2 662.8
11 24 510 3781 3961 0.1 626.6
12 21 370 3520 3718 0.1 726.3
13 4 138 2466 2528 0.1 559.2
14 13 441 4842 4984 0.1 1408.2
16 60 340 3383 3979 0.1 1621.5
17 12 559 3794 3875 0.1 1285.3
19 134 313 3625 5179 0.1 2873.8
MEDIAN 54 374 3625 3934 0.1 971.0
MEAN 63 452 3483 3855 0.1 1086.0
SEM 14 48 194 219 0.0 149.0
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in the calculated mass of LDL apoB derived from VLDL compared to the measured
masses, and it is necessary to postulate direct hepatic synthesis of about 10% to
account for this. The contribution of Lp(a)-associated apoB was examined as a
potential explanation for the difference between observed and calculated apoB
mass in LDL: there was no correlation between plasma Lp(a) and the LDL pool,
and no significant association with direct LDL synthesis. There was however a
non-significant association between Lp(a) and total apoB production at baseline (
R = -0.46, p = 0.07). The LDL apoB mass was related at baseline to a number of
observed and calculated parameters, as tabulated in Tab 3xvii:
TABLE 3xvii CORRELATION OF LDL APO-B MASS WITH KINETIC PARAMETERS!
r P
VLDL 1 SYNTHESIS 0.45 0.012
VLDL 2 SYNTHESIS 0.35 0.056
VLDL1 FLUXTOVLDL2 0.45 0.012
VLDL 2 POOL 0.57 0.001
VLDL 2 FLUX TO IDL 0.55 0.001
IDL POOL 0.48 0.006
TOTALAPO-B PRODUCTION 0.54 0.001
N
3.2.3 Effects of intervention
The repeat studies were performed four weeks after the last apheresis treatment,
the achievement of a new steady-state confirmed by weekly lipoprotein profiles.
The labelling of VLDL1 in patient D was not successful, possibly due to the wrong
pH, and there are therefore nine patients only from the apheresis group with
complete datasets at baseline and post-intervention. Three of the drug-treated
group did not undergo repeat metabolic studies due to time constraints, and the
data on two others was incomplete. Comparisons of parameters at baseline and
post-intervention are therefore derived from the fourteen patients with complete
data at both time-points, and the statistical tests done on paired data from each
individual (Table 3xviii).
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TABLE 3xviii(a) VLDL1 METABOLISM
PATIENT # Synthetic Rate Pool Direct catabolism Flux to VLDL2
(mg/day) (mg) (pools/day) (pools/day)
BASELINE
01 1025 73 11.6 2.4
02 803 90 6.9 2.1
03 263 67 0.5 3.4
05 260 43 2.7 3.4
06 199 26 3.7 3.8
07 822 93 6.4 2.3
08 722 67 5.7 5.1
09 586 57 5.8 4.4
10 104 7 9.6 4.4
11 151 21 0.0 7.2
12 389 85 2.5 2.0
13 523 45 3.9 7.7
14 1037 82 8.1 4.6
16 1217 143 6.7 1.8
MEDIAN 554 67 5.8 3.6
MEAN 579 65 5.3 3.9
SEM 98 9 0.9 0.5
REPEAT
01 309 99 2.0 1.2
02 155 19 4.4 3.9
03 874 164 3.9 1.4
05 610 76 5.6 2.4
06 158 21 5.1 2.6
07 612 59 8.9 1.4
08 705 72 6.3 3.5
09 478 44 3.2 7.8
10 305 30 6.8 3.4
11 508 79 5.7 0.7
12 613 97 5.7 0.6
13 496 14 30.5 5.5
14 866 60 10.1 4.4
16 217 21 3.9 6.7
MEDIAN 502 60 5.7 3.0
MEAN 493 61 7.3 3.3
SEM 64 11 1.9 0.6
P N.S. N.S. N.S. N.S.
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TABLE 3xviii(b) VLDL2 METABOLISM
3ATIENT Direct synthesis Flux from VLDL1 Pool Direct catabolism Flux to IDL & LDL
# (mg/day) (mg/day) (mg) (pools/day) (pools/day)
BASELINE
01 1019 175 170 4.49 2.39
02 912 186 227 1.25 3.49
03 531 227 349 0.22 1.85
05 152 144 204 0.30 0.96
06 255 101 186 0.16 1.63
07 253 220 202 0.28 1.70
08 723 339 357 0.86 1.97
09 450 251 154 1.17 3.27
10 419 33 97 0.05 4.40
11 451 151 277 0.24 1.82
12 317 175 235 0.47 1.61
13 33 346 127 1.31 1.65
14 358 374 165 1.47 2.44
16 345 263 266 0.29 1.83
MEDIAN 389 203 203 0.39 1.84
MEAN 444 213 215 0.90 2.20
SEM 74 26 20 0.31 0.25
REPEAT
01 34 115 158 0.34 0.56
02 521 73 199 0.57 2.30
03 1317 233 241 4.05 2.22
05 399 180 222 0.26 2.26
06 39 53 114 0.26 0.42
07 440 84 88 1.48 3.67
08 305 254 190 0.98 1.82
09 175 339 123 2.09 1.91
10 1070 102 137 5.87 2.68
11 277 57 199 0.80 0.55
12 433 58 208 0.99 1.36
13 248 36 78 1.03 2.40
14 492 263 88 4.34 3.98
16 97 137 86 0.22 2.41
MEDIAN 352 109 148 0.99 2.24
MEAN 418 142 153 1.66 2.04
SEM 99 26 15 0.48 0.29
P N.S. < 0.05 < 0.01 N.S. N.S.
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TABLE 3xviii(c) IDL METABOLISM
PATIENT Flux from VLDL2 Pool Direct catabolism Flux to LDL
# (mg/day) (mg) (pools/day) (pools/day)
BASELINE
01 407 617 0.12 0.54
02 792 452 0.12 1.63
03 644 720 0.00 0.90
05 196 435 0.01 0.44
06 303 300 0.00 1.01
07 343 436 0.04 0.75
08 703 541 0.18 1.12
09 505 270 0.49 1.39
10 427 253 0.06 1.63
11 503 359 0.00 1.40
12 378 409 0.02 0.91
13 209 337 0.21 0.41
14 402 314 0.15 1.13
16 486 551 0.34 0.54
MEDIAN 417 422 0.09 0.96
MEAN 450 428 0.12 0.98
SEM 46 37 0.04 0.11
REPEAT
01 89 224 0.00 0.40
02 460 291 0.03 1.54
03 537 310 0.00 1.73
05 501 378 0.00 1.33
06 48 199 0.03 0.22
07 323 198 0.02 1.62
08 347 318 0.00 1.09
09 236 254 0.25 0.68
10 366 260 0.74 0.67
11 109 312 0.01 0.34
12 283 272 0.01 1.03
13 189 159 0.11 1.07
14 352 183 0.55 1.36
16 207 190 0.50 0.59
MEDIAN 303 257 0.02 1.05
MEAN 289 254 0.16 0.98
SEM 41 17 0.07 0.13
P < 0.01 < 0.001 N.S. N.S.
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TABLE 3xviii(d) LDL METABOLISM
Direct Flux from VLDL-derived Total Total apoB
PATIENT synthesis IDL&VLDL2 plasma pool ApoB pool FCR synthesis
# (mg/day) (mg/day) mg mg (pools/day) (mg/day)
BASELINE
01 111 355 2520 3307 0.14 2155
02 155 738 3856 4664 0.19 1870
03 49 660 3961 4253 0.17 843
05 3 220 4874 4934 0.05 415
06 45 326 2901 3302 0.11 500
07 82 364 3191 3907 0.11 1156
08 116 627 4040 4788 0.16 1561
09 64 374 2474 2897 0.15 1099
10 140 433 2073 2741 0.21 663
11 24 510 3781 3961 0.13 627
12 21 370 3520 3718 0.11 726
13 4 138 2466 2528 0.06 559
14 13 441 4842 4984 0.09 1408
16 60 340 3383 3979 0.10 1621
MEDIAN 54 372 3451 3934 0.12 971
MEAN 63 421 3420 3855 0.13 1086
SEM 14 44 233 219 0.01 149
REPEAT
01 1 93 1813 1839 0.05 344
02 0 473 4357 4286 0.11 676
03 83 546 3012 3471 0.18 2274
05 85 501 3349 3918 0.15 1094
06 3 57 1666 1768 0.03 200
07 62 388 2254 2616 0.17 1114
08 128 365 2382 3219 0.15 1139
09 53 172 2364 3092 0.07 706
10 0 179 4202 4118 0.04 1375
11 0 128 2873 2808 0.04 785
12 0 281 2931 2925 0.10 1046
13 264 183 883 2158 0.21 1008
14 461 269 1765 4787 0.15 1819
16 22 112 1848 2214 0.06 336
MEDIAN 38 226 2373 3008 0.10 1027
MEAN 83 268 2550 3087 0.11 994
SEM 35 43 262 251 0.02 152
P N.S. < 0.01 < 0.05 < 0.01 N.S. N.S.
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Analysis of the 1-131 specific activity curves shows no differences in decay in the
VLDL1 fraction, activity falling below 1% of initial dose at 24 hours (Fig. 3.18). Peak
activity in VLDL2, IDL and LDL is lower in the repeat studies than at baseline in the
drug-treated subjects, but in LDL only in the apheresis patients. A reduction in the
amount of apoB entering the delipidation cascade is seen also in the 1-125 curves
(Figs. 3.19).
VLDL1 apoB pool size, fractional transfer rate to VLDL2, and direct fractional
catabolic rate were unchanged by therapy. There was a mean reduction in
synthesis rate of 15% which was not significant. The VLDL2 pool was decreased
from a mean of 215.4 mg to 152.5 mg (p < 0.01), due in part to a decrease of 34%
in the amount of material derived from VLDL1 (p < 0.05); the fractional catabolic
rate increased from a mean of 0.9 to 1.7 pools/day, although this was not
statistically significant due to the wide inter-individual variability. Direct synthesis of
VLDL2 was unaltered, as was the fractional transfer rate. The apoB pool size in IDL
was also reduced by 41%, from 428.1 mg to 253.5 mg (p < 0.001). This was due to
the reduced transfer of apoB from VLDL2, as there was no significant change in
the catabolism of this fraction. Similarly, there was no change in the LDL FCR, but
a 20% reduction in the apoB pool (p < 0.01). There was no significant difference in
direct LDL synthesis, but a 36% reduction in apoB derived from VLDL and IDL (p <
0.01).
The main differences in the post-intervention studies were the reductions in pool
sizes in all the compartments beyond VLDL.,, an increase in direct catabolism of
VLDL2, and no change in total apoB synthesis. The metabolic changes are
illustrated by group in Figs 3.20 - 3.23.
The reduction in VLDL2 derived from VLDL, was greater in the drug-treated group
than for the apheresis group (151.6 mg/day (SD 89) vs. 27.1 (SD 80.2), p = 0.035),
but there was no other parameter in which the changes following intervention
differed significantly between the two groups.
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FIG 3.18 1-131 SPECIFIC ACTIVITY CURVES (GROUP 1)
PRE-INTERVENTION
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FIG 3.20 GROUP 1 BASELINE VLDL METABOLISM
Nos. at arrows = transfer of apoB in mg/day; nos. in circles = mean pool size in mg (SEM);
n=9







FIG 3.21. GROUP 1 VLDL METABOLISM POST-INTERVENTION
Nos. at arrows = transfer of apoB in mg/day; nos. in circles = mean pool size in mg(SEM);
n = 9. *p< 0.05, ** p< 0.01 vs pre-treatment.
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FIG 3.22. GROUP 2 BASELINE VLDL METABOLISM
Nos. at arrows = transfer of apoB in mg/day; nos. in circles = mean pool size in mg
(SEM); n = 5.
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FIG 3.23. GROUP 2 VLDL METABOLISM POST-INTERVENTION
Nos. at arrows = transfer of apoB in mg/day; nos. in circles = mean pool size in mg (SEM); n = 5.
*
p < 0.05, ** p < 0.01 vs pre-treatment.
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Changes in the parameters related to LDL apoB mass at baseline might be
expected to contribute to an alteration of LDL levels. The differences in apoB pools
and fluxes were therefore plotted against the observed alterations in LDL apoB
mass. The correlations and 'p' values are tabulated in table 3xix:
r P
Changes in:VLDL 1 synthesis 0.28 N.S.
VLDL 2 synthesis 0.49 0.075
V1 -> V2 flux 0.34 N.S.
VLDL 2 pool 0.63 0.015
V2-> IDL flux 0.25 N.S.
IDL pool 0.57 0.035
ApoB production 0.41 N.S.
Although there was a highly significant correlation between changes in VLDL1
synthesis and direct VLDL2 synthesis (r = 0.68, p < 0.01), the LDL apoB pool
changes were not correlated with synthesis of the lighter VLDL species. The main
determinants of the apoB pool following intervention were the masses of apoB in
VLDL2 and IDL, related to the synthesis of VLDL2.
3.2.4 Discussion
The decay curves and calculated kinetic parameters obtained at baseline were
similar to those previously noted in tracer studies of patients with similar lipoprotein
levels, although some differences were observed. The masses of apoB in each of
the VLDL.,, VLDL2 and IDL pools were significantly smaller than in other
hypercholesterolaemics, while the LDL apoB mass was at the upper end of
observed values. All the pools other than VLDL, were however considerably
increased compared to those obtained in studies of normocholesterolaemia [Gaw
1992], Synthesis of VLDL, and transfer rates were not significantly different, but
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the fractional catabolic rate was increased compared to other studies in hyper-
cholesterolaemia. The other most striking differences in the present study were the
markedly reduced FCRs of IDL and LDL (0.12 (SD 0.13) and 0.13 (0.05)
respectively, compared to 0.40 (0.20) and 0.26 (0.06)), and increased fractional
transfer of IDL to LDL. These unexpectedly low FCRs are not explained by an
increased proportion of E4 homozygotes, and may reflect the inclusion of some
familial hypercholesterolaemia heterozygotes (including some unrecognised) which
other investigators have excluded from metabolic studies.
Some of the differences in other kinetic parameters may however be due to the
apoE phenotypes [Demant eta11991]; within this population, the E3/E3 phenotype
was associated with significantly larger apoB pools in VLDL2, IDL and LDL than
other phenotypes (Table 3xx).
ITABLE 3xx. BASELINE KINETIC PARAMETERS AND APO-E PHENOTYPES |j
E3/E3 E4/E3 E4/E4 P
(n=6) (n=5) (n=2)
VLDL1 POOL 83.6(33.5) 41.5(34.2) - 0.075
VLDL1 FTR 2.52 (0.68) 4.08 (1.11) - <0.05
VLDL 2 from VLDL 1 195(42.8) - 360(19.9) <0.01
145.7(89.2) 360(19.9) <0.01
VLDL2 POOL 242(61.3) 168(43.6) - <0.05
242(61.3) - 146(26.6) <0.05
IDL POOL 531 (121.5) - 326 (15.7) <0.01
LDL POOL 4142(603) 3312(503) - <0.05
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There were few qualitative differences between the apoE phenotypes in the
response to intervention. The changes in certain parameters however were more
marked in those with particular phenotypes compared to others (Table 3xxi). The
two E4/4 individuals were alone in exhibiting a significant increase in total apoB
production, against the general trend of reduction in all the individuals with other
phenotypes.
[TABLE 3xxi. APO-E PHENOTYPES AND RESPONSE TO INTERVENTION
E3/3 E4/3 E3/2 E4/E4
(n=6) (n=4) (n=2) (n=2)
VLDL 2 from VLDL 1 Pre 195 (43) 146 (89) 240 (94) 360 (20)
Post 132(66) * 145 (131) 155 (140) ** 150 (160)
IDL from VLDL 2 Pre 484 (210) 502 (252) 534 (156) 305 (136)
Post 346 (180) 244 (141) 228 (168) ** 270 (115)
IDL POOL Pre 531 (122) 451 (313) 552 (198) 326 (16)
Post 278 (66) *** 228 (34) 315 (4) 171 (17) *
LDL from VLDL/IDL Pre 447 (204) 482 (244) 484 (159) 289 (215)
Post 335 (201) 199 (138) * 246 (168) 226 (61)
LDLPOOL Pre 4142 (603) 3312 (503) 4643 (622) 3756 (1736)
Post 3109 (961)*** 2898 (980) 3013 (290)* 3473 (1859)
Total ApoB Synthesis Pre 1272 (704) 984 (402) 1687 (1129) 984 (600)
Post 962 (721) 849 (513) 962 (250) 1413 (573) **
*
p < 0.1 ** p < 0.05 *** p < 0.01
J
The effects of intervention were principally to increase the direct catabolism of
VLDL2, and thereby to decrease apoB pools in IDL and LDL. Similar to the effects
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seen during the course of treatment with simvastatin alone, there is little change in
LDL FCR but increased LDL-receptor activity results in increased direct catabolism
of precursors and a diminished influence of lipase-driven processes. At baseline
64% of apoB entering the delipidation cascade was recovered in LDL in the
subjects treated by apheresis combined with drugs, compared to 48% following
treatment. Since these measurements were made after re-attaining steady state
off-treatment, the changes in receptor-mediated clearance during treatment are
likely to have been even greater.
The observation that the most significant changes in kinetic parameters occurred
in reduced flux rates between lipoproteins rather than in direct catabolism does
however suggest some other mechanism in addition to LDL-receptor upregulation.
Lipase activities were not measured, but the concomitant changes in lipoprotein
compositions may suggest an alteration in enzyme activity in response to therapy.
This is difficult to reconcile with the accepted mechanism of action of the drugs
used in this study, which is to promote the removal of apoB/E-containing
lipoproteins by direct catabolism. By combining LDL-apheresis (which should
stimulate cholesterol synthesis in response to depletion of body cholesterol stores)
with a cholesterol synthesis inhibitor the effects on upregulation of the receptors
should be maximised, although extracorporeal therapy does not itself cause any
alteration in LDL FCR [Thompson et al 1981].
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3.3 EFFECTS ON OTHER LABORATORY PARAMETERS
3.3.1 Methods
3.3.1.1 Biochemical
A routine biochemical screen was performed at the same time as the lipoprotein
analyses on a multi-channel SMAC autoanalyser (Technicon, Basingstoke, UK) to
monitor the safety profile of the apheresis procedure and concomitant changes in
non-lipid parameters during long-term combination lipid-lowering therapy. Blood
was withdrawn after cannulation before apheresis treatment, and again
immediately at the end of apheresis. This was placed in a plain glass container,
and the serum separated after standing for ten minutes. The serum was stored at
4°C, and analysed within 24 hours. A routine screen was also performed at
monthly intervals in the drug-treated group.
3.3.1.2 Haematological
A full blood count was obtained before and after each apheresis procedure in
group 1, and at monthly intervals in the remainder. Blood was collected into EDTA
bottles, and analysed in a routine fashion on a semi-automated Coulter counter
(Coulter Electronics, Florida, USA) within 24 hours. The activated partial
thromboplastin time was measured in each of the subjects undergoing apheresis
before each of the first few procedures and again during the treatment to adjust
the bolus and infusion rate of the administered heparin to maintain the APTT at
approximately twice the control value. The prothrombin time was measured
routinely in each of the subjects at baseline and at yearly intervals to test for
effects on the coagulation system.
3.3.1.3 Haemorheological
Samples were taken at baseline and at annual intervals to assess effects of
therapy on whole blood viscosity, plasma viscosity, fibrinogen and plasminogen
levels. Blood was taken into EDTA bottles for viscosity measurements, and
analysed immediately on a Coulter Harkness viscometer (Coulter Electronics,
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Luton, UK) at 25°C. Blood for fibrinogen was collected with minimal venostasis
into 1 ml 3.8% citrate solution, and immediately put on ice. This was then
centrifuged at 4°C, separated and the plasma stored at -70°C for subsequent
analysis. Samples were also taken pre- and post-apheresis in an identical fashion
from all the group 1 subjects on a number of occasions to assess the acute effects
of the procedure on these variables, and on a weekly basis following
discontinuation of apheresis in a subset of the patients as described below.
Following the premature death of one of the subjects (#06) within a few weeks of
completion of apheresis, the effects of withdrawal from lipid-lowering treatment on
platelet function was studied in those remaining on therapy to assess whether the
platelets may become hyperaggregable when treatment is discontinued. Freshly
obtained platelets were resuspended in normal serum and the maximum
aggregation and the rate of aggregation in response to standard stimuli -
arachidonate, ristocetin and collagen - was measured and compared to normal
controls selected from young healthy members of hospital staff. These were
performed immediately prior to the final apheresis procedure and again in the
fasting state at weekly intervals for four weeks.
3.3.2 Effects of intervention
3.3.2.1 Biochemical parameters
A number of parameters were affected acutely by LDL-apheresis (Fig 3.24). There
were no significant differences between pre- and post-apheresis serum creatinine,
urea or sodium. Other cations were significantly reduced during the procedure,
although there was no change over time in the pre-apheresis levels. Overall the
reduction in Ca2+ was 2.37% (SD 2.72), which was consistent if only modest (p <
0.0001). The mean reduction in Mg2+ was 2.91% (SD 4.86, p < 0.0001), but did
not vary significantly in three of the subjects. The mean intra-subject change in
Mg2+ tended to be inversely related to the pre-apheresis levels. There was a trend
in reduction of the pre-apheresis magnesium level, but this was of borderline
significance statistically, the levels were not significantly different from baseline at
24 months, and the values for all the subjects remained within the reference limits.
The mean reduction in K+ during the procedure was 3.81% (SD 9.26, p < 0.0001).
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In nine of the subjects the average reduction was significant, varying from 1.9% to
9.9%; in the other patient there was a mean increase during apheresis from 4.15
mmol/l (SD 0.25) to 4.24 mmol/l (SD 0.27) (p < 0.02).
Plasma glucose fell during the procedure by an average of 19%, from 5.41 to 4.23
mmol/l (p < 0.0001). In some individuals the reduction in plasma glucose was
consistently greater than for others, ranging from a mean fall of 5.9% to 32.6%.
The mean percentage reduction was significantly related to the pre-apheresis
glucose level (r = 0.69, p < 0.05).
As has been described previously (Sect 1.6) the procedure results in non-specific
loss of plasma proteins. There was a reduction in total proteins from 66.0 to 57.8
g/l, a mean change of 12.3% (p < 0.0001). There was little inter-subject variability,
and the percentage reduction was not related to either pre-apheresis levels or the
number of procedures performed. The same pattern was observed for albumin
and the globulin fractions, although the percentage decrease was slightly greater
for the latter (mean reduction of 14.8%).
Long-term changes were assessed by comparing the measured parameters at
three-monthly intervals in both treatment groups (Fig 3.25). Inter-group
comparisons were made using unpaired t-tests, and paired t-tests were employed
for changes within the groups.
Clinical andMetabolic Effects 166






35 I I I I I I I I I





p < 0.05, ** p < 0.01,
***
p <0.001 vs Group 2
p < 0.05
I I I I I I










p <0.05, ** p <0.01,
***
p < 0.001 vs Group 2
Calcium
2.5 -
2.3 I I ■ I II III






Clinical andMetabolic Effects 168
There was no change in the urea or creatinine levels in either group over time.
Pre-apheresis plasma glucose levels were higher at each time-interval compared
to baseline, and these differences were significant for the first year. There were
however no statistically significant differences (after Bonferroni correction)
between the groups.
The pre-apheresis serum potassium concentration was reduced compared to
baseline (the differences being greater and statistically significant in the second
year), while there were non-significant increases from baseline in group 2. The
differences between the groups at each time-point other than at baseline and at
24 months averaged 0.51 mmol/l and were highly significant; the serum K+ did not
fall below the lower limit of normal in any of the subjects at any of the
measurement times, however, and the differences between the groups was
largely due to unexplained transient elevation in a number of the group 2 subjects.
The pre-apheresis Ca2+ and Mg2+ levels tended to be slightly lower than at
baseline, but the differences were not statistically significant either from baseline
nor from the other treatment group.
No changes were seen in the albumin or globulin fractions or in the total serum
proteins in group 2, and the pre-apheresis albumin did not alter significantly from
baseline in the group 1 subjects. The globulin fraction however was progressively
reduced compared to baseline in the apheresis group, the difference being highly
significant, and resulted in a significant reduction also in total serum proteins in
this group. The differences in globulin fraction and total proteins between the
groups became significant after three months.
3.3.2.2 Haematological parameters
During each apheresis procedure, there were small changes in the haemoglobin
concentration and packed cell volume. Although changes in the former were
statistically significant overall, the mean increase was just 0.25% (Table 3xxii). For
one individual (#03) the average rise was 0.5 g/dl (4%); for this subject and three
others the individual changes in haemoglobin and haematocrit were statistically
significant. Overall however the average increase in haematocrit was 0.72% (SD
4.72), which was not significant. Alterations in white cell count were variable,
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ranging from a mean individual fall of 14.6% to a mean increase of 17.4%, and for
all the procedures the mean fall was 2.3% (SD 18.5, N.S.). Platelet counts were
more consistent: a highly significant reduction was observed in each of the
individuals, the average change being 13.3% (S.D. 9.2, p < 0.0001).





















Long-term changes in haematological parameters were assessed as described in
3.3.2.1. Small reductions in pre-apheresis haemoglobin levels were noted in
group 1 over the first few months, before increasing significantly above
concentrations prior to commencing regular treatment (FIG 3.27). Analysis of our
early experience with the first six patients showed more dramatic decreases - to
the extent of requiring transfusion in two patients (#03 and #06) for worsening
angina (FIG 3.26). All the subjects undergoing apheresis were maintained
thereafter on oral iron supplements. In the drug-treated group there was a steady
increase from baseline in haemoglobin concentration, even without enhanced iron
intake. Long-term alterations in haematocrit mirrored closely those in haemoglobin
levels, while pre-apheresis platelet levels remained unchanged despite the
marked fluctuations seen during each procedure. There were no long-term
changes in either group in coagulation.
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3.3.2.3 Haemorheological parameters
During apheresis sessions there was a reduction in fibrinogen of 39.9% (SEM
2.49), from an individual pre-apheresis average of 2.66 mg/dl (SEM 0.10) to 1.84
mg/dl (SEM 0.12) following the procedure. Whole blood viscosity and plasma
viscosity were reduced on average by 10.8% (SEM 1.35) and 12.0% (SEM 1.23)
respectively, and these changes were all highly significant (p < 0.0001). The
reduction in plasma fibrinogen was significantly correlated with the volume of
plasma processed (R = 0.46, p < 0.02); it was not, however, correlated with the fall
in total or LDL-cholesterol, nor was there a significant association with the degree
of reduction in plasma viscosity. Although whole blood and plasma viscosity fell by
roughly the same extent, the changes in these parameters were not correlated.
Although packed cell volume is the single greatest determinant of whole blood
viscosity [Begg & Hearns 1966], there was no correlation between changes in the
latter and the measured haematocrit.
In this study there were no significant alterations in pre-apheresis results at 12 or
24 months, neither were there any differences between the two treatment groups
in any of the measured rheology parameters at any time-point (FIG 3.28).
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The change in haemorheology following withdrawal of apheresis treatment is
shown in Fig 3.29. No consistent pattern emerged, and there was no statistically
significant alteration in these parameters in this small group of subjects.
Compared to the controls, platelet aggregability during regular apheresis
treatment was significantly diminished to all stimuli except at the highest
concentrations. Over the ensuing weeks the response to collagen remained
unchanged, with no increase in aggregability following withdrawal of lipid-lowering
treatment. 3 of the 4 patients were however taking aspirin, and in the remaining
patient - who avoided aspirin due to dyspepsia - aggregability exceeded that of
the control group between 1-3 weeks after cessation of therapy.
3.3.3 Discussion
The acute effects of dextran sulphate adsorption on plasma proteins is
well-documented [Schulzeck et al 1992, Nakajima et al 1988, Eriksson et al 1989]
and compares favourably with other selective methods of LDL-removal [Olbricht
1993]. The results of the present study show that the long-term consequences of
their slight reduction over time is not of clinical significance. It is also well-known
that an acute reduction in serum cations is observed: these changes are of small
magnitude, and unlikely to be of clinical consequence. The mild reduction in
Clinical andMetabolic Effects 173
magnesium levels after prolonged therapy was monitored closely in view of the
underlying ischaemic heart disease in the subjects, but at no time did these fall
outwith the reference range in any individual.
The acute reductions observed in plasma glucose are unlikely to be attributable to
the apheresis procedure. Apart from fasting specimens at 12 and 24 months the
apheresis patients were not routinely required to refrain from eating immediately
prior to each treatment; the fall in plasma glucose is therefore likely to be due to
physiological post-prandial reduction. The pre-treatment non-fasting state also
accounts for the apparent decrease in glucose tolerance in this group over the
study period. Analysis of only those specimens obtained in the fasting state show
(Fig 3.25) a reduction from baseline at 12 months of 0.06 mmol/l (SD 0.8), and an
increase at 24 months of only 0.16 mmol/l (SD 0.7) (N.S.).
Minor fluctuations in haemoglobin during the apheresis procedure were
accompanied by alterations of the same magnitude and direction as the
haematocrit, and are attributed to dilution or (more commonly) concentration of
plasma constituents due to net gain or loss of fluid. It is unclear why these
changes were more marked or more consistent in some individuals than in others;
those with the largest changes were not more prone to symptomatic hypotension,
although the most profound episodes of hypotension were associated with
significant haemoconcentration.
The fall in haemoglobin during the early weeks of apheresis is almost certainly
due to frequent venous sampling: a fall in haemoglobin from screening values was
seen in all subjects before commencement of apheresis or drug therapy due to
frequent venesection during metabolic studies. This was associated with the
development of a degree of iron deficiency in a number of patients, and was
corrected by prescription of oral iron supplements. The occurrence of a
hypochromic anaemia during repeated plasma exchange and LDL-apheresis has
been reported, is accompanied by marked reductions in serum ferritin [Richter et
al 1990, Lane et al 1993], and has been shown to respond to oral iron
supplementation [Berger et al 1978, Saito et al 1988].
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The reduction in platelets averaged 13.3% per procedure, but with reductions
noted on occasion of up to 61 % - despite a degree of haemoconcentration - and
also increases of the same magnitude. This finding has not been a constant
feature of LDL-apheresis in earlier reports, and most investigators have noted no
significant alteration [Stefanutti et at 1988, Saito eta/ 1988]. There were however
no significant changes over time in pre-apheresis values (Fig 3.27).
Acute reductions in fibrinogen levels have been documented with all types of
LDL-apheresis, with the smallest changes being seen with the dextran sulfate
method [Keller 1991], and the greatest with HELP. It has been previously shown
that long-term treatment with LDL-apheresis does influence plasma fibrinogen
levels [Schuff-Werner et al 1989, Seidel et al 1988], although this is more
pronounced with the HELP system [Suhler et al 1990] and may not be significant
with other methods [Richter et al 1990]. The absence of long-term effects on
fibrinogen levels may be explained in part by the variability of fibrinogen levels: the
plasma fibrinogen concentration was measured on two occasions in seven
individuals during the pre-treatment phase. The means of the measurements of
viscosity and fibrinogen were very constant, but the correlation between the
individual results taken just 4-6 weeks apart was weak (R = 0.55), and
non-significant.
Although haematocrit is a critical determinant of blood viscosity in larger vessels,
in vivo viscosity in many parts of the circulation - particularly the microcirculation -
is relatively independent of packed cell volume and more closely dependent on
plasma viscosity and fibrinogen levels [Dormandy 1981]. Patients with
hyperlipidaemia have higher plasma viscosities than controls, and viscosity has
been shown to be significantly correlated with triglyceride and cholesterol levels
[Leonhardt et al 1977, Seplowitz et al 1981]. Treatment with fenofibrate in patients
with type II hyperlipidaemia was shown to significantly reduce whole blood
viscosity and plasma viscosity, but had no effect on plasma fibrinogen levels; no
correlation was seen between the fall in LDL or VLDL and change in viscosity
measurements [Arntz et al 1990]. In another study treatment of a similar group of
hyperlipidaemic patients with gemfibrozil resulted in significant increases in
fibrinogen and plasma viscosity despite reductions of 12.5% and 28.4% in
cholesterol and triglycerides respectively [Stringer et al 1990], The 32% reduction
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in cholesterol levels with lovastatin in a further study however was associated with
lowering of plasma viscosity and red cell aggregation with no effects on fibrinogen
levels [Koppensteiner et al 1990]. The marked reductions in lipid levels during
apheresis using HELP, immunoadsorption or dextran sulfate columns has been
shown to be associated with acute decreases in plasma viscosity and red cell
aggregation rates [Schuff-Werner et al 1989, Siihler et al 1990, Agishi et al 1992],
Repeated apheresis with dextran sulfate in familial hypercholesterolaemia has
been shown to result in decreased whole blood viscosity and enhanced peak
peripheral blood flow [Rubba et al 1990], and this is thought to explain the rapid
improvement in angina commonly experienced within weeks of commencing
regular treatment [Keller 1991],
Platelet aggregability has been documented by some investigators to be
increased in hyperlipidaemia [Carvalho et al 1974] , but this has not been found in
other studies which also failed to show a change in aggregability during
cholesterol-lowering therapy [Lowe et al 1982, Koppensteiner et al 1990]. The
withdrawal of such therapy could potentially lead to an increased likelihood of
thrombosis; the effects of aspirin however appear to be much greater in
magnitude than any changes induced by alteration of the lipid milieu, and any
effects on platelet adhesion of withdrawal of treatment or recurrence of elevated
levels of lipids would appear to be transient.
During the apheresis procedures which were terminated prematurely because of
profound hypotension, there were distinctive changes in both haematological and
biochemical parameters. Each of these episodes occurred after the processing of
2000-3000 mis of plasma. They resulted in an impalpable brachial pulse with a
systolic blood pressure of 70 mmHg or less, with or without loss of consciousness.
On each occasion the subjects remained hypotensive for some hours after
cessation of the procedure despite administration of fluids, unlike other treatments
complicated by hypotension, which was transient and readily reversed. Changes
in laboratory parameters are illustrated in FIG 3.30 : there were no significant
alterations in serum potassium, urea or platelets compared to normal, while
alterations in calcium and magnesium were generally only slightly more marked.
The reductions in plasma proteins were more than two to three times greater than
usual, with acute reductions of up to 40%. Reductions in total and LDL cholesterol
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were less than average since the treatment was discontinued after processing
only half the usual volume of plasma, but HDL fell by 18-30% compared to a
mean of only 2% (SD 1) for all other procedures. Increases in haemoglobin and
haematocrit were also strikingly different, with changes of up to 24% compared to
procedure means of 0.25 and 0.72% respectively. The white cell count usually fell
by an average of 2.3%, and although this parameter was normally widely variable
(SD 18.5), in these instances the response appeared uniformly different to the
norm.
During these treatment sessions there was no evidence of malfunction of the
apheresis equipment. There was no loss of plasma or blood, and it is clear that
loss of either would not result in the changes observed. The clinical course and
associated laboratory changes would be consistent with the extravasation of
plasma proteins, including lipoproteins (or at least HDL); unbound ions would
simply diffuse into the ECF with the fluid, while ions with protein-binding would
suffer a greater drop in plasma concentration. Although the disproportionate
increase in leucocytes is consistent with a response to an infective or
immunological initiating event, the underlying cause remains unclear.
FIG 3.31 Hypothesis to explain hypotensive episodes
?lnitiating event
f plasma glucose
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All of the episodes occurred within a two-month period, and the disposable
components of the equipment originated from two identified lots from the supplier.
These were tested bacteriologically for contamination, but cultures were sterile
and pyrogen tests of both implicated disposables and unused samples from the
same lots were negative. Further, disposables from these two lots were used
without problem in fourteen other locations. Serum from each of the apheresis
subjects were tested for antibodies to dextran sulphate (Dr. Otto Scheiner,
University of Vienna, Austria), but these were not increased in those who had
suffered such reactions .
Complement levels were measured during a number of apheresis procedures,
including one of those complicated by hypotension. Initially these were measured
from plasma which had been immediately separated and stored at +4°C until
analysis, with a mean storage time of 15.7 days (SD 7) and a range of 6-30 days.
It was however noted that the pre-apheresis samples showed evidence of
activation, the mean C3d level being twice the upper reference range, and later
review of the data demonstrated correlation between the C3d level and the time to
analysis (R = 0.75, P < 0.001). Subsequent samples were thereafter immediately
frozen and stored at -70°C. The pre-apheresis values for C4, C3c and C3d were
consistently within the reference ranges, and there was a clear statistically
significant reduction in the first two components associated with an increase in C3d
during apheresis (FIG 3.32).
C \
FIG 3.32 COMPLEMENT ACTIVATION DURING APHERESIS
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These results demonstrate that there is complement activation during routine
procedures. Unfortunately the plasma taken at the time of one of the severe
hypotensive episodes (which proved to be the last one) was not frozen
immediately, and the results therefore are unreliable. It is not established whether
the degree of complement activation is increased at the time of such episodes,
nor whether this might play a role in its mechanism.
Bradykinin is a potent vasodilator and is generated by activation of the contact
activation system [Parnes & Shapiro 1991], eg by dextran sulphate. It is usually
rapidly inactivated by kininase II, which is identical to angiotensin-converting
enzyme (ACE). Severe hypotensive reactions have been documented during
apheresis with dextran sulphate columns in patients on ACE inhibitors, although
none of the subjects in the present study were prescribed such agents [Olbricht et
al 1992], and brochospasm was not a feature in any of the episodes of collapse.
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3.4 EFFECTS ON SUBJECTIVE RESPONSE
3.4.1 Rationale
While the main outcomes of these studies have relatively 'hard' end-points which
are readily assessed by measurements which can be defined in terms of
distributions, means and standard deviations, the effects of the interventions
experienced by the patients are more difficult to appreciate, far less quantify. The
physician's perception of the patient's 'well-being' has been shown to be poorly
correlated with subjective reporting [Slevin et al 1988].
Measurement of the 'quality of life' has become an important issue with regard to
the management of chronic illness, and most studies of oncology patients
incorporate some assessment of the effects of intervention on overall well-being
rather than simply side-effects of therapy. Other areas which have been studied
include arthritis, chronic respiratory disease and cardiac disease [Guyatt et al
1986]. There is increasing recognition of the importance of measuring outcome in
terms other than simply of survival [Wiklund et al 1989, Rogers et al 1990].
The subjects in this study were not only limited to a variable degree by ischaemic
symptoms, but also were required to attend more frequently than usual, to take
more medication (sometimes on a four-times daily regimen) and 50% had to attend
for a half-day weekly for LDL-apheresis. There was thus considerable interference
with our patients' usual activities, and it was felt desirable to measure their
perception of any changes in their general well-being resulting from their
participation.
There may in addition be risks other than the physical restrictions imposed by
participation in the study. Previous cholesterol-lowering studies have noted a slight
excess of deaths due to suicide in the treatment groups [Muldoon et al 1990], A
number of hypotheses have been proposed to account for this [Engelberg 1992,
Law et al 1994], but in view of the possible causal relationship between
perturbations of cholesterol homeostasis and psychological disturbance it was
considered prudent to monitor the impact of such profound cholesterol reduction.
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3.4.2 Choice of measurement tool
A number of quality-of-life instruments have been developed for population
screening for psychological disturbance (such as the General Health
Questionnaire), but these are unlikely to be sensitive to small, but clinically
important, changes. Other questionnaires have been developed and validated for
specific clinical settings, some of which have a narrow range of applicability [Guyatt
et al 1986]. The Nottingham Health Profile (NHP) was chosen on the basis of its
simplicity and its known acceptability and reliability [Hunt et al 1980]. It has been
previously validated in patients with cardiac disease, and is regarded as an
appropriate tool to evaluate the effects of interventions in a pre/post test design
and to monitor changes over time in the subjective health of patients with chronic
illness [O'Brien et al 1987], and gives more weight than other measurement tools
to the infuence of symptoms on lifestyle [Taylor 1987].
The NHP is self-administered and consists of two parts: the first is made up of 38
simple queries to which a yes/no response is required; areas covered by the
statements are sleep, energy, emotions, pain, social isolation and physical
mobility. The second part assesses a number of aspects of everyday life which are
affected by health problems, incorporating employment, jobs around the home,
personal relationships at home, sex life, hobbies, holidays, and social life. The
queries from each section in Part I are in random order on the questionnaire, and
responses are weighted according to severity (calculated from responses by 1200
people aged 18 to 74 about the relative seriousness of the statements employed -
using Thurstone's Method of Paired Comparisons [McKenna et al 1981]).
3.4.3 Baseline results
Initial assessments were carried out soon after commencement of the study.
Median scores were higher in every category in the group 1 subjects (Table 3xxiii),
and their overall restriction of activies (reflected by the total weighted score) was
significantly greater (P < 0.05, Wilcoxon rank sums). The only single category in
which the difference in scores was significant was that of 'pain' (P < 0.01).
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\ TABLE3xxiii. BASELINE QUESTIONNAIRE RESULTS
PART I
GROUP MEAN S.D. MEDIAN Q. 3 P
(Wilcoxon)
ENERGY 1 26.16 27.62 24.00 63.20 N.S.
2 17.60 31.90 0.00 27.80
EMOTIONAL 1 9.36 9.95 8.49 18.33 N.S.
2 6.98 14.98 0.00 10.46
SLEEP 1 22.72 30.80 12.57 45.11 N.S.
2 14.06 25.04 0.00 20.64
SOCIAL 1 4.27 13.49 0.00 0.00 N.S.
2 0.00 0.00 0.00 0.00
PHYSICAL 1 13.04 16.02 5.39 24.62 N.S.
2 1.08 3.41 0.00 0.00
PAIN 1 23.36 23.10 17.05 32.80 <0.01
2 1.58 3.48 0.00 1.46
TOTAL 1 98.90 83.40 70.20 154.8 <0.05
2 41.30 69.10 18.30 45.30
J
The weighted scores for the responses to enquiries regarding pain were strongly
correlated to the total scores (R = 0.71, P = 0.001). With the exception of one
individual in group 1 who responded in the affirmative to all statements inquiring
about pain, including "I'm in constant pain" (although was able to exercise for 15
minutes on the treadmill protocol), the weighted scores for pain were also
correlated with exercise duration on the treadmill at baseline (R = 0.5, P < 0.05).
The patients completed in addition an abbreviated version of the General Health
Questionnaire, 'GHQ 28' [Goldberg & Hillier 1979]. The total scores from this were
strongly correlated with the NHP scores (R = 0.86, P < 0.0001), although failed to
discriminate physical limitation as well as the latter.
Six of the patients in group 1 felt that their condition interfered with their
employment, and an equal number felt similarly restricted in terms of pursuit of
hobbies. Fewer of the group 2 patients felt limited in these domains by their
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symptoms, but none of the differences between the groups in this part of the test

































3.4.4 Effects of intervention
The NHP was completed by all the patients again immediately prior to the end of
the intervention period. Compared to the baseline responses, there were
significant changes in reporting of problems. Group 1 had fewer restrictions due to
pain and physical limitation than previously (Table 3xxv), although the changes in
total scores just failed to achieve statistical significance. There was no evidence for
any change in psychosocial disturbance.
The change in scores for pain were compared with percent change in exercise
duration. The correlation co-efficient was 0.19 (N.S.), but the predictive value of a
reduction in pain score being associated with an improvement in exercise
tolerance was 87.5%, the relative risk being 4.0. Sensitivity and specificity were
87.5% and 100% respectively, although test accuracy was only 53%.
The patients in the group treated by apheresis tended to feel less restricted in most
areas of their lives than they had previously and the others more so, although the
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differences were not sufficiently striking to achieve levels of significance
statistically.
/ |TABLE 3xxv. CHANGESIN zl=oZ
\
IEALTH PR<DFILE SCOR
GROUP MEAN S.D. MEDIAN Q. 3 P
(Wilcoxon)
ENERGY 1 -18.40 21.99 -24.00 0.00 N.S.
2 -5.20 38.90 0.00 0.00
EMOTIONAL 1 3.53 23.93 0.00 3.54 N.S.
2 -0.69 22.56 0.00 1.77
SLEEP 1 -5.75 28.82 0.00 8.05 N.S.
2 1.75 12.02 0.00 12.57
SOCIAL 1 7.10 21.30 0.00 0.00 N.S.
2 5.73 12.49 0.00 5.50
PHYSICAL 1 -6.10 5.81 -10.57 0.00 <0.05
2 3.09 8.55 0.00 10.79
PAIN 1 -14.26 17.82 -8.06 0.00 <0.05
2 4.77 13.94 0.00 7.18
TOTAL 1 -33.90 52.40 -35.20 9.1 N.S.
2 9.50 52.40 1.50 16.20
3.4.5 Discussion
The assessment of perception of changes in symptoms and their severity is not
frequently part of clinical practice. The self-completion at different times of a
questionnaire requiring some consideration of exactly which activities may be
associated with difficulty and whether they are coping with any emotional or
psychological stress should be considerably more reliable than a straight enquiry
about whether the patient is feeling "better" or "worse". The use of the weighted
scores for the responses should also give a more representative picture of their
limitations than simply a diary of their use of GTN or frequency of angina attacks.
The difference in reported limitation by pain between the groups at the time of the
initial questionnaire was not anticipated but since the scores were correlated to
exercise duration, this is likely to be a chance difference between the groups at
baseline rather than a spurious finding attributable to an insensitive device.
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The most important analysis however is the difference in the degree and direction
of change. In this case the results are entirely consistent with the objective data:
the patients subjected to the more rigorous intervention experienced a significant
decrease in the restriction of their activities, resulting in fewer physical limitations
and less pain during their normal activities than they had earlier reported. The poor
correlation between the change in scores and the relative improvement in objective
measures of exercise tolerance is readily understood. The items pertaining to pain
inquire predominantly about fairly major limitation, and are unlikely to be sensitive
to relatively small changes. This is suggested by 7 of the 19 patients reporting no
difference in scores for pain, although three of these had increases of at least 50%
in exercise duration. An additional series of questions specific to patients with
chronic stable angina would undoubtedly improve the ability of the inquiry tool to
detect changes of smaller magnitude, but would require rigorous testing of
reliability and validity in suitable populations.
The findings of high specificity and sensitivity of the changes in weighted scores to
pain to predict changes in exercise tolerance do not imply that questionnaires
should be used as a surrogate for objective assessment. It does however
demonstrate that the improvement in reported symptoms was due to demonstrable
changes in the patients' performance (and conversely that the NHP was measuring
what it purported to be).
The absence of evidence of any systematic change in emotional or psychological
distress is of note. Although the number of subjects in the present study is very
small, the changes in the serum lipids were profound and the period of foliow-up of
sufficient duration to give some small reassurance. It was observed that the
responses were successful in identifying the individuals who had recently been
bereaved or were experiencing significant marital disharmony. However it could be
argued in the same way as for the pain scores that the NHP lacks sufficient
discrimation to detect subtle psychological changes which may nonetheless be of
clinical relevance.
The results support the contention that, despite major disruption of the patients'
normal activities, there were no untoward effects on the quality of life. In particular
there were no problems experienced in the incorporation of regular extracorporeal
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therapy into the treatment regimen, and that marked alterations in serum lipids
were not accompanied by significant psychological disturbance.
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3.5 EXERCISE TESTING
3.5.1 Methods
The subjects were exercised on each occasion using a standard protocol, the
Sheffield modification of the Bruce protocol, which entails increases of speed
and/or gradient at intervals of three minutes. The procedures were performed to a
symptom-limited maximum up to the end of stage 6 (13 METS*) of this protocol.
The subjects were exercised in the morning either fasting or after a very light
breakfast, without routine omission of their usual anti-anginal medication. The
tests were performed on each occasion in the same room - and therefore with little
change between tests in ambient temperature. Due to technical failure the
treadmill employed for the tests was changed during the course of the study, but
these were both maintained and calibrated on a regular basis by hospital
physicists. The time to onset of symptoms was recorded, together with total
exercise duration. Blood pressure was measured manually before exercise,
towards the end of each three-minute stage, and at termination. A 12-lead ECG
with the Mason-Likar modification was recorded standing before exercise, at the
end of each stage, at maximal exercise, immediately on cessation of the test and
at one-minute intervals thereafter until recovery of the exercise-induced changes.
The protocol was performed at baseline and repeated at 6-month intervals to
completion of the study in an identical fashion, the technician and the attending
doctor being blinded to the results of the previous tests.
The analysis was performed blinded to patient identity and sequence. The
ST-segment was measured manually at 80 msec after the J-point. The 'maximum
ST-depression' was calculated by aggregating the change from the resting
recording in the displacement of the ST-segment from the isoelectric line in each
of six leads: II, III, aVF, V4, V5 and V6. The ST depression at the 'maximal
comparable workload' was calculated in an identical fashion, using the recordings
at the lowest workload achieved at any of the time-points and comparing ECG
changes obtained on each occasion at this level of exercise.
[ * Note: 1 MET is equivalent to 3.5ml/min/kg body weight, the resting respiratory oxygen uptake for a 70kg
man aged 40. ]
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Anti-anginal therapy was unchanged throughout the period of intervention, with
three exceptions:
#05 Isosorbide mononitrate was increased from 20mg b.d. to 40 mg b.d. for a
period of 5.5 months between the baseline test and the 6-month test. The dose at
the time of each of the procedures, however, was constant.
#07 Atenolol 100 mg was added six weeks before the final exercise test. This was
discontinued for three days before the test was performed.
#11 Adalat retard 20mg b.d. was being taken for each of the first three tests; this
was discontinued (because of side-effect of headache) at the time of the 18-month
examination, when he was receiving no anti-anginal therapy. Atenolol was
prescribed (because of hypertension) following the fourth test, but was
discontinued for 24 hours before the final exercise test. Rate-pressure product
(see below) for this individual was only slightly altered, being 19.2 bpm.mmHg/103
and 18.0 at baseline and on study completion respectively.
3.5.2 Baseline Results
The exercise tests were performed after allocation to the treatment groups.The
mean exercise time in group 1 was 10.3 minutes (SD 4.2), exercise being
discontinued because of chest pain in 8, dyspnoea in 1, while the other patient
managed to complete 18 minutes of the protocol and was stopped electively. Time
to onset of symptoms was 6.5 minutes on average, and mean time to 1mm
ST-depression (in any single lead) was 10.3 minutes. Maximum (aggregate) ST
depression averaged 6.44mm (SD 3.6), including one subject with left bundle
branch block.
There were no significant differences between the groups at baseline in any of the
parameters measured above. Mean exercise duration in group 2 was 11.85
minutes (SD 4.2). Time to onset of symptoms and time to 1mm ST-depression
were 7.3 minutes and 9.2 minutes respectively. ST segment changes were
evaluated in all subjects, although 1 had left bundle branch block and another
developed ST-elevation in response to exercise; the average maximum ST
depression was 3.45mm (SD 3.5).
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The principal reason for stopping the test was chest pain in only 3 subjects; 2
stopped with dyspnoea, 3 developed pain from arthritis or claudication before the
onset of chest pain, 1 was stopped because of the development of severe ST
depression, and the other reached the end of the prescribed sixth stage. Although
three subjects in this group were limited more by locomotor or peripheral vascular
causes, this did not adversely affect the mean exercise time of the group, since
their exercise duration averaged 12.5 minutes; one of these subjects had bundle
branch block, but the other two both showed evidence of ST-segment depression.
3.5.3 Effects of intervention
Patients treated by regular apheresis experienced an early benefit in exercise
tolerance, and this was significantly different (using paired T-test) from baseline by
six months (Fig 3-34). The improvement continued in this group up to 18 months,
before levelling off. The average percentage increase in exercise duration in this
group at completion of the study was 77% over baseline, a mean increase in
exercise duration of 5.31 (SD 3.09) minutes (P < 0.001). There was no change in
maximum ST-depression, and the rate-pressure product was also unchanged
(Table 3xxvi). Time to 1mm ST-depression was increased, as was time to onset of
symptoms. ST-depression at maximum comparable workload decreased from 5.5
(SD 4.1) mm to 2.1 (SD 3.4) mm (p < 0.05).
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In Group 2 there were also improvements in exercise duration at each time-point
compared to baseline, although these were more modest, and were significant
only at 12 and 18 months (Fig 3.35). Mean percentage increase in exercise time at
24 months was 31%, the average increase 1.9 (SD 3.0) minutes (P = 0.078).
There was a non-significant increase in maximum ST-depression from 3.45 (SD




ST depression at maximum comparable workload was unchanged: 3.0 (SD 3.3)
mm at baseline, and 3.2 (SD 4.8) mm at completion. The difference between the
groups in changes in ST-depression at maximum comparable workloads was
statistically significant (P = 0.05).
Eight of the nine patients in Group 1 to complete the study were limited by some
manifestation of myocardial ischaemia (chest/arm pain, dyspnoea, fall in systolic
blood pressure, or development of 5mm ST-depression) at the initial exercise test,
while the other completed the full protocol with evidence of silent ischaemia. At the
final test, only four continued to be limited by ischaemia; two others were able to
complete the protocol, while the other two were limited by fatigue. In contrast, all
five of the patients initially limited by ischaemia in group 2 continued to be so
limited after two years, and two of the remaining five who had been stopped
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previously by fatigue or other non-cardiac endpoint now experienced symptomatic
ischaemia. Fig 3.36 clearly shows the differences in improvement in exercise
tolerance between the treatment groups. This was significant at the 95% level at
24 months (Wilcoxon sum-ranks test).
When the two groups are pooled to examine the determinants of improvement in
exercise tolerance there was a weak, but significant, correlation between the mean
individual reduction in total cholesterol achieved and the percentage improvement
in exercise duration (R = 0.47, P = 0.041) (Fig 3.37). This correlation was improved
when the TC/FIDL ratio was used rather than total cholesterol, the correlation
coefficient in this case being 0.56 (P = 0.014) (Fig 3.38). The effects of blood
viscosity changes were also examined: alterations of whole blood viscosity
accounted for less than 20% of the variability in changes in exercise tolerance, and
did not improve the fit of the regression model on multivariate analysis.
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The best predictor of the change in exercise tolerance with treatment was the
baseline exercise duration. There was a highly significant negative correlation
between the duration of effort tolerance at baseline and percentage change during
the study (R = -0.84, P < 0.001). The fit of the regression line was further improved
by the addition of the TC/HDL ratio changes, the equation obtained,
% change in exercise duration =
74.6 - 10.5 (baseline ex duration) + 1.86 (% change TC/HDL)
accounting for 83% of the changes in exercise tolerance.
3.5.4 Discussion
The graded treadmill exercise test affords a means of testing objectively the effort
tolerance in a physiological manner to which the subjects are accustomed. It is
less likely to be limited by poor physical conditioning than is bicycle ergometry and
the metabolic work required for any given workload is less dependent on body
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weight, although the quality of the ECG recording may be impaired due to
increased motion artefact. The results for an individual are quite reproducible over
time, providing variables such as ambient room temperature, time of day, time
interval from last meal, and medication and time interval from last administration
are constant. Its use in evaluation of functional capacity in patients with coronary
disease subjected to alteration in cardiovascular therapy is well-accepted [Schlant
et a/1986].
Baseline results showed a small, non-significant difference in exercise tolerance
between the groups. This is in accord with the greater limitation by pain that
subjects in this group described (see Sect 3.4.3), and also with the greater degree
of ST depression at maximum workload. The double-product (DP) is an index of
the myocardial perfusion requirement and characterizes cardiovascular
performance. Thus the increase in exercise time without any change in DP or
ST-depression at maximal exercise suggests that the coronary blood flow is
increased (since oxygen extraction by the myocardium is already optimal); this is
supported further by the reduction in ST-depression at maximum comparable
workload. The subjects in Group 2 achieved their maximal exercise at a lower DP
than those in Group 1, although the difference between the groups at baseline just
failed to achieve significance (P = 0.061). The difference may be explained either
in terms of greater severity of coronary disease in Group 2, or may be due to
differences in drug therapy affecting response to exercise. It may be seen from Fig
2.1 that the use of anti-anginal drugs were dissimilar: only six of the apheresis
patients were prescribed a beta-blocker at the outset compared to 8 subjects in
group 2. The differences in use of calcium-antagonists and long-acting nitrates are
even more striking, with a significantly greater number of subjects in group 1 taking
each of these classes of agents (eg. only one subject in group 2 was prescribed an
oral nitrate preparation compared to 8 in the apheresis group, P = 0.006 by
Fisher's exact test). The differences in drug prescription were not attributable to
ejection fraction, since there were no differences between the groups in this
regard. Analysis of the initial coronary angiograms show there was no difference in
the extent or severity of disease between the groups (see 3.7.2).
Although the groups were not well-matched for concurrent drug therapy, the
anti-anginal treatment was constant for all the subjects (with the exceptions
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outlined in 3.5.1) and comparison of the exercise tests appears to be valid with
respect to the effects of the lipid-lowering intervention, since each individual acts
as his own control.
The effects on exercise tolerance were dramatic: considering the two groups in
combination, the average increase from baseline was 3.5 minutes (SD 3.4), P <
0.001 (paired t-test). This compares favourably with the effects of other
interventions in coronary disease including coronary artery bypass surgery and
coronary angioplasty, when an identical exercise protocol was repeated after the
same time interval [RITA Trial 1993]. Large-scale primary and secondary
prevention studies [Lipid Research Clinics Program 1984b, Buchwald et at 1990]
have described a reduction in new positive exercise tests, and lipid-lowering
therapies have been shown to improve haemorheology and blood flow in
resistance vessels [Rubba et at 1990] by reducing the impaired endothelium-
dependent vasodilation seen in hypercholesterolaemia [Leung et at 1993, Harrison
et at 1987, Creager et at 1990, Chowienczyk et at 1992], The documentation of
such marked improvements in exercise tolerance by lowering cholesterol in
subjects with coronary disease has not been described previously, although Brown
and colleagues demonstrated a significant relationship between the degree of lipid
reduction and the likelihood of disease regression [Brown et at 1990].
The degree of change in objective measurement of exercise capacity following
prolonged treatment is striking in the apheresis group, and the differences from the
baseline examination are highly significant. Although the 'p' value for the
differences between the groups is considerably smaller (Fig 3-36), this is probably
of greater consequence, as the alternative treatment strategy has been
demonstrated to yield a significantly better outcome in this regard despite the small
numbers and the unfavourable differences at baseline. The clinical importance of
such variation in improvements is clearly demonstrated by the limiting symptoms
on exercise, half of those in group 1 no longer having limiting symptomatic
ischaemia while more subjects in group 2 were limited by angina on completion of
the study than at baseline.
The strong negative correlation between baseline exercise tolerance and
percentage change during treatment is unsurprising: individuals with 'normal'
Clinical andMetabolic Effects 196
exercise capacity can hardly improve on that, while the scope for improvement
remains greatest for those who are most limited. Furthermore, the expression of
any change as a percentage of the initial test duration will inevitably amplify the
apparent benefit to those in this latter group. Notably however, the changes in lipid
levels remained significantly correlated with improvements in exercise tolerance
even after correction for baseline test duration.
The finding of a significant correlation between the degree of reduction in total
cholesterol and improvement in exercise tolerance is an important one. There is
now a large body of evidence that the reduction in 'coronary risk' is proportional to
the extent of reduction in cholesterol levels, and the angiographic trials appears to
support the suggestion that more profound alterations in lipid levels may be
associated with a greater likelihood of regression. The relationship between
cholesterol reduction and cardiac symptoms on an individual basis however has
not been well-established.
The TC/HDL ratio has been demonstrated to be better correlated than total
cholesterol with the occurrence of disease in epidemiological studies [Gouldbourt
et al 1985, Assman & Schulte 1992] and a more specific marker than total
cholesterol for progression/regression in intervention studies [Brensike et al 1984],
The finding in the present study that the changes in TC/HDL are also correlated
with improvement in exercise tolerance is therefore consistent.
While the total exercise test duration is the most readily measured variable, the
other parameters monitored (see Table 3xxvi) yield results which are wholly
consistent. Time to onset of symptoms and to 1mm ST depression both increase
to a greater extent in group 1. The rate-pressure product is fairly constant within
each group, with consistently lower results for group 2, presumably reflecting the
greater proportion of patients on li-antagonists. The aggregate ST-depression at
peak workload is unchanged in group 1 over the duration of the study, while the
increase in values for this variable for the group 2 subjects suggest the increase in
exercise time may be bought only at the expense of increased ischaemia and this
would be consonant with the increase in maximum ST depression in any single
lead in this group. Further support for a reduction in the degree of ischaemia is
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obtained from the trends in the ST segment changes at maximum comparable
workloads, which is significant for the apheresis-treated group only.
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3.6 RADIONUCLEIDE IMAGING
3.6.1 Methods
Thallium scintigraphy was performed after exercise on a bicycle ergometer at
baseline, at one year, and on study completion. The procedure was performed in
the morning on each occasion without witholding the subject's usual medication.
The same equipment, including mechanically-braked bicycle which was calibrated
at regular intervals, was employed for the duration of the study. A standard
protocol was utilised starting at 50W with 50W increments at 3-minute intervals to
a symptom-limited maximum [Martin et at 1987], The patients were required to
pedal at 50 rpm, and the test discontinued if they developed limiting pain or
dyspnoea or if they were unable to maintain a cycling frequency above 40 rpm. A
12-lead electrocardiogram using the Mason-Likar modified limb-lead placement
was obtained before exercise, at the end of each stage, at termination of the test
and at one-minute intervals thereafter. A continuous ECG recording was obtained
throughout exercise on a six-channel Siemens recorder. 60 MBq of thallium-201
was injected at peak exercise via a previously-sited intravenous cannula, and
standard views obtained using a high sensitivity parallel collimator in the anterior,
40°- and 75°-left anterior oblique (LAO) projections using a mobile gamma camera
(GE Portacamera IIC). A 25 keV photopeak centred on thallium's 80 keV X-ray
emission peak was employed. Data gated to the electrocardiogram were acquired
and stored on computer (LINK MAPS 2000). The patient was then rested for 3-4
hours and redistribution scans obtained in identical projections. The stored images
were retrospectively reconstructed into representative cardiac cycles of eight
frames in each projection, using an image size of 64 x 64, and subsequently
analysed independently on study completion by two observers blinded to patient
identity and scan sequence.
Each projection was divided into five equal segments (Fig 3.39) and, after
normalisation of the linear-gray scale to the "hottest" pixel, the segments graded
visually for perfusion: < 10%, 10-34%, 35-65%, 66-90% and > 90%. Segments
were deemed to have a reversible perfusion defect if perfusion was impaired on
the stress scan and normal during the re-distribution images, and a partially
reversible perfusion defect if the segment was abnormal on exercise and improved
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by at least one category on the reperfusion scan. Abnormal segments were
classified as having 'fixed' defects if abnormal on exercise without changes at the
redistribution scan, and 'reverse reperfusion' defects if the latter scan had
diminished perfusion compared to the exercise image.
FIG 3.39 PROJECTIONS AND SEGMENTS FOR RADIONUCLEIDE SCANNING
ANTERIOR 40 LAO 75 LAO
At the time of the redistribution thallium scan, patients were administered stannous
pyrophosphate for in-vivo labelling with 600 MBq technetium 99-m pertechnetate
which was injected 20 minutes later. A gated equilibrium blood pool ventriculogram
was obtained using a single-plane collimator. Images were obtained in the 40° and
70° left anterior oblique views, and from these were derived ejection fractions for
each ventricle, as well as total and segmental wall motion scores. Segments were
scored 1-5, according to whether the motion was normal, slightly reduced,
markedly reduced, immobile, or dyskinetic. Ejection fractions were calculated from
a mean of four estimates measured in two planes.
The scores accorded by the individual observers (GWT/WM) for both perfusion
and wall motion were well-correlated, with greater than 90% identical, and the
remainder varying by no more than one group. Intra-observer variability of
assessment of the area shaded on the perfusion scans was also examined: the
identical score was assigned in 92% of segments, with less than 1% varying by
more than one group.
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3.6.2 Baseline Results
Of the nine patients to complete the study in group 1, the stress images obtained
in the anterior and 70° LAO views for one subject (#04) were not traced in the
computer storage system. There were five segments in each of three views for the
remaining eight, and thus a total of 125 segments could be analysed. A
redistribution scan was not performed on one (#14) of the group 2 patients, and in
another (#19) no computer record of the redistribution scan was found. Records
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There were 50 segments with reversible perfusion defects at baseline in group 1,
18 of which were partially reversible only; there were 9 fixed defects, 12 segments
with reversed reperfusion, and 54 with normal perfusion on stress and at rest. The
subjects in group 2 had 46 segments with reversible perfusion defects (20 only
partially reversible); 17 abnormalities were fixed, eight reversed, and 49 segments
were normal.
Left ventricular ejection fraction (LVEF) calculated from the blood pool studies
showed a wide inter-subject variation with a range of 15 to 45%, and mean 29.7%
(SEM 1.69). The groups were well-matched in this regard with no significant
differences, neither were there any systematic differences between the groups in
localised wall motion abnormalities. An overall wall motion score (WMS) was
derived from the summation of the segmental scores assigned from the two LAO
views, and this was highly significantly correlated with the LVEF (R=0.83, P <
0.0001).
Limited information was obtained from the exercise data, since only five of the
patients were limited by symptoms of ischaemia and the remainder of the tests
were discontinued due to fatigue. Total exercise duration on the protocol was
recorded, together with time to 1mm ST-depression, maximum ST-depression,
and rate-pressure product; there were no differences between the groups in any of
the parameters recorded.
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TABLE 3xxviii REP EAT SCAN
NORMAL REPERF PART. REP. FIXED REVERSE TOTA
BASELINE SCAN +/ - +/ -
NORMAL GROUP 1 41 9 2 0 2 54
GROUP 2 32 9 2 1 5 49
REPERF GROUP 1 8 10 16 4 1 3 32
GROUP 2 10 9 12 1 0 4 26
PART. REP. GROUP 1 1 6 3 /1 3 4 18
GROUP 2 4 3 3 /3 3 4 20
FIXED GROUP 1 2 3 3 1 0 9
GROUP 2 1 3 6 6 1 17
REVERSE GROUP 1 3 4 1 4 0 12
GROUP 2 3 1 0 1 3 8
3.6.3 Effects of intervention
Of the 32 segments with completely reversible perfusion defects at baseline in
group 1, 8 were normal at the two-year scan, 1 had developed a fixed defect, 3
reverse reperfusion and 4 were now only partially reversible. 16 remained fully
reversible: 10 had better perfusion on exercise at the repeat scan than at baseline,
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while the others were worse or unchanged (see Table 3xxviii). 18 segments from
patients in this group had had partially reversible perfusion defects at baseline;
only 1 of these was normal at the final scan, and 6 had become completely
reversible. 3 were either less ischaemic on exercise or were more reversible than
previously, while one was worse. The remainder had developed either fixed or
reversed reperfusion defects.
Similar results were seen in Group 2, with more than 50% of completely reversible
lesions at baseline becoming normal or having improved perfusion on exercise,
while the majority of partially reversible deficits remained incompletely reversible or
developed fixed or reverse lesions (see Table). The proportion of segments
showing improvement was not significantly different between the treatment
groups. New reversible perfusion defects arose in 11 previously normal segments
in each group.
A scoring system was devised to assess semi-quantitatively the changes in
perfusion seen in individual segments from the baseline scan to that at
completion, in an attempt to predict arteriographic changes in the coronary arteries
supplying these territories. Each segment was assigned a value according to the
degree of reduced perfusion at exercise and the extent of reversibility at both time
points and the change assigned a value on a scale of -4 to +4; segments which
were completely normal at baseline and developed a perfusion defect obtained a
negative score, while those with reduced uptake initially and subsequently
improved or normalised were accorded a positive score commensurate with the
degree of improvement. The scoring system used for each permutation is
documented in Appendix I. The scores were noted for each segment by group,
and also aggregated for each individual:
BETTER WORSE TOTAL
GROUP 1 44 29 +15
GROUP2 48 25 +23
V
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TAB 3xxx THALLIUM SCORE - BY SUBJECT
BETTER UNCHANGED WORSE
GROUP 1 7 0 2
GROUP2 5 1 2
LV ejection fraction did not change significantly in either group, although small
increases were observed (30.3% (SEM 2.3) to 32.2% (3.7) in group 1, and 29.0%
(3.0) to 30.4% (3.5) for group 2). Wall motion of individual segments did show
minor changes but there were no systematic differences.
Exercise duration assessed by bicycle ergometer did not alter significantly in either
group over the study, although there was a significant reduction in exercise time in
group 1 at 12 months; this was not due to ischaemic symptoms, but there was a
significant increase in maximum ST-depression noted at this point. At two years
however, neither group showed any significant change in exercise duration, time
to 1mm ST-depression, maximum ST-depression or rate-pressure product (Table
3xxvii).
3.6.4 Discussion
The purpose in obtaining this non-invasive imaging data was to evaluate the
usefulness of perfusion scans in reliably assessing changes in blood flow
consequent on regression of coronary artery lesions. It is recognised that thallium
scintigraphy has greater sensitivity in the detection of coronary disease than
electrocardiographic data alone obtained by exercise stress testing [Kotler &
Diamond 1990], although the improvement in predictive accuracy compared to
ECG-stress testing is small in patients not taking digoxin and with a normal resting
ECG [Gibbons et al 1990]. It can be used to assess alterations in perfusion
defects following interventions to achieve revascularisation (such as PTCA and
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coronary bypass surgery) [Kiat et at 1988], but it was not known whether it might
be sufficiently sensitive to detect changes in perfusion of a much smaller
magnitude.
The data obtained confirms that for the duration of the study there was no new
silent infarction in any of the participants. Both groups however had an
approximately equal number of segments showing evidence of improved and
diminished perfusion. Weighted (according to the extent of changes in perfusion)
and unweighted scores showed no significant changes between the groups in
either the proportion of subjects experiencing net benefit, or the number of
segments per group demonstrating improvement (see Tables 3xxix and 3xxx).
Since there is a degree of subjectivity in the assessment of perfusion of each
segment and some variation in adjustment to the visual display from the recorded
data, quantifying the difference in reversibility between two pairs of scans will
greatly amplify any systematic errors. Devising an arbitrary score to compare -
what some see as - two other rather subjective assessments may be criticised as
intrinsically flawed. However the intra-observer (GWT) and inter-observer variation
(WM/GWT) in assessing perfusion was remarkably consistent and of sufficiently
small magnitude to allow acceptably reproducible scoring. If the evaluation of the
change in reversibility by the scoring system adopted is shown to be correlated
either with angiographic change or some measure of clinical outcome, then it
could be justifiably used as a useful surrogate for invasive assessment and I shall
examine this following discussion of the angiographic results (Sect 3.7.4, p 212).
Despite the lack of difference between the groups, it may be seen from the table
that, of the 17 patients for whom the scans were analysed, 12 had an overall
improvement in perfusion. Although it is possible that improved myocardial
perfusion may have contributed to the benefits observed in exercise tolerance as
exhibited in the serial treadmill tests, individual changes in thallium scores were
not correlated with alterations in symptomatic status or exercise tolerance. This
may be due to insufficient sensitivity of this approach to small changes in
perfusion; however exercise time may remain unchanged even with marked
improvements to all myocardial segments except one with the culprit lesion.
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There were no significant correlations between the scores obtained and any of the
lipid parameters, although a weak trend was evident when plotted against change
in haematocrit (R = 0.45, P = 0.084).
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3.7 CORONARY ANGIOGRAPHY
3.7.1 Methods
Coronary angiography was performed at the outset of the study and on completion
in all the patients by a modified Judkin's technique under local anaesthesia.
Patients were admitted on the evening prior to the procedure, or fasting on the
morning of the angiogram. Patients were premedicated with 10mg oral diazepam
before angiography, and received also their usual medication. Written informed
consent was obtained before each investigation.
Biplane ventriculography was followed by selective coronary catheterisation using
marked catheters (Cordis 7F, Miami, Florida, USA). Vasodilation was achieved by
sublingual or intracoronary nitrates or intracoronary nifedipine according to the
routine practice of the angiographer. If further doses were required during the
procedure the dose and timing of administration was documented, and this was
repeated at subsequent angiography at the same stage of the procedure. At least
two orthogonal views were obtained of each coronary artery. The procedure was
repeated after two years of intervention by the same angiographer using the same
radiographic equipment. The views were replicated and performed in the same
order as in the initial angiogram.
The films had all patient identifiers removed and replaced by a code number
known only to non-study personnel. Film pairs were analysed blindly with a
computerised method (CAAS system) by a trained technician [Reiber et al 1984],
The paired films were first viewed simultaneously by an experienced cardiologist
who visually compared coronary segments to ensure adequate quality of
angiography, matching of angulation, absence of foreshortening, and vessel
overlap. Each segment [Austen et al 1975] suitable for analysis then had the
edges detected by an automated method and the mean width of the segment
overall measured from each film. The minimum arterial width and percent diameter
stenosis was measured in both films for those segments in which there was a
reduction of at least 20% of the reference diameter for part of its length in either
film (Fig 3.42). The focal score and global score was calculated for each patient,
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the former being the average of all minimum lumen diameters per patient, and the
latter representing the average of all mean widths per patient.






MEAN ARTERIAL WIDTH OF SEGMENT (MAWS) = AVERAGE OF ALL DIAMETERS
% DIAMETER STENOSIS = MINIMUM ARTERIAL WIDTH / REFERENCE DIAMETER
FOCAL SCORE = AVERAGE OF ALL MinAWS PER PATIENT
GLOBAL SCORE = AVERAGE OF ALL MAWS PER PATIENT
3.7.2 Baseline results
133 segments in total were suitable for computer-assisted evaluation from the film
pairs, 59 from group 1 with a mean segment width at baseline angiography of 2.47
mm (SD 0.71) and 74 from group 2, mean 2.49 mm (SD 0.82). Average minimal
luminal diameter was 1.64 mm (SD 0.57) and 1.59 mm (SD 0.55) respectively,
while percent diameter stenosis for the initial lesions ranged in group 1 from 20%
to 64% with a mean of 34.4% (SD 11.1) and in group 2 from 12% to 67%, mean
35.8% (SD 13.7) (Table 3xxxi).
The focal score (the average for all minimum lumen diameters per patient) and
global score (the average of all the mean arterial widths per patient) at baseline
was strongly correlated with total cholesterol, LDL cholesterol, and TC/HDL ratio
(Table 3xxxii). There was no significant correlation between the severity of
angiographic disease and age in this selected population, nor between the extent
of disease and anti-anginal therapy or haemorheological variables.
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TABLE 3xxxi BASELINE ANGIOGRAPHIC RESULTS
# Min AWS %DIAMETER STENOSIS M AWS
GROUP 1 n AV SD AV SD n AV SD
01 5 1.666 0.24 25.2 6.3 8 2.401 0.509
02 4 1.619 0.14 32.25 8.3 8 2.785 0.924
03 4 1.95 0.23 27.75 13.3 7 2.517 0.446
04 2 2.505 0.9 38.5 2.12 3 3.113 1.145
05 6 1.493 0.74 40.33 14 8 2.225 0.674
06 6 1.446 0.36 34.17 13.24 8 2.18 0.319
07 5 2.048 0.66 36 13.44 8 2.81 0.704
08 6 1.553 0.31 34 11.85 6 2.189 0.297
09 5 1.165 0.32 33.6 7.02 8 2.218 0.74
10 2 2.205 1.27 39 18.4 2 3.08 1.202
GROUP 2
11 4 1.56 0.51 34 19.54 5 2.209 0.511
12 7 1.288 0.48 37.57 7.37 9 2.017 0.722
13 9 1.663 0.6 33.22 15.55 11 2.435 0.67
14 4 1.465 0.24 30.5 7.19 10 2.33 0.648
15 5 1.845 0.8 43.6 14.05 5 2.775 0.765
16 3 2.222 0.66 23.33 3.51 6 3.483 1.154
17 3 1.605 0.3 27.33 12.01 5 2.455 0.962
18 5 1.453 0.22 39.2 6.83 7 2.583 1.047
19 4 1.328 0.35 42 17.49 10 2.448 0.682
20 5 1.693 0.83 40 20.63 6 2.671 0.866
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FOCAL SCORE GLOBAL SCORE
R P R P
TC -0.61 0.005 -0.61 0.006
LDL -0.52 0.024 -0.52 0.025
HDL 0.27 N.S. 0.23 N.S.
TC/HDL -0.50 0.03 -0.54 0.02
V
3.7.3 Effects of intervention
Follow-up angiography demonstrated a mean change in segment width of 0.015
mm (SD 0.39) in group 1 and -0.025 (SD 0.38) in group 2, a non-significant
difference. Similar changes were observed for the minimal lesion diameter and
percent diameter stenosis for the groups overall. Although there was no significant
improvement or deterioration in the angiographic appearances on average, there
were marked changes in the appearances of individual lesions. Certain individuals
achieved statistically significant changes in their minimal luminal diameters or
percent diameter stenosis, although within most subjects there was a mixed
response to intervention (Tab 3xxxiii).The degree of 'progression' and 'regression'
was similar for each group, a change of at least 8 percentage points in diameter
stenosis being regarded as a definite change [Gibson et al 1992] (FIG3.44). Four
of the nine apheresis patients had more lesions with an increase in mean arterial
width of at least 0.17mm than a reduction by the same amount, four showed
overall 'progression' by this criterion and one was unchanged. In the drug-treated
group, six had more lesions altered in a favourable direction than had progressed,
while only three had an excess of stenoses undergoing progressive change.
Overall 40% of the lesions showed a significant alteration in the percent diameter
stenosis, half of these in a favourable direction, and thus 80% of all stenoses were
stabilised or made to regress over the two-year period.
Clinical andMetabolic Effects 211
The severity of the stenosis at base-line did not affect the degree or direction of
change in the lesions. A measure of roughness (or 'edge irregularity index') was
calculated by a computer-derived algorithm. This showed no significant change in
either group, and changes were not correlated with alterations in serum lipids. A
weak positive correlation was noted between the roughness index and changes in
mean segment width (R = 0.24, P < 0.01). The mean roughness change per
patient, however was not related to the focal or global score measures.
[TABLE 3xxxiii ANGIOGRAPHIC RESULTS POST-INTERVENTION
# Min AWS %DIAMETER STENOSIS M AWS
GROUP 1 n AV SD AV SD n AV SD
01 5 1.744 0.22 26.4 9 8 2.372 0.29
02 4 1.622 0.13 28 5.9 * 8 2.879 1.02
04 2 2.345 0.9 35.5 0.7 3 2.978 1.06
05 6 1.629 0.72 37.2 10.6 8 2.208 0.7
06 6 1.302 0.22 37 9.8 8 1.971 0.23 ***
07 5 2.056 0.67 34.8 13.4 8 3.033 0.72 *
08 6 1.909 0.27 ** 31.7 12.1 6 2.642 0.22 ***
09 5 1.239 0.39 39.8 15 8 2.232 0.72
10 2 1.67 2.37 59.5 57.3 2 2.06 2.91
GROUP 2
11 4 1.987 0.91 26 22.1 5 2.415 0.75
12 7 1.318 0.35 34.7 10.9 9 2.109 0.78
13 9 1.49 0.49 * 37 12.6 11 2.327 0.64
14 4 1.57 0.38 26.2 7.6 10 2.314 0.64
15 5 2.001 1.44 45.2 35.6 5 2.692 1.65
16 3 2.408 0.72 27.7 10.7 6 3.421 1.08
17 3 1.36 1.46 50 43.7 5 2.06 1.4
18 5 1.436 0.21 42.8 3.6 7 2.451 0.96 *
19 4 1.345 0.43 38.3 22.5 10 2.519 0.83
20 5 1.593 0.42 45.8 11 6 2.724 0.83
* _ P < 0.05, ** = P<0.01, *** _ p < o 001 vs baseline (Table 3xxxi)
On combining the two study groups, no relationship was observed between the
change in global score and improvement in exercise tolerance; neither was this
related to patient age, extent of angiographic disease at baseline, or lipid levels at
the outset of the trial or during treatment. There was a weak non-significant
correlation (R = 0.31, P < 0.2) between the reduction in LDL/HDL ratio and change
in global score. Within the group treated by apheresis there was a stronger
correlation between the change in focal score and LDL/HDL ratio reduction (R =
Clinical andMetabolic Effects 212












> 24 17 - 24 9- 16 1 -8 0 1 -8 9- 16 17 - 24 >24
0.60, P = 0.08); similarly, within group 2 there was a correlation between change in
global score and TC/HDL ratio (R = 0.60) which just failed to achieve statistical
significance (P = 0.067).
3.7.4 Correlation of scintigraphic and angiographic changes
3.7.4.1 Methods
As described in 3.6.1, the thallium images obtained at rest and redistribution were
divided into five segments in each of three projections, and the perfusion assessed
on each as normal (N, or greater than 95%), nearly normal (M, 65 - 95%) half
normal (H, 35 - 65%), abnormal (B, 10 - 35%) or absent (A, or less than 10%). The
rest and redistribution scans were then reviewed and graded for degree of
reversibility of any perfusion deficits. These grades obtained for each segment
from the baseline and the final scans were assigned a numerical value according
to changes in the degree of reversibility (see Appendix). A summary measure of
perfusion change for the area of distribution of each coronary artery was
calculated by the summation of the values for the segments(S - see fig 3.39)
subtended by the respective vessel:
Proximal RCA - Ant S4 + S5
Distal RCA - Ant S4 + S5, LAO-40 S3, + LAO-70 S3 + S4
Proximal LAD - Ant S1, LAO-40 S1, + LAO-70 S1 + S2
Clinical andMetabolic Effects 213
Distal LAD - Ant S2 + S3, LAO-40 S2, + LAO-70 S2
Prox LCx - LAO-40 S5 + LAO-70 S5
Distal LCx - LAO-40 S4 + LAO-70 S
The coronary arterial tree was divided into segments according to guidelines of the
American Heart Association [Austen et al 1975]. The segments used for the
proximal arteries were #1 for the right, #5 and #6 for the left anterior descending,
and #11 for circumflex arteries. Changes in all three measures outlined above,
namely minimum lumen diameter, mean absolute segment width and percent
diameter stenosis were plotted against the scores of the changes in perfusion.
3.7.4.2 Results
CHANCE IN HAWS
ALL SECS RCA LAD LCX PROXSEGS
CORRELATION (R) 0.27 ** 0.45* 0.16 0.16 0.39**
SENSITIVITY (%) 56 17 74 45 69
SPECIFICITY (%) 46 100 59 57 80
POS PRED VALUE (%) 50 14 71 45 64
NEGPRED VALUE (%) 61 50 62 40 75
TEST ACCURACY (%) 42 35 57 26 49
RELATIVE RISK 1.15 2.0 1.88 0.76 2.57
CHANGE INMinAWS
ALL SEGS RCA LAD LCX PROXSEGS
CORRELATION (R) 0.10 0.31 0 0.24 0.32
SENSITIVITY (%) 52 33 64 44 50
SPECIFICITY (%) 38 100 36 9 63
PCS PRED VALUE (%) 42 100 47 25 50
NEG PRED VALUE (%) 36 45 36 17 50
TEST ACCURACY (%) 29 33 35 18 29
RELATIVE RISK 0.83 1.83 1.04 0.30 1
CHANCE IN%DS
ALL SEGS RCA LAD LCX PROXSEGS
CORRELATION (R) -0.12 -0.59** 0.09 0.09 -0.39*
SENSITIVITY (%) 60 50 64 60 70
SPECIFICITY (%) 48 100 33 18 70
POS PRED VALUE (%) 47 100 47 38 70
NEG PRED VALUE (%) 46 73 36 33 70
TEST ACCURACY (%) 39 46 35 24 41
RELATIVE RISK 1.11 3.67 1.04 0.56 2.3
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The sensitivity, specificity and predictive values for the perfusion change scores
were determined for all the segments combined, for each artery separately and for
only the proximal segments of all the arteries (Table 3xxxiv).
For all the angiographic measures, changes were most closely correlated with
perfusion changes for the right coronary artery, and none were useful in
assessment of changes in the circumflex artery. Changes in MLD were not reliably
predicted by perfusion scores, and even for the proximal arterial segments relative
risk was only 1.
The predictive value of perfusion changes was similar for percent diameter
stenosis and mean segment width. The latter measure retained a significant
correlation for all the segments and, although poorer for changes in RCA, was
more powerful a predictor than changes in % diameter stenosis for lesions in the
LAD distribution. The predictive accuracy of the thallium scores compared to the
mean arterial width when applied to proximal segments (n=45) was 75% and 64%
for progression and regression respectively, the score giving a relative risk of 2.57.
3.7.5 Discussion
Quantitative coronary angiography (QCA) directly assesses the effects of
interventions, and at present is the most reliable means of studying progression
and regression of disease despite the inherent difficulties due to both
patient-related variables (such as vasomotor tone, presence of thrombus, vessel
motion, and arterial geometry), and technical factors (such as comparability of
angulation of the image intensifies calibration and presence of pincushion
distortion) [Gibson et at 1992, Selzer et at 1989, de Feyter et at 1991]. It has been
suggested that the change seen at angiography is a useful surrogate endpoint for
clinical events [Buchwald et at 1990]. Angiographic studies have clearly shown that
the progression of the atherosclerotic process may be influenced by effective
modification of serum lipids [Blankenhorn et at 1987, Brown et at 1990, Buchwald
et at 1990, Kane et at 1990, Ornish et at 1990, Watts et at 1992, Blankenhorn et at
1993, Waters efa/1994, MAAS Investigators 1994], and that there does appear to
be a relation between the extent to which cholesterol is lowered and the likelihood
of plaque regression [Watts et at 1992, Brown et at 1990, Levy et at 1984],
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The primary outcome measure in this study was the effects of lipid lowering on the
angiographic appearances. Although there are in total 285 coronary arterial
segments potentially analysable in this number of patients, the segments require
to be completely comparable in each projection on two angiograms. The proportion
of segments analysed in this study is similar to that obtained in others using QCA.
These were selected entirely on technical grounds using film pairs by an observer
blinded to the angiogram sequence, patient identity, and the nature of the
intervention, and represent the fullest possible data available from the angiograms
obtained. Whenever possible a mean of two or three projections were used for
each segment, and multiple projections were used in 44.4% of the segments
analysed.
There has been debate about which angiographic measures are the most relevant,
and how best to present them. Prominent authorities highlight the relative merits of
each of the measures, and recommend that percent diameter stenosis, minimum
lumen diameter and mean segmental diameter should all be presented as both
per-patient and per-lesion analysis [deFeyter eta! 1991].
The significance of the correlations at baseline between the lipid levels and the
angiographic scores were surprising, given that the patients were selected to have
both severe hyperlipidaemia and advanced coronary disease. This would tend to
support the strength of the link between cholesterol and heart disease, and
increase the expectation that modification of the lipoproteins may result in
alteration of the atheromatous plaques.
Analysis of the angiograms shows that only a minority of lesions may be induced
to undergo regression. The extent to which this occurred did not differ between the
groups, although within each there was a correlation between the degree of
change in the TC/HDL ratio (the 'atherogenic index') and changes in the global
score. The most striking finding was the marked reduction in progression in both
groups, best appreciated by a comparison with results from control subjects in
similar studies (Figure 3.45). Clearly the proportion of lesions exhibiting significant
change is entirely dependent on the definition employed of 'regression' and
'progression'. The cut-off point requires to be related to the accuracy of the
measurement, and its reliability in detecting small differences. Since blood flow is
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Fig 3.45 Trials used in the above figure are for percentage of patients exhibiting
angiographic change. Groups marked 'a' are control groups, 'b' intervention groups, and 'c'
where trials involved a second intervention group. 1 Buchwald et al 1990; 2 Blankenhorn et
al 1987; 3 Watts et al 1992; 4 Levy et al 1984; 5 Brown et al 1990; 6 Kane et al 1990.
proportional to the fourth power of the radius of the vessel, small differences in the
arterial lumen may well be of importance. In view of the number of other biological
and technical variables present however, it is necessary to demand a difference in
the measurements of at least 2 S.D. before accepting the variation to be definite.
One possible explanation of the lack of difference in response between the
treatment groups is that there is in fact a threshold of cholesterol levels for
inducing regression. This is quite possible since the relationship between the
incidence of ischaemic heart disease and total cholesterol level is clearly
curvilinear rather than linear, with a significant rise in the curve for most
populations with cholesterol levels above 5.2 mmol/l (see Sect 2.1). Previous
intervention trials have documented a reduction in risk of 2.5% for each 1%
reduction in cholesterol level [Holme 1990], but have not achieved large enough
reductions to test whether this continues to hold true with more profound lowering.
It could also be argued that the disease in our patients was too advanced to be
readily reversed, and that more profound reductions may improve the probability of
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regression in more lipid-rich plaques [Dollar et at 1991]. If this was the case
however it might reasonably be expected that the younger patients in our study
might have exhibited a greater tendency to regress, and this was not the case.
The failure of the more profound lipid lowering therapy to uniformly induce
regression, despite achieving the TC/HDL ratio associated with this in animal
models is probably related to the difference in composition of the plaques in those
cholesterol-fed models and the advanced plaques in our subjects. Alternatively, we
have perhaps missed a real difference in the effects of our lipid levels because of
an inadequate number of subjects: the difference between the groups for change
in focal score of 0.055mm in favour of group 1 is well within the 95% confidence
intervals of a difference of 0.163mm in this direction, and a difference of 0.273mm
in favour of group 2. The 95% confidence intervals for changes in the global score
are equally wide (Table 3xxxv).
Since the correlation in changes in lesions within an individual however appears to
be very weak, lesions may be regarded as behaving independently and reduce
drastically the number of patients required to detect differences between treatment
groups [Gibson et al 1992], Assuming an average of 5 lesions per patient, and a
standard deviation in measurement of mean segment width of 0.24mm [Watts et al
1992], there is 95% power at the 0.01 level to detect a difference of 0.2mm in the
n mean median S.D. Q1 Q3 95% C.I.
Change in focal score Group 1 9 -0.020 0.009 0.245 -0.152 0.101 } -0.273
Group 2 10 +0.035 0.006 0.195 -0.118 0.164 } 0.163
Change in global score Group 1 9 -0.115 -0.135 0.412 -0.250 0.159 } -0.39
Group 2 10 -0.052 -0.072 0.168 -0.139 0.077 } 0.265
Change in MinAWS Group 1 41 0.037 0.010 0.312 -0.100 0.227 }-0.137
Group 2 49 0.018 -0.003 0.434 -0.175 0.238 } 0.176
Change in MAWS Group 1 59 +0.015 0.050 0.389 -0.145 0.170 } -0.089
Group 2 74 -0.029 0.005 0.379 -0.166 0.171 } 0.177
Change in % D.S. Group 1 41 0.80 -1.0 13.94 -5.0 5.0 } -7.4
Group 2 49 1.76 -1.0 16.9 -6.5 7.0 } 5.5
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change in mean absolute width of the coronary segments - the difference
described between the dietary intervention and 'usual care' groups in the STARS
with reductions in total cholesterol of 2.0% and 14.2% respectively [Watts et al
1992] - with twenty patients. This would imply that there is sufficient power in the
present data (Table 3xxxv) to conclude there is no difference in angiographic
outcome between achieving a total cholesterol of 5.2 mmol/l using drug therapy
and maintaining a lower level by the addition of regular LDL-apheresis in subjects
with moderate hypercholesterolaemia and advanced coronary disease. This
conclusion is supported by the lack of angiographic benefit seen in the intensively
treated group of normocholesterolaemic patients in the Harvard Atherosclerosis
Reversibility Project (HARP) [Sacks et al 1994], Despite achieving similar
percentage changes in serum lipids as in CLAS (although it may be significant that
the rise in HDL was only 13% in HARP compared to 37%) [Blankenhorn et al
1987] to achieve the treatment goals of TC < 4.1 mmol/l and LDL/HDL < 2.0, there
was no significant difference in angiographic outcome from the control subjects
who maintained a mean total cholesterol level of 5.56 mmol/l for the 2.5 years of
the study.
Further support for the "threshold hypothesis" comes from STARS - in which the
degree of improvement with diet alone (and on-trial cholesterol of 6.17 mmol/l) was
not significantly different from treatment with diet and cholestyramine (on-trial TC
5.56mmol/l) [Watts et al 1992] - and analysis of behaviour of lesions in subgroups
in other studies: progression was reduced to a lesser extent in
normocholesterolaemic subjects than in hypercholesterolaemic patients in CLAS ;
in familial hypercholesterolaemic subjects reducing LDL from 5.2 to 2.6 mmol/l
resulted in no greater improvement than in those in whom the LDL was lowered
from 7.32 to 4.45 mmol/l [Kane et al 1990]; and, in CCAIT [Waters et al 1994]
there was significant benefit for those with a baseline LDL above the median value
of 4.5 mmol/l, but not for those below this level. In FATS there was angiographic
improvement even in those with baseline levels below 4.1 mmol/l [Brown et al
1990], but the patients in this study were required to have elevated serum apoB at
baseline which may affect the response to therapy.
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A difference in progression or regression of lesions with varying severity of
stenosis at baseline has been described [Stone ef a/1993, Sacks et al 1994], This
may be partly due to "regression to the mean", but may also reflect genuine
differences in the behaviour of these plaques. In the present analysis lesions
initially greater than 40% diameter stenosis (n=34) had a mean decrease of 2
percentage points (SD 14.5), while 22 lesions with < 25% stenosis at baseline
increased by a mean of 10% (SD 19.2) (P = 0.02). However the lesions with a
baseline diameter stenosis less than 20% which did not progress above this level
were not analysed in this way, and this is likely to have introduced some selection
bias. The mean arterial width (MAWS) was examined for all segments which were
suitable for analysis, and this demonstrates that there was no difference in the
change in MAWS between segments with less than 20% diameter stenosis at
baseline and those with an initial stenosis greater than 40%.
It is held by some observers that genuine 'regression' of an established lesion will
be achieved only rarely due to the presence in the plaque of less reversible
components. Stabilisation of the plaque may be a more readily attainable goal.
The 'roughness index' may be a measure for this, since it incorporates some
measure of the degree of irregularity of the lesion, including ulceration. Its
usefulness however has not been established and results from this study do not
suggest that even profound alterations in the cholesterol level have any effect.
Indeed there was, surprisingly, a positive correlation between the degree of
irregularity and increases in segment width.
The relationship between changes in the atherogenic index and the summary
measures of lesion progression within each of the treatment groups, with a less
clear trend for the groups combined, may indicate a difference in response to lipid
modification dependent on the means used to achieve it. As previously discussed,
there is a relationship between the degree of cholesterol reduction and both
clinical events and extent of angiographic changes both within and between
published studies. The extent of change per unit reduction in TC or TC/HDL does
however differ, and changes achieved by dietary means appear to be greater than
those achieved in studies in which pharmacotherapy was employed, which in turn
are greater than those seen with physical interventions such as ileal bypass
surgery.
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Numerous studies have demonstrated the diagnostic value of thallium scintigraphy
combined with either physical or pharmacological stress, and have documented
the difficulties in relating the distribution of reversible perfusion defects to specific
coronary lesions. The present study has not attempted to correlate the
scintigraphic and angiographic findings at baseline, but sought to determine
whether changes in lesions at angiography might be detectable as differences in
perfusion, and whether it might be suitable as a non-invasive marker for disease
progression or regression. Since the analysis is only semi-quantitative, it had been
anticipated that it would be insufficiently sensitive to detect the relatively small
changes expected.
The results however show not only a significant correlation between arteriographic
changes and scores of changes in myocardial perfusion, but also indicate that the
thallium scores may be of some value in predicting changes in individual lesions
assessed angiographically. The overall accuracy of the scoring is reduced by a
significant proportion of the thallium scores being zero. This might be improved by
quantifying the regional myocardial uptake, so that absolute differences in
perfusion might still be determined between scans rather than only differences
relative to the hottest pixel. Another possibility which was examined was to adjust
the zero scores to a positive or negative value depending on whether segmental
wall motion had improved or deteriorated. Inserting 1 or -1 from regional wall
motion scores (derived from either the moving reconstructed thallium image or
from the blood pool scan) did increase the test accuracy, but at the expense of
decreased sensitivity, specificity and predictive values.
The poorer predictive value of the scores for circumflex lesions might be
anticipated, since the myocardial territory supplied is less well-visualised on the
three projections of the thallium scan than are the other two arteries, and the low
sensitivity of the technique in detecting circumflex artery lesions is well-recognised
[Hargreaves & Muir 1992], The degree of overlap of the territories of distribution of
all three arteries due to right- or left-dominance and the extent of collateralisation is
illustrated by the improvement in the predictive values for the scores when only the
proximal arterial segments are considered.
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The correlations found in this study would suggest that changes in perfusion and
the degree of reversibility of perfusion defects may be of value in the non-invasive
assessment of interventions which alter flow in the right coronary artery and
possibly in the proximal segments of the left coronary artery.
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4 GENERAL DISCUSSION
The studies cited in the section on the pathogenesis of atherosclerosis have
focused for the purpose of the development of the thesis on the role of
lipoproteins, while seeking to identify those other factors which act in concert with
lipids and those aspects of the development of the disease process which may
require the examination of alternative mechanisms. The nature of the plaque itself
indicates that lipids are an essential component of the process, and the low
incidence of disease in other animal species and of clinical endpoints in
populations with high levels of other risk factors but lower median levels of
cholesterol highlights the central role of lipoproteins. This recognises the existence
of populations in which the prevalence of the precursor lesion, the 'fatty streak', is
as high as in others but with a lower incidence of progression to plaque-formation,
and does not deny the necessity of presence of other factors in addition to
hypercholesterolaemia.
In attempting to find a unifying hypothesis for atherogenesis, it must be recognised
that hypercholesterolaemia is not a prerequisite for the development of
atherosclerosis, neither is the latter an inevitable consequence of the former. This
is supported by the (uncommon) occurrence of the disease in subjects with none
of the recognised risk factors. The variety of possible injurious agents which may
initiate the process in different individuals however, are likely to have a final
common pathway which is aggravated and accelerated by the presence of excess
LDL which may undergo oxidative modification and accounts for the regression
which may take place in lesions which occur in individuals with normal or even low
levels of serum lipids.
Following the acceptance of the association between cholesterol levels and
coronary disease both within and between populations, attempts to elucidate the
causal nature of the relationship and the desire to reduce clinical events led to a
considerable number of trials of intervention. As in other areas of research the
early studies were flawed in design and failed to substantiate the hypothesis of a
causal role for lipids. The dietary trials of unifactorial intervention (Tables 1i - 1ii)
were largely ineffectual because of reductions in cholesterol levels being too
small, too short a period of follow-up, too few participants, or having an event rate
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which proved inadequately low. The first two of the three major primary prevention
trials finally proved the 'cholesterol hypothesis' in significantly reducing the
combined cardiac end-points (in the LRC-CPPT [Lipid Research Clinics Program
1984]) or coronary events (in the WHO trial [WHO Collaborative Group 1983]). The
WHO clofibrate study however moderated the urge to adopt widespread use of
clofibrate to prevent coronary disease by its unexpected and worrying finding of
an increase in overall mortality in the treatment group. This has cast a long
shadow over the treatment of raised lipid levels with drugs which has affected also
the need for more intensive treatment of subjects with established disease, and
this has only recently begun to be redressed.
The increase in non-cardiac deaths in the drug-intervention studies had no single
statistically significant cause, lacked an association between the degree of
cholesterol-lowering and the likelihood of an adverse event, tended to occur in
non-compliers, and lacked a biologically plausible explanation. However the trends
were consistent in all the studies, and consonant with the epidemiological findings
of an increased overall mortality rate (including deaths from malignancy) at the
lower end of the cholesterol distribution [Jacobs et al 1990, Neaton et al 1992],
Although it had been felt that the low cholesterol levels might result from some
pathological process which was ultimately responsible for death, rather than the
stimulus for the cause of death itself, some studies report the same relationship
between total mortality and low cholesterol levels even after discounting the
deaths occurring within the first few years of cholesterol measurement (eg Isles et
al 1992). It is quite possible that the agents used in the intervention trials had
untoward side-effects unrelated to their cholesterol-lowering activity in the same
way as some of the benefits of treatment may be derived by other mechanisms
[Research Committee of the Scottish Society of Physicians 1971, Group of
Physicians of the Newcastle upon Tyne Region 1971], and it is noteworthy that the
trials of dietary therapy were largely free of deleterious effects on mortality (Table
1 ii), but this does not explain the epidemiological observations which should not be
dismissed.
Although some individuals would appear to be resistant to the effects of prolonged
hypercholesterolaemia, for those who develop the lesions of atherosclerosis it
would seem that "whatever their level of cholesterol, it is too high for them". Since
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the occurrence of a prior cardiac event is one of the strongest predictors of
subsequent cardiovascular morbidity and mortality, the benefits of cholesterol-
lowering in the secondary setting has always appeared to be more promising in
yielding a favourable risk:benefit ratio. The drug treatment of moderate elevations
of cholesterol in this population has consistently led to a reduction in cardiac
events (Table 1 iv); the prospect that this might lead ultimately to improved survival
overall is supported by the long-term follow-up of the Coronary Drug Project
[Canner et al 1988]. Although it has been argued that the lack of effect of
treatment on total mortality of the other studies is unsurprising given that the
studies were not designed to have the power to detect this, the results of the
Program on the Surgical Control of Hyperlipidemias (POSCH, [Buchwald et al
1990]) set out with this objective in survivors of myocardial infarction. Although the
reduction in total mortality failed to achieve statistical significance at ten years, the
curves continue to diverge and further follow-up of this cohort of obligate
adherents may yet yield this elusive goal (although the increasing use of effective
therapy in the control group will reduce the apparent impact of this heroic
intervention).
The recent publication of the Scandinavian Simvastatin Survival Study (4S) has
altered irrevocably the approach to management of moderate hypercholesterol-
aemia in patients with existing disease. The highly significant reduction in total
mortality and all primary and secondary cardiac endpoints (in both men and
women, and also in older age-groups) combined with the absence of increased
non-cardiac deaths both justifies the enthusiasm for secondary prevention and
reassures the sceptics that the benefits of cholesterol lowering (at least with some
groups of agents) can be obtained without the spectre of simply changing the
cause of death. Further studies using other HMG CoA reductase inhibitors in both
primary and secondary settings should firmly substantiate the impressive findings
of this trial.
Although a large-scale and prolonged clinical trial would be desirable to assess the
effects of any agent used for primary or secondary prevention in order to evaluate
the risk of unanticipated adverse events, the adoption of surrogate endpoints may
be one method of predicting the effects of any therapy on atherosclerotic events
and may be of value in selecting therapies for more rigorous clinical scrutiny. The
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use of computerised methods for analysing coronary angiograms permits the study
of a smaller number of patients over a shorter time period, using the changes in
atherosclerotic plaques as the endpoint. Studies that have documented beneficial
alterations in angiographic appearances and reduction in clinical events [Buchwald
et al 1990, Brown et al 1990, Watts et al 1992] attest to the validity of this
approach. The optimal means of presenting the results from such studies should
include both per-patient analyses and per-lesion changes [deFeyter et al 1991],
since the intraclass correlations have been shown to be low in all cases (0.05 -
0.2), indicating virtual independence of lesion changes from each other within
individual patients [Sacks et al 1994, Watts et al 1992]. As discussed in Section
3.7.5 (pp 218 - 219), this would imply that the power of the present study was
sufficient to detect a significant difference between the treatment groups and that it
would be reasonable to conclude a lack of effect of the more intensive treatment
schedule.
The biological significance of the angiographic findings analysed by
computer-assisted edge-detection algorithms has been questioned. The absolute
change in lesions was small: the mean change (S.D.) in minimum lesion diameter
was -0.05mm (0.14) for the conventionally treated group in the Familial
Atherosclerosis Treatment Study [Brown et al 1990] compared to -0.002mm (0.14)
in the lovastatin-colestipol group and +0.04mm (0.12) for the statin-niacin group.
The other studies demonstrating benefit have yielded changes of similar
magnitude. The strength of the results however lie not so much in the magnitude
of the response, as in the consistent relationship with the clinical outcome. It is
likely that the alterations in the circulating lipids lead to a degree of resorption of
the lipid component of the atherosclerotic plaque resulting in minimal change in the
overall dimensions, but fundamentally altering its composition and reducing its
propensity to rupture with the attendant complications.
Recent angiographic studies employing monotherapy with an HMG CoA reductase
inhibitor [Blankenhorn et al 1993, Waters et al 1994, MAAS 1994] have shown
significant reductions in serum lipids and angiographic evidence of enhanced
regression and decreased progression (see Tables 1 vi and 1 vii, pp 74 - 75), but
have failed to produce a significant reduction in clinical endpoints, despite
intervention periods similar to that of FATS. The latter study also showed a
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significant correlation between the changes in LDL and HDL with the alteration in
arterial stenosis, and this was not a finding of the statin studies. It may be of note
that the investigations yielding some of the best clinical results have employed
niacin as part of the treatment regime. While this may be due in part to actions
other than lipid-lowering (or HDL-raising), such as vasodilation, its effects on Lp(a)
may also be of import. Niacin is the only cholesterol-lowering drug shown to have a
beneficial effect on Lp(a) and while statins lower LDL, various reports indicate a
rise in Lp(a). Although the benefits of reducing Lp(a) per se are as yet unproven,
the evidence for its influence in promoting atherosclerosis is considerable. Its
reduction is therefore likely to be beneficial: since LDL requires to undergo
oxidative modification before uptake by the macrophage scavenger receptor, the
presence of a bound modified particle in the subendothelial space may accelerate
the oxidation of native LDL, and the presence of excess LDL would lead to more
rapid formation of foam cells. In the absence of Lp(a) the residence time of LDL
may not permit much modification of the particles in the absence of another
oxidative source, even if the serum LDL concentration was high.
It is well-accepted that the architecture of the stenosis contributes only in part to
the overall clinical importance of the lesion, and that endothelial dysfunction
resulting in abnormal vasomotor tone will influence both the angiographic
appearances and the vascular function. The impaired vasomotor tone seen in
hypercholesterolaemia [Creager et al 1990] is reversed with effective lipid-lowering
therapy in animal models as well as man [Osborne, Lento et al 1989]; the authors
of the Lifestyle Heart Trial noted that Improvements in functional status occurred
after only one month, which they attributed to alterations in platelet-endothelial
interactions, vasomotor tone, or other dynamic characteristics of stenoses [Ornish
et al 1990], Such early symptomatic improvements in patients with coronary
disease is an almost universal experience during regular therapy with
LDL-apheresis [Keller 1991], including the present study. The benefits of rigorous
reduction in lipids compared to more modest changes in serum cholesterol has not
however been better-demonstrated than in the present investigations, and were
greatest for those whose exercise capacity was most limited prior to treatment (see
section 3.5).
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It had been thought that the early improvement in symptoms may be due to
favourable alterations in haemorheology, as had been described elsewhere. As
described in Sect 3.3.3 however, there was a small unexpected (but significant)
increase in blood viscosity. The changes in blood viscosity were negatively
correlated with percentage reduction in cholesterol, so that those with larger falls in
TC had the smallest increases, or largest decreases, in whole blood viscosity.
Despite more profound lipid reductions than previously documented maintained
over a prolonged period (and despite acute changes in fibrinogen levels and
viscosity during apheresis), there was not a significant reduction in the longterm in
pre-apheresis haemorheological values; this is underlined by the absence of
changes after withdrawal of therapy. It is likely therefore that the changes in
endothelial function were responsible for much of the impressive benefit obtained
during treatment.
The sustained symptomatic improvement following prolonged therapy gave
grounds for optimism that regression would have occurred more frequently in the
more intensively treated group. It is clear from the results (sect 3.7.3) that however
the terms are defined, the groups did not differ in the proportion of lesions in each
in which 'progression' and 'regression' occurred. The results are remarkable
however for the extent to which the lesions could be stabilised in both groups,
despite the advanced nature of the disease before intervention and the severity of
the hypercholesterolaemia. The results from other studies tend to suggest that this
is a more readily attainable goal of therapy; even lesser reductions in the
proportion of subjects exhibiting disease progression has been shown to be
associated with reduced clinical endpoints [Buchwald eta! 1990].
As previously stated, the multifactorial nature of atherosclerosis is well-
recognised. However it is possible that for an individual only one factor is the
'determining factor', and correction of this dominant cause may be sufficient to
arrest or reverse the process [Steinberg 1987], For individuals with proven
coronary disease and marked hypercholesterolaemia the management clearly
should include effective lipid-lowering therapy.
Recent research has focused on the mechanisms involved in the uptake of lipid
into the artery wall. It is now established that oxidation of LDL is central to this
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process, and it is possible that the prevention of this step will prove more
rewarding than cholesterol-reduction in the stabilisation of the atherosclerotic
plaque. Nevertheless, as observed by Salonen and colleagues, "..even if oxidation
of LDL were the 'whole story'....it is obvious that if there were fewer LDL particles
to be oxidised, there would be less atherosclerosis."[Salonen et al 1992],
Interestingly the use of captopril following myocardial infarction is increasing
following the publication of studies showing improved long-term mortality in this
setting. While the reduction in mortality is related mainly to reduced progression to
heart failure, a reduction in re-infarction has also been noted. The anti-oxidant
activity of captopril (but not the non-sulfhydryl-containing angiotensin converting
enzyme inhibitors) has been noted [Balla et al 1991], and may account for this
hitherto unanticipated benefit.
LDL-apheresis has been shown to allow the attainment of any chosen lipid goal,
and for those individuals unable to tolerate drug combinations or in whom the
effects of such therapy is ineffective in resulting in the achievement of the desired
lipoprotein levels (ie. total cholesterol < 5.2 mmol/l, LDL < 3.5 mmol/l) it may be a
useful adjunct to conventional treatment. Its use in homozygous familial
hypercholesterolaemia is well-established and uncontroversial. The widespread
availability of effective drug therapy however limits its applicability to a small group
of subjects. While most procedures were uncomplicated, the unpredictable nature
of the small number of serious adverse reactions pose a hazard to those with
impaired myocardial function and diminished coronary reserve.
While the documented benefits of effective cholesterol-lowering should not be
denied to those who stand to gain most from its application, the majority of patients
with familial hypercholesterolaemia will however be able to achieve normal or near-
normal lipoprotein levels with effective combination drug therapy. Also, the advent
of gene therapy in certain disorders is likely to be applied in FH patients within the
next few years, and it is possible that extracorporeal removal of lipoproteins will be
superseded by such definitive therapy.
In the meantime the evidence would suggest that even modest elevations of
cholesterol in patients with proven coronary disease should be corrected by lipid-
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lowering drugs and that it is safe to do so, but that extreme measures do not
appear to yield significant additional benefit and that lowering lipid levels further in
subjects with normal levels is not warranted. Within the latter group however there
may be subgroups with an atherogenic lipoprotein phenotype who might benefit
from lipid modification, and this requires to be studied further. Further work is also
needed to ascertain whether the addition of anti-oxidant therapy confers any
advantage, and whether the development of agents which have greater effect on
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APPENDIX
Determination of score for change in myocardial perfusion
1st scan -> 3rd scan Score
Ex Redist Ex Redist
Normal Normal
N, N N, N 0
Normal Reperfusion
N, N M, N -1
N, N H, N -2
N, N B, N -3
N, N A, N -4
Normal Partial reperfusion
N, N H, M -1
N, N B, M -1
N, N A, M -1
N, N B, H -2




























































































































































































































































































1st scan -> 3rd scan
Ex Redist Ex Redist
A, M M, N
A, M H, N
A, M A/B N
B, H M/H/B/A N
A, H M, N
A, H H/B/A N

































































































































> 3rd scan Score
Ex Redist
Reverse reperfusion
















































H H, etc. }
Reverse reperfusion
1st scan ->
Ex Redist
Reverse reperf
N, M/H/B/A
M/H/B H/B/A
Reverse reperf
N, M/H/B/A
M/H/B H/B/A
N, M/H/B/A
M/H/B H/B/A
Score
0
} 0
}
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